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Abstract
The diagnostic accuracy and cost-effectiveness of magnetic 
resonance spectroscopy and enhanced magnetic resonance 
imaging techniques in aiding the localisation of prostate 
abnormalities for biopsy: a systematic review and 
economic evaluation
G Mowatt,1* G Scotland,1,2 C Boachie,1 M Cruickshank,1 
JA Ford,1 C Fraser,1 L Kurban,3 TB Lam,4 AR Padhani,5 
J Royle,3 TW Scheenen6 and E Tassie2
1Health Services Research Unit, University of Aberdeen, Aberdeen, UK
2Health Economics Research Unit, University of Aberdeen, Aberdeen, UK
3Aberdeen Royal Infirmary, Aberdeen, UK
4Academic Urology Unit, University of Aberdeen, Aberdeen, UK
5Mount Vernon Cancer Centre, Northwood, Middlesex, UK
6Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
*Corresponding author
Background: In the UK, prostate cancer (PC) is the most common cancer in men. A diagnosis can be 
confirmed only following a prostate biopsy. Many men find themselves with an elevated prostate-specific 
antigen (PSA) level and a negative biopsy. The best way to manage these men remains uncertain.
Objectives: To assess the diagnostic accuracy of magnetic resonance spectroscopy (MRS) and enhanced 
magnetic resonance imaging (MRI) techniques [dynamic contrast-enhanced MRI (DCE-MRI), diffusion-
weighted MRI (DW-MRI)] and the clinical effectiveness and cost-effectiveness of strategies involving their 
use in aiding the localisation of prostate abnormalities for biopsy in patients with prior negative biopsy 
who remain clinically suspicious for harbouring malignancy.
Data sources: Databases searched – MEDLINE (1946 to March 2012), MEDLINE In-Process & Other Non-
Indexed Citations (March 2012), EMBASE (1980 to March 2012), Bioscience Information Service (BIOSIS; 
1995 to March 2012), Science Citation Index (SCI; 1995 to March 2012), The Cochrane Library (Issue 3 
2012), Database of Abstracts of Reviews of Effects (DARE; March 2012), Medion (March 2012) and Health 
Technology Assessment database (March 2012).
Review methods: Types of studies: direct studies/randomised controlled trials reporting diagnostic 
outcomes. Index tests: MRS, DCE-MRI and DW-MRI. Comparators: T2-weighted magnetic resonance 
imaging (T2-MRI), transrectal ultrasound-guided biopsy (TRUS/Bx). Reference standard: histopathological 
assessment of biopsied tissue. A Markov model was developed to assess the cost-effectiveness of 
alternative MRS/MRI sequences to direct TRUS-guided biopsies compared with systematic extended-cores 
TRUS-guided biopsies. A health service provider perspective was adopted and the recommended 3.5% 
discount rate was applied to costs and outcomes.
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Results: A total of 51 studies were included. In pooled estimates, sensitivity [95% confidence interval (CI)] 
was highest for MRS (92%; 95% CI 86% to 95%). Specificity was highest for TRUS (imaging test) (81%; 
95% CI 77% to 85%). Lifetime costs ranged from £3895 using systematic TRUS-guided biopsies to £4056 
using findings on T2-MRI or DCE-MRI to direct biopsies (60-year-old cohort, cancer prevalence 24%). The 
base-case incremental cost-effectiveness ratio for T2-MRI was < £30,000 per QALY (all cohorts). 
Probabilistic sensitivity analysis showed high uncertainty surrounding the incremental cost-effectiveness of 
T2-MRI in moderate prevalence cohorts. The cost-effectiveness of MRS compared with T2-MRI and TRUS 
was sensitive to several key parameters.
Limitations: Non-English-language studies were excluded. Few studies reported DCE-MRI/DW-MRI. The 
modelling was hampered by limited data on the relative diagnostic accuracy of alternative strategies, the 
natural history of cancer detected at repeat biopsy, and the impact of diagnosis and treatment on disease 
progression and health-related quality of life.
Conclusions: MRS had higher sensitivity and specificity than T2-MRI. Relative cost-effectiveness of 
alternative strategies was sensitive to key parameters/assumptions. Under certain circumstances T2-MRI 
may be cost-effective compared with systematic TRUS. If MRS and DW-MRI can be shown to have high 
sensitivity for detecting moderate/high-risk cancer, while negating patients with no cancer/low-risk disease 
to undergo biopsy, their use could represent a cost-effective approach to diagnosis. However, owing to the 
relative paucity of reliable data, further studies are required. In particular, prospective studies are required 
in men with suspected PC and elevated PSA levels but previously negative biopsy comparing the utility of 
the individual and combined components of a multiparametric magnetic resonance (MR) approach (MRS, 
DCE-MRI and DW-MRI) with both a MR-guided/-directed biopsy session and an extended 14-core TRUS-
guided biopsy scheme against a reference standard of histopathological assessment of biopsied tissue 
obtained via saturation biopsy, template biopsy or prostatectomy specimens.
Study registration: PROSPERO number CRD42011001376.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Atypical small acinar proliferation A diagnosis of ‘atypical small acinar proliferation’ signifies an 
unusual cellular appearance. Atypical small acinar proliferation is not, in general, considered a pre-
malignant condition, but is an indication for repeat biopsy.
Benign prostatic hyperplasia Non-malignant increase in number of cells in the prostate.
Case series Descriptive study of a group of people with the same disease or the same treatment. This 
type of study cannot determine how people with the disease compare with those without the disease or 
those who are treated differently.
Case–control study This type of study compares a group of people who have the disease and a group 
who do not have it.
Central zone Located at the centre of the prostate. Surrounds the ejaculatory ducts.
Clinical T staging Four categories for describing the local extent of a prostate tumour, ranging from T1 
to T4. T1 represents localised tumours with no spread, whereas T4 represents tumours that have spread.
Comparator The best diagnostic test currently available.
Cross-sectional study A study in which data are collected at one point in time and relationships 
between factors are explored.
Diagnostic odds ratio The ratio of the odds of testing positive in those with the disease relative to the 
odds of testing positive in those without the disease.
Direct head-to-head study A study in which people receive both index and comparator tests and the 
tests are therefore evaluated in the same participants.
False-negative/true-negative/false-positive/true-positive In terms of diagnostic accuracy, indicators 
of index test results compared with the reference standard: negative index test, positive reference 
standard/negative index test, negative reference standard/positive index test, negative reference standard/
positive index test, positive reference standard, respectively.
Gleason score A system of grading prostate cancer tissue based on how it looks under a microscope. 
Gleason scores range from 2 to 10 and signify the likelihood of a tumour spreading. Lower Gleason scores 
mean that the cancer tissue is similar to normal prostate tissue and the tumour is less likely to behave 
aggressively; higher Gleason scores mean that the cancer tissue is very different from normal tissue and the 
tumour is more likely to behave aggressively.
(High-grade) prostatic intraepithelial neoplasia An abnormality of prostate cells. Associated with a 
finding of prostate cancer on repeat biopsies.
Hypoechoic In ultrasonography, describes areas of abnormally low echoes due to pathological changes in 
tissue density. Hypoechoic lesions are commonly found to be malignant.
Index- or reference test-directed biopsy This refers to the method used to identify suspicious areas 
prior to biopsy, i.e. where one or more index tests are used to identify cancer-suspicious areas for use in a 
subsequent biopsy.
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Index- or reference test-guided biopsy This refers to the method used at the time of obtaining tissue 
samples, i.e. where the specified test is used to locate previously identified cancer-suspicious areas as part 
of the biopsy procedure.
Index test The diagnostic test that is being evaluated.
Isoechoic In ultrasonography, describes similarity between two or more tissues. Isoechoic lesions are less 
likely than hypoechoic lesions to be malignant.
Likelihood ratio A description of how many times more likely it is that a person with the disease will 
receive a particular test result than a person without the disease.
Meta-analysis The quantitative pooling of data from two or more studies.
Negative predictive value The proportion of those with negative test results who do not have 
the disease.
Nomogram A prognostic indicator incorporating multiple risk variables to produce mathematical models 
that predict the likelihood of disease recurrence or progression.
Observational study A study in which people are observed without input from the researchers.
Peripheral zone Located around the outside of the prostate gland, next to the rectum.
Positive predictive value The proportion of those with positive test results who actually have 
the disease.
Prostate-specific antigen A protein manufactured by the prostate which aids the liquefaction of semen 
and is released and detectable in the bloodstream in a number of conditions related to the prostate.
Randomised controlled trial A study in which people are randomly allocated to receive – or not receive 
– a particular treatment or intervention. This is said to be the best study type to determine effectiveness of 
a treatment.
Reference standard The best available method for establishing the presence or absence of the disease.
Sclerotic Hard or hardening (of tissue).
Sensitivity The proportion of those who actually have the disease and who are correctly identified with 
positive test results.
Specificity The proportion of those who actually do not have the disease and who are correctly identified 
with negative test results.
TNM staging system This describes the local extent of the primary tumour (T stage), the absence or 
presence of spread to nearby lymph nodes (N stage) and the absence or presence of metastasis (M stage).
Transition zone Located in the interior of the prostate. Surrounds the proximal urethra.
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List of abbreviations
ADC apparent diffusion coefficient
AIF arterial input function
ASAP atypical small 
acinar proliferation
ASCO American Society of 
Clinical Oncology
CC/C choline-plus-creatine–
citrate ratio
CEAC cost-effectiveness 
acceptability curve
CI confidence interval
CT computed tomography
CZ central zone
DCE-MRI dynamic contrast-enhanced 
magnetic resonance imaging
DOR diagnostic odds ratio
DRE digital rectal examination
DW-MRI diffusion-weighted magnetic 
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EAU European Association 
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EBRT external beam radiotherapy
ED erectile dysfunction
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GP general practitioner
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HIFU high-intensity 
focused ultrasound
HRG Healthcare Resource Group
HSROC hierarchical summary receiver 
operating characteristic
ICER incremental 
cost-effectiveness ratio
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Care Excellence
NMB net monetary benefit
NPV negative predictive value
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TNM tumour, node, metastasis 
staging system
TRUS transrectal ultrasonography
TRUS/Bx transrectal 
ultrasound-guided biopsy
TZ transition zone
UI urinary incontinence
UTI urinary tract infection
All abbreviations that have been used in this report are listed here unless the abbreviation 
is well known (e.g. NHS), or it has been used only once, or it is a non-standard 
abbreviation used only in figures/tables/appendices in which case the abbreviation is 
defined in the figure legend or at the end of the table.
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Executive summary
Background
In the UK, prostate cancer (PC) is the most common cancer in men. Many men find themselves with the 
dilemma of having an elevated prostate-specific antigen (PSA) level and a negative prostate biopsy, and the 
best way for doctors to manage these patients remains uncertain. The strategy of further repeat biopsies 
for these men remains controversial, with uncertainties surrounding the optimal number of cores, which 
area of the prostate to target, and imaging modality for guidance. This has led to the introduction of new 
imaging techniques. Conventional standard (T2-weighted) magnetic resonance imaging (T2-MRI) can be 
performed with add-on modalities, including three-dimensional magnetic resonance spectroscopy (MRS), 
dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted MRI (DW-MRI).
Objectives
This review aims to assess the diagnostic accuracy of MRS and enhanced MRI techniques (DCE-MRI, 
DW-MRI) and the clinical effectiveness and cost-effectiveness of strategies involving their use in aiding 
the localisation of prostate abnormalities for biopsy in patients with prior negative biopsy in whom there 
remains a clinical suspicion that they are harbouring malignancy.
Methods
Electronic databases searched included MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, 
EMBASE, Bioscience Information Service (BIOSIS), Science Citation Index (SCI), Cochrane Central Register 
of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts 
of Reviews of Effects (DARE), Medion, Health Technology Assessment database, conference abstracts from 
the American Society for Clinical Oncology (ASCO) and current research registers. Searches were carried 
out from 1995 to March 2012. Types of studies considered were direct studies or randomised controlled 
trials reporting absolute numbers of true- and false-positives and true- and false-negatives, allowing 
the calculation of sensitivity, specificity or predictive values. The population was men with suspected PC 
and elevated PSA level but previously negative biopsy. Index tests were MRS, DCE-MRI and DW-MRI, and 
comparator tests were standard T2-MRI and transrectal ultrasonography (TRUS). The reference standard 
was histopathological assessment of biopsied tissue obtained via transrectal needle biopsy, saturation 
biopsy, transperineal template biopsy or from prostatectomy specimens.
Two reviewers independently screened the titles and abstracts of all reports identified by the search 
strategy and full-text papers were subsequently obtained for assessment. Data extraction was undertaken 
by one reviewer and checked by a second. Two reviewers independently assessed the risk of bias of the 
diagnostic studies using a modified version of the QUADAS-2 (quality assessment of diagnostic accuracy 
studies, version 2) instrument.
The results of the individual studies were tabulated and sensitivity, specificity and their 95% confidence 
intervals (CIs) presented for each test or combination of tests at both patient and biopsy level. The 
presence of heterogeneity was assessed by visual examination of pairs of forest plots of sensitivity and 
specificity. Separate summary receiver operating characteristic (SROC) curves were derived for different 
levels of analysis. Meta-analysis models were fitted using hierarchical SROC (HSROC) curves. Summary 
sensitivity, specificity, positive and negative likelihood ratios and diagnostic odds ratios for each model 
were reported as median and 95% CI. An indirect comparison of tests was also undertaken.
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An economic model was developed to assess the cost-effectiveness of using alternative MRS/MRI 
sequences to direct TRUS-guided biopsies (TRUS/Bx), compared with the standard practice of relying on 
systematic extended TRUS-guided biopsies (in patients with a previous negative biopsy). The alternative 
diagnostic pathways were embedded in a Markov model simulating the progression of undiagnosed 
cancer and the downstream impact of diagnosis and treatment on survival and health-related quality 
of life (QoL). Costs incorporated in the model included the costs associated with obtaining the final 
diagnosis (cancer/no cancer), management of biopsy complications, cancer staging, cancer treatment, and 
the management of complications resulting from cancer treatment. Survival benefits of diagnosis were 
captured through the application of relative risk parameters reflecting the benefit of appropriate treatment 
by stage of underlying cancer. Health-state utilities associated with cancer stage and the occurrence of 
treatment complications were incorporated in the model to estimate quality-adjusted life-years (QALYs). 
Experimental strategies were compared incrementally with standard practice in terms of their incremental 
cost per life-year and QALY gained.
Results
Number and quality of studies
Fifty-one studies (39 full text and 12 abstracts) were included, involving over 10,000 men. Only full-text 
studies were assessed for risk of bias, the majority of which were considered to have a low risk of bias for 
the patient selection (74%, 29/39), index test (100%, 39/39) and flow and timing (92%, 36/39) domains. 
In the reference standard domain, the majority of studies (64%, 25/39) were considered at high risk of bias 
owing to a lack of follow-up.
Summary of benefits and risks
In meta-analyses of the individual tests, sensitivity was highest for MRS at 92% (95% CI 86% to 95%), 
followed by T2-MRI at 86% (95% CI 74% to 93%) and DCE-MRI at 79% (95% CI 69% to 87%), whereas 
specificity was highest for TRUS (used as an imaging test) at 81% (95% CI 77% to 85%), followed by MRS 
at 76% (95% CI 61% to 87%). In pooled estimates for combinations of tests, sensitivity was highest for 
‘MRS or T2-MRI’ at 96% (95% CI 90% to 98%) followed by ‘DCE-MRI or T2-MRI’ at 88% (95% CI 80% 
to 96%), whereas specificity was highest for ‘MRS and T2-MRI’ at 74% (95% CI 65% to 84%). Only one 
small study involving 43 patients reported DW-MRI, with sensitivity of 100% (specificity not reported). The 
results of the indirect comparison broadly reflected those of the meta-analyses of the individual tests and 
combinations of tests.
Summary of costs
The base-case analysis showed average discounted lifetime costs to range between £3895 using systematic 
TRUS-guided biopsies and £4056 using positive findings on either T2-MRI or DCE-MRI to determine and 
direct biopsies (60-year-old cohort, cancer prevalence 24%). The corresponding figures for the same 
strategies in a 70-year-old cohort were £3199–3660. Using T2-MRI to direct biopsies represented the least 
costly approach in low-prevalence (10%) cohorts.
Summary of cost-effectiveness
Survival and QALY differences between strategies were very small but these favoured more sensitive 
approaches. Under base-case parameter values and assumptions (with underlying cancer prevalence 24%), 
the incremental cost-effectiveness ratio (ICER) for T2-MRI was < £30,000 per QALY in comparison with 
systematic extended-cores TRUS/Bx (all cohorts) and T2-MRI was found to dominate extended-cores TRUS/
Bx in low-prevalence cohorts. However, probabilistic sensitivity analysis demonstrated a high degree of 
uncertainty surrounding the incremental cost-effectiveness of T2-MRI compared with extended-cores TRUS/
Bx in the moderate prevalence cohorts. The cost-effectiveness of MRS compared with T2-MRI was less 
favourable under base-case assumptions, although its ICER did fall to < £30,000 compared with extended-
cores TRUS/Bx in the moderate prevalence 60-year-old cohort, and also compared with T2-MRI-directed 
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biopsy in the high-prevalence 60-year-old cohort. The ICER for MRS, or any of the other more sensitive 
strategies, did not fall to < £30,000 in any of the 70-year-old cohorts under base-case assumptions.
Sensitivity analyses
Base-case findings were found to be highly sensitive to a number of uncertain parameters and 
assumptions. The cost-effectiveness of using MRS to direct biopsies was found to be particularly sensitive 
to the cost of prostate biopsies relative to the cost of obtaining a MRS sequence. When the cost of 
obtaining biopsies was raised by ~£115 relative to the cost of MRS, MRS-directed biopsy was found to 
dominate extended-cores TRUS/Bx in all of the cohorts, and its ICER dropped to < £30,000 in comparison 
with the T2-MRI-directed approach in the moderate- and high-prevalence 60-year-old cohorts (although 
it remained > £30,000 in all of the 70-year-old cohorts). The cost-effectiveness of MRS was also crucially 
sensitive to its modelled ability to discriminate between low- and moderate-/high-risk cancer. When all of 
its false-negative findings were modelled to occur in patients with low-risk disease, its cost-effectiveness 
improved substantially in the moderate- and high-prevalence 60-year-old cohorts, although its ICERs 
remained less favourable in the 70-year-old cohorts. Factors undermining the cost-effectiveness of MRS 
included the application of lower disease progression rates and lower relative risk reductions associated 
with diagnosis and treatment. Although a lack of available evidence precluded its inclusion in our base-
case analysis, if DW-MRI could be shown to perform similarly to MRS in terms of diagnostic accuracy, it 
would probably be favoured over MRS for its lower cost.
Discussion
Strengths, limitations of the analyses and uncertainties
In terms of strengths, a comprehensive literature search was undertaken. A HSROC model was used, which 
takes account of the trade-off between true/false-positives and models between-study heterogeneity. 
Pooled estimates were performed at both patient and biopsy level and an indirect comparison of tests was 
undertaken. In terms of limitations, non-English-language studies were excluded. Few studies reported 
DCE-MRI or DW-MRI or included a period of follow-up as part of the reference standard. The index and 
comparator tests were not independent of the reference standard.
In terms of uncertainties, where studies reported an ‘equivocal’ results category, this was classed with 
positive rather than negative results, increasing sensitivity and decreasing specificity, whereas the reverse 
would have been the case if ‘equivocal’ had been classed with negative results. There was only limited 
evidence available of the ability of MRS and other MRI techniques to detect clinically significant disease. In 
studies reporting MRS or other MRI techniques a systematic TRUS/Bx was also undertaken and in most of 
these studies it was unclear how this contributed to sensitivity and specificity values reported.
Generalisability of the findings
All studies included in the pooled estimates reported men with suspected PC and elevated PSA level 
but previously negative biopsy, and therefore these findings would be broadly generalisable to patients 
meeting the above criteria. However, in one study the spectrum of patients was not representative (all had 
atypical small acinar proliferation). In two studies imaging was MR-guided (rather than TRUS-guided), a 
method not generally used in the UK. Six studies reporting TRUS-guided systematic biopsies were large 
screening studies, which is not representative of how men are detected with PC in the UK.
Conclusions
Implications for service provision
Given the level of uncertainty surrounding several key model inputs, it is difficult to arrive at definitive 
conclusions on the cost-effectiveness of using different MRS/MRI sequences to aid the localisation of 
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prostate abnormalities for biopsy. However, our modelling suggests that, under certain circumstances, 
T2-MRI may be considered cost-effective in comparison with systematic TRUS/Bx, and if MRS and DW-MRI 
can be shown to have high sensitivity for detecting moderate-/high-risk cancer, while negating the need 
for patients with no cancer or low-risk disease to undergo biopsy, then their use could represent a cost-
effective approach to diagnosis.
The introduction of MRS and other MRI techniques (T2-MRI, DCE-MRI, DW-MRI) for evaluation of men 
with negative TRUS/Bx but in whom there remains suspicion of cancer would have a range of implications 
for the NHS. These would arise primarily because of a shift in the test–treatment pathway for this 
group, with changes in the method of making diagnosis resulting in changes to the types of patients 
being treated, offered patient options and timings of treatments. This would have consequential effects 
on service provision, costs and training. If urological and/or radiological services were to undertake 
targeted biopsies of MRS-/MRI-suspicious regions then extra provision would be required for this. A new 
generation of equipment and software would be needed to enable accurate, documentable biopsies to be 
obtained from all regions of the prostate. If MRS/MRI identified more patients with localised disease with 
intermediate and high risk of progression then this would increase the proportion of patients considered 
eligible for radical therapies. If MRS or MRI detected few patients with low risk of disease progression 
then fewer patients in this category would undergo perhaps inappropriate radical therapies. Thus, the 
total number of patients undergoing radical therapies would be appropriately decreased, requiring a 
rebalancing of resources currently allocated to surgical and radiation therapy services. Furthermore, if 
MRS or MRI contributed to the more accurate classification of patients with a low risk of progression, this 
would lead to an increase in the proportion of appropriately selected patients who are likely to undergo 
‘active surveillance’, helping to mitigate the current high dropout rate of this approach. The implications 
for the follow-up of active surveillance patients would include repeated PSA testing, repeated interval 
biopsies and follow-up clinics (much of this work is protocol driven and could be nurse practitioner led). 
Taken together, earlier, more accurate diagnoses and more appropriate treatments of PC may improve 
patient outcomes by reducing treatment-related morbidity, improving survival and, in the longer term, 
reducing the requirement for end-of-life and palliative care services. There would be cost implications of 
these service reconfigurations and for changes in treatment patterns mentioned above. Implementation 
would also result in the need for further training of all staff involved in delivering care to patients with PC.
Suggested research priorities
Prospective studies are required in men with suspected PC in whom PSA level is elevated but a previous 
biopsy has been negative, comparing the utility of the individual and combined components of a 
multiparametric magnetic resonance (MR) approach (MRS, DCE-MRI and DW-MRI) with both a MR-guided 
or -directed biopsy session and an extended 14-core TRUS/Bx scheme against a reference standard 
of histopathological assessment of biopsied tissue obtained via saturation biopsy, template biopsy or 
prostatectomy specimens. A follow-up time of 12 months should form part of the reference standard. 
Investigations of DW-MRI should be encouraged, as it is already gaining widespread acceptance in 
the clinic owing to its relatively easy use. These studies should also report the sensitivity of the tests 
in detecting clinically significant disease (Gleason score of ≥ 7 and/or volume > 0.5 ml). In addition to 
diagnostic outcomes, adverse event data and impact of the tests on subsequent physician attitudes to 
patient management should also be obtained, as well as cost-effectiveness data including impact of 
testing on health-related QoL.
Uncertainties surrounding cost-effectiveness could be significantly reduced by future research focusing on 
generating comparable estimates of (1) the sensitivity of MRI-/MRS-directed and systematic approaches to 
TRUS/Bx (using a robust and common reference standard); (2) the prospective sensitivity or specificity of 
MRS or MRI sequences for detecting different grades of localised disease in the repeat biopsy setting; and 
(3) the full economic costs of MRI sequences and systematic approaches to TRUS/Bx based on different 
numbers of cores.
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Further, with the survival and QALY differences between strategies being so small, and of questionable 
clinical significance, the choice between strategies might be better informed by patient or public 
preferences for process of care factors to which the standard QALY model may be insensitive. Scope 
exists to carry out preference elicitation studies to identify and value the key factors influencing patients’ 
preferences for alternative diagnostic, monitoring, and subsequent treatment pathways.
Study registration
This study is registered as PROSPERO CRD42011001376.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National 
Institute for Health Research.
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Chapter 1 Background
Description of health problem
Brief statement describing the health problem
The diagnosis of prostate cancer (PC) is based on a combination of measuring the serum prostate-specific 
antigen (PSA) level, performing a digital rectal examination (DRE) to palpate the prostate, and a prostate 
biopsy. Men with an elevated PSA level and/or abnormal DRE undergo a prostate biopsy, which is normally 
performed using a transrectal probe guided by greyscale ultrasound [or transrectal ultrasound-guided 
biopsy (TRUS/Bx)]. The prostate biopsy procedure is associated with some morbidity,1 including risk of 
infection, discomfort during the procedure, blood in urine (i.e. haematuria), rectal bleeding, blood in 
semen (i.e. haematospermia), risk of precipitating acute urinary retention, and perineal pain afterwards. 
In some cases, the TRUS/Bx will not show cancer and a repeat biopsy may be necessary. The strategy of 
repeat biopsies remains controversial, with TRUS/Bx-based protocols often resulting in high adverse effect 
profiles2 or low diagnostic accuracy. In order to overcome some of the current limitations, new imaging 
modalities and technologies such as magnetic resonance spectroscopy (MRS) and enhanced magnetic 
resonance imaging (MRI) techniques have been introduced. This present review was tasked with evaluating 
MRS and enhanced MRI techniques in aiding the localisation of prostate abnormalities for biopsy in men 
with suspected PC and elevated PSA level but previously negative biopsy, from the perspective of the NHS.
Aetiology and pathology
The prostate is located in the pelvis, lying below the bladder and encompassing the prostatic urethra 
(Figure 1). In a normal young adult male the gland is approximately 3 cm long and weighs approximately 
20 g.3 Histologically, the prostate consists of glandular epithelial cells and fibromuscular stroma, and is 
surrounded by a capsule. There are three glandular regions: peripheral zone (PZ), central zone (CZ) and 
transition zone (TZ).4 The vast majority of PCs originate from glandular epithelial cells; hence, they are 
adenocarcinomas. Up to 70% of cancers arise in the PZ, 15–20% arise in the CZ, and 10–15% arise in the 
TZ.5 The aetiology of PC remains controversial, although several risk factors have been identified. The most 
important risk factors include family history, ethnicity (especially men of black African, African American or 
black Caribbean ancestry6) and increasing age.
Bladder
Prostate
gland
Penis
Urethra
Testis
Rectum
FIGURE 1 Location of the prostate. Taken from CancerHelp UK, the patient information website of Cancer Research 
UK: http://cancerhelp.cancerresearchuk.org.
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Cancer spread occurs by three possible routes: direct (or local) spread to the rectum or bladder, spread 
through the lymphatic channels to the pelvic lymph nodes, or spread through the blood vessels to solid 
organs, especially bone. Clinically, the extent of spread can be classified as localised (i.e. confined to the 
prostate gland), locally advanced (i.e. spread outside the capsule of the prostate gland), metastatic (i.e. 
distantly spread from site of origin) or hormone refractory (i.e. when the cancer becomes unresponsive to 
hormonal manipulation).
Epidemiology and prognosis
In the UK, PC is the commonest cancer in men and the second most common cause of cancer death in 
men after lung cancer.7 Each year around 35,000 men in the UK are diagnosed with PC and more than 
10,000 men die from it.7 At the end of 2006, the number of men in the UK still living with the disease up 
to 10 years after diagnosis was estimated at 181,463.7
The prognosis of patients with PC depends on several factors, especially stage of disease (i.e. extent of 
spread), grade of disease (i.e. histological assessment of aggressiveness, measured by the Gleason sum 
score), PSA level, and extent and volume of disease determined by biopsy. Since the advent of PSA testing, 
there has been a gradual stage migration towards the earlier stages of the disease, such that the majority 
of men (i.e. 80%) with PC are diagnosed when the disease is at the localised stage.8 It has been estimated 
that, of asymptomatic men in whom PC is detected by prostate biopsy following PSA measurement, 
around 50% do not require active treatment.9 Nearly half of patients with clinically diagnosed organ-
confined disease have extraprostatic disease pathologically, whereas one-third of patients with clinically 
diagnosed extraprostatic disease have organ-confined disease pathologically.10,11 With the introduction of 
MRI in clinical management of PC, these numbers are very likely to change.12
Impact of health problem
Many men find themselves with the dilemma of having a persistently elevated PSA level, or persistent 
suspicion of cancer, and a negative biopsy. There are two possible explanations: either cancer has been 
missed (i.e. false-negative) or there is no cancer (i.e. true-negative). This situation can be a source of 
considerable uncertainty and anxiety for patients, families and friends, resulting in reduced QoL. Some 
patients may have friends or relatives who have PC, which may further increase anxiety. In part, anxiety is 
caused by a perceived delay in diagnosis and subsequent treatment.13–15
Most men in whom there is suspicion of cancer but a previous biopsy was negative are asymptomatic. 
Symptoms occur when a tumour causes the prostate gland to enlarge to a significant degree or cancer 
spreads to areas beyond the prostate. A range of symptoms can result, including increased frequency of 
urination, problems starting or stopping urination, a painful burning sensation or blood in urine.16
From a health-care services perspective, a significant amount of time and resources are directed at 
managing men with a suspicion of cancer but negative biopsy. These men are usually monitored 
either 3- or 6-monthly with PSA tests. Significant numbers of men will undergo further biopsies, either 
immediately or subsequently. For these men there is a risk of the diagnosis being delayed, possibly leading 
to disease progression (and hence compromising cure), increased morbidity and the need for more 
costly services.
Measurement of disease
Diagnosis of prostate cancer
Men with an elevated PSA level and/or abnormal DRE undergo a prostate biopsy, which is normally 
performed using TRUS/Bx. Some men with negative biopsies will require a repeat biopsy, either 
immediately [owing to suspicious features on histology, such as atypical small acinar proliferation (ASAP)] 
or subsequently (owing to a further rise in PSA, persistently raised PSA or rapidly rising PSA).17 Achieving a 
diagnosis at repeat biopsy can be challenging either because they have an enlarged central prostate gland 
due to benign prostatic hyperplasia or because cancer is present in locations difficult to biopsy.18 Recently, 
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promising alternatives have emerged, which include MRS and enhanced MRI techniques. Lesions identified 
on MRS/MRI are sampled either by MRI-directed biopsy (tissue obtained under direct MRS/MRI imaging) or 
by TRUS guidance (TRUS/Bx used to identify and biopsy suspicious lesions on MRS/MRI).
Staging
Staging is performed to determine the extent of disease spread. Information from staging is essential, 
because it influences treatment decisions and affects prognosis.
Pre-treatment imaging staging of PC is usually individualised according to risk stratification based on 
clinical parameters that are predictive of the likelihood of extraprostatic disease. These clinical parameters 
normally include pre-treatment PSA level and rate of rise or doubling time, Gleason score, clinical T 
staging and volume of disease detected on biopsy. Imaging potentially improves these general estimates 
of risk by specifically identifying lesions with anatomical abnormalities. The most commonly used imaging 
modalities for staging of PC are MRI, computed tomography (CT), isotope bone scan and positron 
emission tomography.
Staging can be divided into local, regional and distant categories. Local staging is usually performed by 
DRE and MRI; regional staging is performed by either CT or MRI; and distant staging is performed by CT, 
bone scanning and plain bone radiography. In addition, measurement of PSA level in the blood19–21 and 
Gleason sum score22 can also yield useful information regarding stage. Pathological staging determines the 
actual extent of spread (i.e. if it is either confined to, or spread outwith, the prostate gland, or if resected 
lymph nodes have cancer) through histological examination. The staging system most commonly used is 
the tumour, node, metastasis (TNM) staging system.23 This describes the local extent of the primary tumour 
(T stage), the absence or presence of spread to nearby lymph nodes (N stage) and the absence or presence 
of metastasis (M stage).
Grading
Grading is the histological assessment of cancer tissue to determine its aggressiveness. This is done on 
either biopsy tissue, resected tissue (e.g. from transurethral resection of prostate) or surgical specimens. 
Pathologists usually assign a grade from 1 to 5 to the most common tumour pattern observed and then a 
second 1–5 grade to the next most common tumour pattern. The Gleason score is the sum of these two 
grade assignments.24 This scoring system describes a score between 2 and 10, with ‘2’ being the least 
aggressive and ‘10’ being the most aggressive,25 although most pathologists now group scores 1–6 as 
Gleason 6.26
Use of nomograms to predict treatment outcomes
Nomograms are a means of predicting the probability of important outcomes following treatment using 
pre-treatment variables as predictors. For PC, several nomograms exist, which predict various outcomes 
following treatment for men with localised PC, based on pre-treatment variables such as PSA, clinical stage 
and Gleason score. The outcomes predicted include the probability of biochemical disease recurrence 
following curative treatment (Kattan nomograms21,27,28 and the D’Amico nomogram29) and the probability 
of various pathological stages following surgery (Partin tables30). These nomograms may be used by 
clinicians and health-care professionals with patients and their families to facilitate decision-making. Use 
of some of these nomograms has enabled the stratification of men with localised PC into risk groups 
according to their risk of biochemical recurrence if they were treated with radical treatment, such as radical 
prostatectomy or external beam radiotherapy (EBRT) (Table 1).31 Studies have shown the added value of 
MRS and/or MRI in enhancing the value of normograms.32–34
Monitoring of disease following treatment
Men who have undergone curative treatments are monitored via PSA measurements, to ensure 
eradication of disease. Patients who develop disease recurrence will have gradual rises in their PSA level 
(i.e. biochemical recurrence). In addition, men with suspected local recurrence (i.e. in the pelvis) may be 
imaged with either MRI or CT scans, or undergo TRUS-guided prostate biopsy to confirm local disease 
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recurrence. However, the benefit of these investigations remains controversial.17 Patients with more rapid 
rises in PSA level may have disease outside of the pelvis and more extensive investigations are performed, 
including a bone scan.
Current service provision
Management of disease
Management of localised prostate cancer
A range of treatment options exist for men with localised PC, ranging from active surveillance for low-
risk disease, whereby treatment is deferred until the cancer progresses or becomes more aggressive, 
to minimally invasive treatments that ablate a part of the prostate [such as high-intensity focused 
ultrasound (HIFU) and cryotherapy] and to immediate curative treatments (including invasive treatments 
such as radical prostatectomy, radiation treatment or brachytherapy).35 Curative treatments may result 
in significant side effects, including urinary incontinence (UI), erectile dysfunction (ED) or troublesome 
urinary symptoms.36
Based on current National Institute for Health and Care Excellence (NICE) guidance,9 Table 2 outlines 
the alternative treatment modalities recommended by PC stage at time of diagnosis. It has been noted 
that the vast majority of patients identified from second biopsies have localised cancer and few fall into 
TABLE 2 Treatment/surveillance options for patients with newly diagnosed PC
Treatment options
Cancer stage (risk stratification)
Localised 
(low risk)
Localised 
(intermediate risk)
Localised 
(high risk)
Locally 
advanced Metastatic
Hormone 
refractory
Watchful waiting ü ü ü
Active surveillance üa ü
Prostatectomy ü üa üa
EBRT ü üa üa
Brachytherapy ü ü
Cryotherapy
HIFU
EBRT + neoadjuvant/
adjuvant hormone 
therapy
ü
Hormone therapy (first, 
second lines)
ü ü
Chemotherapy ü
a Indicates recommended treatment option for stage.
TABLE 1 Risk stratification for men with localised PC
Risk PSA (ng/ml) Gleason score Clinical stage
Low < 10 and ≤ 6 and T1–T2a
Intermediate 10–20 or 7 or T2b–T2c
High > 20 or 8–10 or T3–T4
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the high-risk group.2,37,38 Based on routinely collected data on hospital episodes in Scotland (Dr Karina 
Laing, MSc in Surgical Sciences thesis, University of Edinburgh, May 2012, personal communication), it 
is estimated that the majority of patients with localised disease receive active surveillance (40%), radical 
prostatectomy (35%) or EBRT (25%) in the first year following diagnosis.
Management of locally advanced prostate cancer
The vast majority of patients with locally advanced PC will undergo potentially curative hormone 
manipulation [castration, luteinising hormone-releasing hormone (LHRH) agonists or antagonists] for a 
minimum of 2 years plus radiotherapy. In the UK, for radical radiotherapy, most men receive 72 grays (Gy) 
in 36–37 fractions.
A small percentage of men may undergo radical prostatectomy for previously unsuspected T3 disease, 
T3 disease with severe lower urinary tract symptoms or patient preference where radiotherapy is 
contraindicated or problematic. Some will be cured by their surgery but those who are not will mostly 
be offered adjuvant radiotherapy. Men who would not benefit from radical treatment because of 
comorbidities are usually offered immediate or deferred hormone manipulation.
Management of metastatic disease
Patients who are initially diagnosed with metastatic disease receive first-line treatment with hormone 
manipulation. When first-line treatment fails, second-line hormone manipulation with the addition 
of an anti-androgen is usually initiated. If this is unsuccessful, those who are fit enough are offered 
chemotherapy. If unsuitable for chemotherapy, or after unsuccessful chemotherapy, third-line hormonal 
treatment may be initiated. Timing of third-line hormonal treatment, with respect to chemotherapy, varies 
throughout the UK and may change with the introduction of abiraterone (Zytiga®, Janssen Biotech).39
Current service cost
It is difficult to estimate current PC diagnosis costs in the UK owing to limitations in the reporting of 
biopsies carried out as outpatient procedures. However, the number of new PC cases diagnosed in 2009 
was 40,841. If we assume that approximately 25%40 of these cancers were detected by repeat TRUS-
guided needle biopsies, and the cancer detection rate is approximately 25%,14,38 then it is not unreasonable 
to assume that approximately 41,000 repeat biopsies were performed in the UK in 2009. The 2009–10 
NHS reference cost for the Healthcare Resource Group (HRG) to which needle biopsy of the prostate 
maps (LB27Z, outpatient procedure) was £212.41 This would suggest an absolute lower limit for the cost 
of repeat prostate biopsies to the NHS of ~£8.7M in 2009. In reality, this will be higher as a significant 
proportion of biopsies will have been reimbursed as day-case activity, and commissioning practice may 
vary by location. Given the limitations of outpatient reporting, it is difficult to ascertain exactly what this 
proportion is.
Considering the impact of diagnosing localised disease, the estimated first-year costs of receiving 
treatment under the modalities reported in Table 2 are presented in Table 3 (see Chapter 5 for details). 
TABLE 3 Estimated average first-year treatment costs per patient identified with cancer through repeat biopsy
Treatment modality
First-year costs per 
patienta (£)
Proportion receiving 
treatment modality
Weighted cost of 
treatment (£)
Active surveillance 284 0.40 113.46
Radical prostatectomy 4650 0.35 1627.44
EBRT 4809 0.25 1202.21
Total 2943.10
a See Chapter 5 for details of cost estimates.
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Assuming again that 25% (10,205) of cancers diagnosed in the UK each year are identified through 
repeat biopsies, and that all are treated with these modalities in the proportions derived from routine 
Scottish data, then the approximate first-year costs to the NHS of treating this cohort would equate to 
approximately £30M.
Variation in services and/or uncertainty about best practice
A degree of variation has been brought about by government targets, meaning that in some centres 
patients undergo a standard T2-weighted magnetic resonance imaging (T2-MRI) of the prostate prior 
to biopsy for lesion detection and staging purposes (the latter just in case a cancer is eventually found). 
The MRI before biopsy strategy in some centres is done so that the wait for a staging MRI after biopsy is 
removed. Most centres still perform their staging MRI post biopsy at around 3–6 weeks to allow time for 
post-biopsy haemorrhage to resolve but this may lead to breaches in national targets.
There are a number of different diagnostic pathways for patients who have an initial negative biopsy. If 
histopathological assessment indicates suspicion of cancer or abnormalities, most centres would proceed 
to a further biopsy, either a repeat 10- to 12-core TRUS/Bx or extended 14–16 core. Some centres would 
perform a pre-biopsy MRI, enhanced MRI techniques or MRS, to assist in targeting larger lesions. Where 
available, some centres may also use TRUS-guided transperineally obtained template biopsies, or TRUS-
guided transrectally obtained saturation biopsies, dependent upon physician preference, the latter usually 
after a second negative TRUS/Bx.
Further variation in services will depend upon:
 z local policy
 z interpretation of national policy (MRI pre biopsy in some centres)
 z access to prostate biopsy services
 z access to MRI, enhanced MRI and MRS facilities
 z access to template biopsy equipment.
Relevant national guidelines, including National Service Frameworks
The 2008 NICE PC guideline9 states that men with high-risk localised and locally advanced PC who 
are being considered for radical treatment should have pelvic imaging with either MRI or CT, if MRI is 
contraindicated. Qualifying statement: ‘there is evidence from observational studies to support making 
this recommendation’. Furthermore, ‘MRS is not recommended for men with PC except in the context of a 
clinical trial’. Qualifying statement: ‘there is no evidence to support routine use of MRS’.
The Prostate Cancer Risk Management Programme in 2006 issued guidance for prostate biopsies 
recommending a 10- to 12-core scheme at first biopsy, which samples the mid-lobe PZ and the lateral 
PZ only (NHS Cancer Screening Programmes. Undertaking a transrectal ultrasound guided biopsy of the 
prostate. 2006. URL: www.cancerscreening.nhs.uk/prostate/pcrmp-guide-1.html). Directed cores should 
also be sampled from any hypoechoic areas identified during the procedure. Anterior/TZ samples may 
be appropriate at a repeat biopsy. However, no comments were made on the number of cores on repeat 
biopsies or any other methods of guiding the biopsy protocol.
The European Association of Urology (EAU) guidelines state17 ‘if clinical suspicion for prostate cancer 
persists in spite of negative prostate biopsies, MRI may be used to investigate the possibility of an anterior 
located prostate cancer, followed by TRUS or MRI-guided biopsies of the suspicious area’.
The European Society of Urogenital Radiology (ESUR) guidelines for MRI in PC,42 issued in April 2012, 
recommend that when TRUS biopsy is negative, and an interval rise in PSA justifies further investigation, 
enhanced MRI using the ‘detection protocol’ must be applied before further TRUS/Bx. In this context, the 
detection protocol consists of T2-MRI, diffusion-weighted magnetic resonance imaging (DW-MRI) and 
dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), with MRS being an option.
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The UK Royal College of Radiologists (RCR) guidelines43 recommend the use of MRI for staging known PC. 
The use of MRI to detect PC is indicated only in specific circumstances, making the comment that ‘MRI is 
capable of detecting prostatic carcinoma when clinical suspicion is high but transrectal US-guided biopsy 
negative. Focal areas of abnormal signal can be targeted for biopsy or repeat biopsy under ultrasound 
guidance’. Guidance published in 2006 by the RCR outlined in detail the usage of MRI in PC emphasising 
T2-MRI. DCE-MRI and MRS were mentioned as techniques that could be useful for staging, therapy 
planning and for detecting recurrent disease. The 2006 RCR guidance is currently being updated under the 
Cancer Staging Proforma Reporting Project (CASPAR),44 which is a pilot programme to test the design and 
utility of proforma-based reporting for a number of cancers. The CASPAR PC imaging proforma provides 
guidance on the use of T2-MRI, DW-MRI and DCE-MRI (Dr Gina Brown, Project Lead, 27 February 2012, 
personal communication). No mention is made of the clinical utility of MRS in this setting. The RCR in its 
guidance does not detail a strategy for evaluating patients with negative TRUS biopsy.
Description of technologies under assessment
Summary of technologies (index tests)
This review is concerned with three technologies: MRS, DCE-MRI and DW-MRI.
Magnetic resonance spectroscopy
Further to imaging of water and lipids, which is normally performed with MRI, MRS is a technique 
that provides detail on protons of molecules other than water and lipids. MRS makes use of the slight 
differences in chemical environment of protons attached to small metabolites present in the tissue or 
organ of interest. Signals of the different protons in these molecules are presented in a spectrum, in which 
the position on the x-axis is representative for the exact so-called chemical shift of the protons at hand 
(which molecule), and the intensity on the y-axis represents the amount of that particular proton pool 
present (how much of that molecule is present). In this way, MRS can give quantitative information on the 
presence and quantity of metabolites in the prostate. Magnetic resonance spectroscopy imaging (MRSI) 
does the same, but also provides this information according to spatial location of spectra superimposed on 
an imaginary two- or three-dimensional grid over the prostate.
In the prostate, three-dimensional MRSI is the current standard of doing spectroscopy, providing spectra 
of the whole organ with a spatial resolution in the order of 0.5 cc.45–47 In the prostate the relative 
concentrations of four metabolites are routinely detectable:
1. citrate, an intermediate of the Krebs cycle, which accumulates in the luminal space of healthy 
prostate tissue
2. choline, free and phosphorylated choline compounds, which are involved in the phospholipid 
metabolism of the cell, elevated in cancer tissue
3. creatine, involved in the energy metabolism of cells
4. polyamines (spermine, spermidine and more), accumulating in the luminal space.
As the chemical shifts of choline, polyamines and creatine do not differ greatly, these resonances cannot 
always be separated, and are therefore incorporated into one clinically useful biomarker for the presence 
of PC: the choline (+ polyamines) + creatine to citrate ratio (CC/C). After spectral fitting of the different 
metabolites, this CC/C ratio can be calculated and used either qualitatively48 or quantitatively49 in the 
so-called standardised threshold approach50,51 to estimate the presence and aggressiveness of cancer in 
prostate tissue.52
Differences in the concentrations of these metabolites between normal and malignant prostate tissues 
allow for increasing the accuracy of staging among less-experienced readers, and decreasing interobserver 
variability.53 Furthermore, correlations have been demonstrated between the metabolic signal pattern 
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and a pathological Gleason score, suggesting the potential for a non-invasive assessment of tumour 
aggressiveness.52,54
Dynamic contrast-enhanced magnetic resonance imaging
Dynamic contrast-enhanced MRI is a fast T1-weighted imaging technique that dynamically measures a 
bolus pass of an intravenously administrated MR contrast agent through the prostate. For its nutrient and 
oxygen supply, a tumour forms new vessels made through the process of neoangiogenesis. In tumour 
tissue these vessels are often leaky or incomplete, which makes it easier for a contrast agent to extravasate 
into the extravascular extracellular space. In this extracellular space, the gadolinium-based contrast agent 
increases the signal intensity of T1-weighted images. In this way, tissues with increased perfusion and 
vessel leakage stand out with respect to normally perfused tissue, which enhances less.
Three-dimensional DCE-MRI measures the time course of the contrast agent passing through the prostate 
by repeatedly acquiring three-dimensional T1-weighted images at high temporal resolution (in the order 
of seconds), providing a signal enhancement curve for every voxel of the three-dimensional MRI data sets. 
These time-curves can be described semiquantitatively or modelled into pharmacokinetic parameters, 
which gives either descriptive measures of the enhancement curve (start of enhancement, wash-in 
gradient, maximum enhancement, time to peak, washout gradient, area under the gadolinium curve, 
etc.) or model parameters (forward leakage rate, washout rate constant and leakage space) usual after 
the fitting to a pharmacokinetic model.55 For an accurate assessment of the model parameters, an arterial 
input function (AIF) is required that describes the shape of the contrast bolus arriving at the prostate. The 
semiquantitative parameters do not need such an AIF. Tumour tissue in the prostate is characterised by 
increased pharmacokinetic parameters compared with healthy tissue. Unfortunately, especially in the TZ 
of older men, benign diseases such as proliferative benign prostatic hyperplasia or prostatitis also show 
marked enhancement after contrast agent administration, making DCE-MRI less specific in the TZ of the 
prostate. Very recently, recommendations have been published on how this technique can best be used.56
Dynamic contrast-enhanced MRI has been shown to be of use in detection and staging of PC within a 
multiparametric protocol57–59 and is especially useful in follow-up after treatment, when normal prostate 
anatomy is either not present60 or disturbed after radiotherapy.61
Diffusion-weighted magnetic resonance imaging
Diffusion-weighted MRI is a technique that evaluates the microscopic mobility of water molecules in 
tissue. Impeded water movements within cellularly dense tissues, such as tumours, appear as high-signal 
regions on diffusion-weighted images and as darker signals on apparent diffusion coefficient (ADC) maps. 
In glandular spaces (healthy prostate luminal spaces) or large extracellular spaces, water motion is less 
impeded, leading to larger signal attenuation (low signal on diffusion-weighted images) and to higher 
ADC values. In addition to its value in the detection of cancer,62,63 DW-MRI has also been shown to be a 
promising marker of tumour aggressiveness, with good correlation between ADC values and Gleason score 
in the PZ of the prostate.64
Current usage in the NHS
As a result of the aforementioned guidelines (see Relevant national guidelines, including National Service 
Frameworks, above), MRI is widely used to evaluate the stage of PC in the UK. Most centres have 1.5-T 
(tesla) scanners, although 3-T machines are found in major teaching hospitals and more recently have 
appeared in non-teaching hospitals. Endorectal coil usage is found only at selected centres. Most centres 
use T2-MRI and DW-MRI routinely for PC imaging, although the quality of DW-MRI is variable on currently 
installed equipment in many centres. Centres with a high volume of PC referrals do perform DCE-MRI in 
selected patients, including patients with prior negative TRUS/Bx and for suspect locally recurrent disease. 
There are very few centres in the UK with prostate MRS experience. Systematic proforma reporting is 
beginning to appear at selected expert centres but this is likely to expand more widely once the findings 
and recommendations of joint RCR/National Cancer Intelligence Network (NCIN) CASPAR project (see 
Relevant national guidelines, including National Service Frameworks, above) are implemented nationwide.
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Anticipated costs associated with the intervention
The anticipated costs associated with the use of MRS/MRI in the diagnostic pathway will depend on the 
specific sequences used. Diagnostic imaging scans of the prostate using T2-MRI, DW-MRI and MRS all 
map to the HRG RA01Z (Magnetic Resonance Imaging Scan, one area, no contrast), whereas sequences 
involving the use of DCE-MRI map to RA03Z (Magnetic Resonance Imaging Scan, one area, pre and 
post contrast). The national average NHS reference costs for RA01Z and RA03Z were £174 and £229, 
respectively, in 2009–10.41 If all 41,000 patients in our estimated annual cohort undergoing a repeat 
biopsy were to receive an MRI scan prior to biopsy (0.4 with pre and post contrast, 0.6 without) then 
this would equate to a cost of approximately £8M to the NHS. If it is assumed that the results of MRI are 
used to direct TRUS biopsies in patients with a visible lesion, while those with no visible lesion receive 
a systematic TRUS/Bx instead, then this £8M represents the additional cost to the NHS of using MRI 
compared with using TRUS alone to guide biopsies. Of course there would be anticipated benefits in terms 
of improved detection rates, reduced need for further biopsies and timely intervention. An alternative way 
of using MRS/MRI could be to use it to safely filter out patients with no visible lesion, such that biopsy 
costs and associated complications would be reduced at the population level. Both these models for its 
use are explored in the chapter on cost-effectiveness. Although the reference costs used in the above 
calculations broadly reflect the cost to the NHS of commissioning different types of MRI, they do not 
capture more subtle differences in costs between different MRI sequences. For this reason we have carried 
out some bottom-up costing of the sequences and combinations of them to inform the cost-effectiveness 
analysis reported in Chapter 5.
Comparator tests
Standard (T2-weighted) magnetic resonance imaging
T2-weighted MR images are usually obtained in two to three planes, with axial and coronal planes being 
the minimum. The axial T2-weighted MRI sequence must cover the entire prostate and seminal vesicles 
with section thicknesses of 3–4 mm. An endorectal coil (ERC) is not an absolute requirement for T2-MRI 
performed on 1.5-T or 3-T scanners but a pelvic phased-array external coil with a minimum of 16 channels 
is required to produce high-quality images. T2-weighted MRI provides the best depiction of the prostate’s 
zonal anatomy, seminal vesicles and the prostatic capsule. T2-MRI is mostly used for PC staging but also 
has some utility for lesion detection and localisation.
It is not recommended that T2-MRI should be used on its own for detection and localisation; it should, 
in general, be used with other enhanced MRI or MRS techniques because their combined use improves 
both sensitivity and specificity.42 PC typically manifests as a round or ill-defined, low-signal-intensity focus 
in the PZ on T2-MRI. However, various conditions [such as prostate intraepithelial neoplasia, prostatitis 
(infection or inflammation), haemorrhage, glandular atrophy, scars from previous infections and biopsies, 
and post-treatment changes] can mimic cancer on T2-MRI in the PZ. The high frequency of non-cancer 
prostate conditions and their ability to affect T2-MRI appearances accounts for the high sensitivity but low 
specificity of T2-MRI for tumour detection and localisation.
Tumours located in the TZ are more challenging to detect on T2-MRI, as the signal intensity characteristics 
of the normal TZ and cancer usually overlap.65 TZ tumour often is shown as a homogeneous signal mass, 
with indistinct margins with lenticular shapes if anteriorly located.
High-grade PCs tend to be larger, more infiltrative and to have lower signal intensity than low-grade 
cancers on T2-MRI, which makes high-grade disease easier to detect.66,67 T2-MRI can be ineffective for 
detecting low-risk PC (small volume disease or sparse variants of Gleason 3 + 3 cancer) because of imaging 
overlaps with non-cancer conditions mentioned above.
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Transrectal ultrasound guided prostate biopsy
The main role of TRUS is to direct biopsies in order to obtain a systematic sampling of the prostate gland 
rather than to target specific lesions, because of the unreliability of greyscale ultrasonography to visualise 
cancer.68,69 A systematic TRUS biopsy simply means that the cores are obtained in an organised manner. 
Template biopsy is a type of systematic biopsy, and uses a grid-based method to guide the random core 
biopsies. A saturation biopsy aims to sample the entire prostate and would routinely use 20 or more cores. 
It should be noted that these techniques are not performed in a targeted manner but rather randomly, 
albeit in a systematic fashion.
It is unclear how repeat biopsies should be performed.70 The standard approach would be to repeat the 
biopsies transrectally under TRUS guidance, increasing the number of cores, and including samples from 
other zones.
As the majority of cancers arise from the PZ of the gland, initial biopsies are targeted at this area.17 The 
sensitivity and specificity of TRUS-guided prostate biopsies in diagnosing cancer vary depending on several 
factors, including the threshold of PSA level used to justify a biopsy, the area of the prostate targeted, 
and the number of prostate tissue cores. Although the patient-level diagnostic accuracy is increased by 
increasing the number of tissue cores,71 this strategy invariably results in more side effects.
Transrectal ultrasound prostate biopsy is usually performed under local anaesthetic as an outpatient 
procedure. Due to the risk of sepsis from the procedure a dose of antibiotic is administered prior 
to the procedure, with one to three doses supplied to the patient postoperatively. The patient is 
commonly positioned in the left lateral position. The scans are performed with either an end- or side-
fire transrectal probe scanning between 7.5 and 9 MHz. A disposable guide is attached over the probe 
prior to its placement in the rectum. Scans are performed in the transverse and longitudinal direction, 
sometimes simultaneously.
Transperineal biopsies are typically performed under a short general anaesthetic. Where the patient has 
a rectum and an anus, a transrectal probe is then introduced to either guide the biopsy needle freehand 
or, in the case of template biopsies, a grid is placed over the perineum and the ultrasound transducer is 
placed into the rectum via a housing that keeps the probe in the correct position. Biopsies are then taken 
using the template with standard 18-gauge needle from predetermined sections of the gland. These can 
then be processed separately to allow a map of the disease to be built up. Biopsies performed in this 
way allow the anterior and apical portions of the gland, which are more difficult to target on transrectal 
biopsies, to be sampled more easily. Where the patient has no rectum the biopsies can be guided using a 
transabdominal probe.
Care pathways
In developing the care pathways, we used a combination of current clinical guidelines and expert 
opinion to devise alternative diagnostic and treatment pathways for the economic modelling reported in 
Chapter 5. The general diagnostic pathway is outlined in Figure 2.
The options for patients following a previous negative biopsy are divided into standard pathways and 
experimental pathways. For the purposes of this review the use of any MRI sequence to direct TRUS/Bx 
is considered experimental, whereas the use of systematic TRUS-guided biopsies is considered standard 
practice. Under standard practice, the options for patients with a previous negative biopsy are to monitor 
PSA and other measures predictive of PC, perform a further standard cores biopsy (10–12 cores based 
on expert clinical opinion) if there is a technical reason to do so, or perform an extended-cores biopsy 
for patients where suspicion of PC remains. For the purposes of the economic modelling carried out in 
Chapter 5, we take patients selected for a repeat biopsy as the starting point for the analysis, and for this 
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cohort the consensus among clinical experts on our team was that a systematic extended-cores biopsy 
(14–16 cores) would be the appropriate comparator under standard practice. The use of MRS/MRI to 
direct TRUS/Bx at this stage offers the alternative experimental approach.
Following a negative result from a second biopsy, patients can remain cycling within the diagnostic 
pathway, with further monitoring of PSA and further repeat biopsies. Clinical opinion within the research 
team was that, in the case of patients selected for a third biopsy, a systematic saturation biopsy would 
probably be performed at this stage. Thus, the economic modelling applied the simplifying assumption 
that any patients with underlying cancer missed by the second biopsy would have persistently elevated 
PSA level and would progress to a TRUS-guided saturation biopsy within 12 months. This last procedure 
is considered the reference standard for the presence of PC. For those patients with no underlying cancer 
(disease negative on a reference standard), the assumption was made that PSA monitoring would continue 
indefinitely and that no further biopsies would be undertaken unless incident cancer developed. Although 
this may seem clinically unrealistic, the proportion of patients with no cancer and their downstream 
management would probably remain constant between the experimental and control arms of the model 
following the index repeat biopsy. Hence, their subsequent treatment, outcomes and costs would not 
influence the decision problem in hand, of whether or not MRS/MRI should be used in men with a 
previous negative biopsy to direct the next biopsy, i.e. we do not model the ongoing use of MRI to direct 
all further repeat biopsies in men who remain negative following their initial MRI-directed TRUS/Bx.
Following a positive diagnosis from any biopsy procedure, staging and subsequent treatment is 
implemented in line with the current guidance by stage and grade of cancer present (see Table 3). The 
Markov model developed to simulate the progression of undiagnosed and diagnosed cancer, and its 
subsequent treatment by stage and grade, is described in detail in Chapter 5.
Standard pathways
Care pathways by cancer
stage
Monitor PSA
Positive
diagnosis
Positive
diagnosis
Negative
biopsy
TRUS
extended
cores biopsy
Technical
indication
MRI, DCE, DWI, or
MRS-directed, TRUS-
guided biopsy
Extended
cores or
saturation
biopsy
Care pathways by cancer
stage
Experimental pathways
FIGURE 2 General diagnostic pathway.
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Chapter 2 Definition of the decision problem
Decision problem
The purpose of this review is to assess the diagnostic accuracy of MRS, DCE-MRI and DW-MRI and the 
clinical effectiveness and cost-effectiveness of strategies involving their use in men with suspected PC and 
elevated PSA level but previously negative biopsy.
Interventions
As data allow, the following tests are considered, alone or in combination:
 z MRS-guided biopsy
 z DCE-MRI-guided biopsy
 z DW-MRI-guided biopsy.
In addition, the above tests are considered in combination with standard (T2-weighted) MRI. In situations 
when both tests are required to be positive for the combination to be positive, the test combination is 
linked by ‘and’. When only one of the tests is required to be positive for the combination to be positive, 
the test combination is linked by ‘or’.
Population including subgroups
The population concerned is men with suspected PC and elevated PSA level of up to 20 ng/ml but 
previously negative biopsy.
The setting considered is secondary or tertiary care.
Where data allow, a subgroup of participants with prostatic intraepithelial neoplasia (PIN) and ASAP 
diagnosed at first biopsy is considered.
Relevant comparators
The comparator tests considered are:
 z standard (T2-weighted) MRI
 z TRUS.
Reference standard
The reference standard is histopathological assessment of biopsied tissue. Tissue samples may be 
obtained by transrectal needle biopsy, saturation biopsy, transperineal template biopsy or from 
prostatectomy specimens.
A maximum follow-up time of 12 months was incorporated into the reference standard. This was to 
distinguish between tumours missed by the index/comparator test (detected before 12 months) and 
interval tumours that were not missed (detected after 12 months).
Outcomes
The following outcomes are considered:
 z Diagnostic performance of MRS, DCE-MRI and DW-MRI in the localisation of abnormalities of 
the prostate.
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These outcomes are considered at both patient-level and biopsy level, where data allow.
The reported Gleason score of the patients diagnosed with PC is presented to assess if index/comparator 
tests detect different grades of tumour.
In studies reporting the above outcome, the following outcomes are also considered, if reported:
 z altered treatment as a result of the tests
 z acceptability of the tests
 z interpretability of the tests
 z effect of testing on QoL (disease-specific and generic instruments)
 z adverse effects of testing.
Key issues
There are several key issues. First, does a single test or a combination of tests provide the greatest 
diagnostic accuracy and cost-effectiveness? MRS, DCE-MRI, DW-MRI or standard (T2-weighted) can be 
used in combination. If a combination of tests is used, is greatest benefit derived when both tests are 
required to be positive or when only one test is required to be positive? Second, are there patient groups 
for which MRS, DCE-MRI and DW-MRI are more effective, for example patients who are diagnosed 
with PIN or ASAP on initial biopsy? Third, does MRS, DCE-MRI or DW-MRI detect more clinically 
significant tumours?
Two significant challenges are worth noting. First, the reference standard (histopathological assessment 
of biopsied tissue) is linked with one of the comparator tests (TRUS). Most studies use TRUS to obtain 
histopathological samples. TRUS can be used to either obtain a systematic, predefined set of biopsies 
(TRUS/Bx) and/or identify suspicious areas. When TRUS is used in a systematic, predefined manner, a 
template is usually used and areas in the prostate are not diagnosed as ‘normal’ or ‘abnormal’. Therefore, 
diagnostic outcomes cannot be measured. However, when TRUS is used to identify ‘abnormal’ areas and a 
subsequent biopsy obtained, diagnostic outcomes can be measured. A number of studies combine these 
two uses of TRUS; suspicious lesions are biopsied and subsequently a systematic, predefined set of biopsies 
is obtained. The situation is further complicated because there is variation in the number and pattern of 
cores obtained on systematic biopsy.
Second, there is no widely accepted definition of ‘guided’, ‘directed’ and ‘targeted’. After a lesion is 
identified on MRS, DCE-MRI, DW-MRI or standard T2-MRI, biopsies can subsequently be obtained using 
a MRI compatible device or TRUS/Bx. For the purposes of this review, the term ‘MRI-guided’ is used when 
biopsies are obtained using a MRI compatible device. The term ‘MRI-directed TRUS-guided’ is used when 
lesions are identified using MRI, but biopsies are obtained using TRUS.
Overall aims and objectives of assessment
This review assessed the diagnostic accuracy of MRS, DCE-MRI and DW-MRI and the clinical effectiveness 
and cost-effectiveness of strategies involving their use in men with suspected PC and elevated PSA level but 
previously negative biopsy. Subsidiary questions to be addressed relating to these techniques included:
 z In which patient group are they most clinically effective?
 z Can they identify cases where PC is present but further procedures are unnecessary?
 z Does their use lead to changes in patient management?
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Chapter 3 Methods for reviewing 
diagnostic accuracy
M ethods were in accordance with the protocol, which is presented in Appendix 1.
Identification of studies
Comprehensive electronic searches were conducted to identify reports of published studies. Highly sensitive 
search strategies were designed including appropriate subject headings and text word terms relating to PC, 
biopsy and the tests under consideration. Searches were restricted to years from 1995 onwards, reflecting 
the time of introduction of the tests, and non-English-language publications were excluded. MEDLINE, 
MEDLINE In-Process and Other Non-Indexed Citations, EMBASE, BIOSIS, Science Citation Index (SCI) and 
the Cochrane Controlled Trials Register (CENTRAL) were searched for primary studies, while the Cochrane 
Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE), MEDION 
and the Health Technology Assessment (HTA) databases were searched for reports of evidence syntheses. 
Recent conference abstracts (2009–11) from the American Society of Clinical Oncology (ASCO) meetings 
were also searched. The date of the last searches was March 2012.
Reference lists of all included studies were scanned in order to identify additional potentially relevant 
reports. The expert panel provided details of any additional potentially relevant reports. Ongoing studies 
were identified through searching Current Controlled Trials (CCT), Clinical Trials, WHO International Clinical 
Trials Registry Platform (ICTRP) and NIH Reporter. Full details of the search strategies used are detailed in 
Appendix 2.
Inclusion and exclusion criteria
Types of studies
For diagnostic accuracy of MRS, DCE-MRI and DW-MRI the following types of studies were included:
 z direct (head-to-head) studies in which index test(s), comparator test(s) and reference standard test 
were done independently in the same group of people
 z randomised controlled trials in which people were randomised to the index and comparator test(s) 
and all received the reference standard test.
In the event that there was insufficient evidence from direct and randomised studies, we considered 
undertaking indirect (between-study) comparisons by meta-analysing studies that compared each single 
test or combination of tests with the reference standard test, and making comparisons between meta-
analyses of the different tests. However, this type of study design is less reliable than direct studies as 
differences in diagnostic accuracy are susceptible to confounding factors between studies. The following 
types of studies were considered:
 z Observational studies, including case series, in which the sample is created by identifying all people 
presenting at the point of testing (without any reference to the test results).
 z Case–control studies in which two groups are created, one known to have the target disease and 
one known not to have the target disease, where it is reasonable for all included to go through the 
tests. We excluded case–control studies comparing severely diseased people with very healthy control 
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subjects or studies excluding people with other urological disease such that the spectrum of disease 
and non-disease was unlike that to be encountered in practice.
The following types of report were excluded:
 z reviews, editorials and opinions
 z case reports
 z reports investigating technical aspects of a test
 z non-English-language reports.
Types of participants
The types of participants considered were men with suspected PC and elevated PSA level but previously 
negative biopsy. Studies were also included in which the participants with previously negative biopsy had 
elevated PSA level and/or abnormal DRE. Studies whose populations included subgroups of men meeting 
these criteria were also included. Studies that included men diagnosed with ASAP or high-grade prostatic 
intraepithelial neoplasia (HGPIN) were included. The setting considered was secondary or tertiary care.
Index tests
The index tests considered were MRS, DCE-MRI or DW-MRI, alone or in combination.
Given sufficient data, we planned to undertake sensitivity analysis around when the studies took place, to 
assess the effects of changes in the technology over time. This was possible only for MRS and T2-MRI.
Comparator tests
The comparator tests considered were standard (T2-weighted) MRI and transrectal ultrasound (TRUS) 
guided prostate biopsy (greyscale only).
Reference standard
The reference standard considered was histopathological assessment of biopsied tissue. Tissue samples 
could be obtained by transrectal needle biopsy, saturation biopsy, transperineal template biopsy or from 
prostatectomy specimens.
A follow-up time of 12 months was specified in the protocol as part of the reference standard. The reason 
for this was to help distinguish between tumours missed by the index/comparator tests (subsequently 
detected within this 12-month period) and interval tumours that were not missed (and subsequently 
detected after the 12-month follow-up period). However, few studies reported a follow-up, and this 
criterion was relaxed to allow those that did not report a period of follow-up but otherwise met the 
remaining inclusion criteria to be included in the review.
Types of outcomes
Studies had to report the diagnostic performance of MRS, DCE-MRI or DW-MRI in the localisation of 
abnormalities of the prostate. In included studies, outcomes relating to altered treatment as a result of the 
tests, acceptability of the tests, interpretability of the tests, effect of testing on QoL and adverse effects of 
testing were also considered.
All included studies reported relevant and interpretable data including the absolute numbers of true-
positives, false-positives, false-negatives and/or true-negatives, or provided information allowing their 
calculation such that at least one indicator of diagnostic performance [i.e. sensitivity, specificity, predictive 
values or likelihood ratio (LR)] was calculable. In addition to studies that reported patient-level analysis, we 
also considered those that reported only a biopsy-level analysis on the basis that these might also provide 
potentially useful information.
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Data extraction strategy
Two reviewers (from MC, JF, KR, PS) independently screened the titles (and abstracts if available) of all 
reports identified by the search strategy. Full-text copies of all studies deemed to be potentially relevant 
were obtained and two reviewers (from MC, JF, GM, KR, PS) independently assessed them for inclusion. 
Any disagreements were resolved by consensus or arbitration by a third party.
A data extraction form was developed and piloted. One reviewer extracted details of study design, 
participants, index, comparator and reference standard tests and outcome data, and a second reviewer 
checked the data extraction. Any disagreements were resolved by consensus.
Critical appraisal strategy
Two reviewers (from MC, JF, GM, KR) independently assessed the risk of bias and applicability concerns 
of all included full-text diagnostic studies using the updated quality assessment of diagnostic accuracy 
studies (QUADAS-2) checklist. The original QUADAS checklist was developed for use in systematic reviews 
of diagnostic studies72 and was designed to be adapted to make it more applicable to a specific review 
topic. QUADAS was developed through a formal consensus method and was based on empirical evidence. 
Following anecdotal reports and feedback which suggested problems with QUADAS, the QUADAS-2 tool 
was developed. QUADAS-2 consists of four key domains: (1) patient selection, (2) index test, (3) reference 
standard, and (4) flow of patients through the study and timing of the index test(s) and reference 
standard. Each domain is assessed in terms of the risk of bias. The first three domains are also assessed 
for concerns regarding their applicability in terms of whether (1) the participants and setting; (2) the index 
test, its conduct or interpretation; and (3) the target condition as defined by the reference standard match 
the question being addressed by the review.
For this review, QUADAS-2 was modified to make it more appropriate for assessing the quality of studies 
of tests for detecting PC. Domains 1 (patient selection) and 4 (flow and timing) were retained in their 
entirety. The title of Domain 2 was amended to ‘index & comparator test(s)’ to accommodate all the 
specified tests. One item was added to the risk of bias section of Domain 2 to assess whether or not tests 
that required subjective interpretation were interpreted by a suitably experienced person. Two items were 
added to the risk of bias section of Domain 3 (reference standard) to assess whether or not (1) the results 
of the reference standard test were interpreted by a suitably experienced person and (2) a follow-up was 
included in the reference standard. The modified tool consisted of 14 items.
Prior to completing the QUADAS-2 tool some decision rules were agreed between reviewers. In general, if 
a particular point was not mentioned in a paper, then the relevant signalling item was marked as ‘unclear’. 
Responses to the risk of bias and applicability questions were based upon the three or four relevant 
signalling questions; in each case, the majority response to signalling questions dictated the overall risk 
of bias or applicability response. There were some exceptions to this. For the Domain 1 (patient selection) 
applicability item ‘Is there concern that the included patients do not match the review question?’, the 
primary criterion was previously negative biopsy, followed by elevated PSA level. The item was classed 
as ‘Low’ if all patients had a previously negative biopsy and > 10% of the sample had elevated PSA 
level. For Domain 2 [index & comparator test(s)], responses of ‘yes’ to the ‘Were the index test results 
interpreted without knowledge of the results of the reference standard?’, ‘not available (N/A)’ to the item 
‘If a threshold was used, was it pre-specified?’, and ‘unclear’ to the item ‘For a test requiring subjective 
interpretation, was it interpreted by someone experienced in interpreting such tests?’ were classed as 
‘low’ risk of bias. For the Domain 2 applicability item, studies that explicitly did not image or analyse the 
entire prostate were classed as high concern for applicability. Otherwise, it was assumed that the entire 
prostate had been imaged and analysed, and studies were classed as low concern for applicability on 
this item. For Domain 3 (reference standard), a ‘no’ response to the item ‘Were the reference standard 
results interpreted without knowledge of the index test?’ and histopathological specimens which had 
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been labelled (as suspicious or not) led to risk of bias being classed as ‘high’, regardless of responses to 
the remaining signalling items. In addition, a ‘no’ response to the item ‘Was a follow-up included in the 
reference standard?’ led to an automatic classification of high risk of bias. Risk of bias for the Domain 4 
(flow and timing) item ‘Were all patients included in the analysis?’ was classed as ‘low’ if the proportion of 
participants included in the analysis was ≥ 90%.
Each item was worded so that a rating of ‘Yes’ was always optimal in terms of methodological quality. Any 
disagreements were resolved by consensus or arbitration by a third party. A sample QUADAS-2 checklist 
used in this review is presented in Appendix 3.
Methods of data synthesis
Data from each study were summarised in a 2 × 2 table of true-positive (TP), false-positive (FP), false-
negative (FN) and true-negative (TN) according to the type of test and whether the primary study analysis 
was based on patient or biopsy level. These 2 × 2 tables were then entered into RevMan 5 software (The 
Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark) and SAS version 9.2 (SAS 
Institute Inc., Cary, NC, USA). All statistical analyses and graphical plots were undertaken in RevMan.
The sensitivity, specificity and their 95% confidence intervals (CIs) were calculated for each 2 × 2 table and 
presented for each test or combination of tests at both patient- and biopsy-level analysis. We investigated 
the presence of heterogeneity by visual examination of pairs of forest plots of sensitivity and specificity.
Sensitivity describes the proportion of those with disease who have positive test results, whereas specificity 
is the proportion of those without disease who have negative test results. A positive predictive value (PPV) 
describes the proportion of those with positive test results who have the disease, whereas a negative 
predictive value (NPV) is the proportion of those with negative test results who do not have the disease. 
A positive LR describes how many more times more likely it is that a person with disease will receive a 
positive test than a person without disease, whereas a negative LR describes how many more times more 
likely it is that a person with disease will receive a negative test result than a person without disease. A 
diagnostic odds ratio (DOR) is a single indicator of test performance and is the ratio of the odds of testing 
positive in those with the disease relative to the odds of testing positive in those without the disease. It 
can be calculated from the sensitivity and specificity values. The DOR summarises the results into a single 
indicator of test performance; however, information contained in sensitivity and specificity is lost and in 
particular a DOR cannot distinguish between tests with high sensitivity and low specificity and vice versa.
We undertook meta-analysis, where adequate data were available, using METADAS macro73 to fit 
hierarchical summary receiver operating characteristic (HSROC) models in SAS. HSROC models including 
random effects terms for variation in accuracy and threshold between studies, and non-symmetrical 
underlying receiver operating characteristic (ROC) curves, were fitted. The average operating point for 
each test was identified on each curve, and average sensitivities and specificities computed. Comparisons 
between tests were made by adding a covariate for test type to the accuracy and threshold parameters 
assuming a common underlying shape.
The comparative analysis was between all tests with three or more studies with relevant data. Comparative 
analysis consisted of uncontrolled/indirect comparison where all tests with relevant data were compared by 
adding covariates for a test type to the threshold and accuracy assuming a common underlying shape. A 
second comparative analysis of paired design where patients received both tests was also conducted.
Given sufficient evidence, we planned to undertake sensitivity analysis to assess the impact of the different 
number of biopsy cores taken (< 10 cores and ≥ 10 cores) on the accuracy of the tests. However, there was 
insufficient evidence to undertake such an analysis.
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Chapter 4 Assessment of diagnostic accuracy
This chapter is structured as follows. The next section (see Quantity of research available, below) provides information on the quantity of research available, including characteristics and risk of bias of the 
included studies. The section Results: assessment of diagnostic accuracy reports the diagnostic accuracy 
results: individual index and comparator tests (see Magnetic resonance spectroscopy, Dynamic contrast-
enhanced magnetic resonance imaging, Diffusion-weighted magnetic resonance imaging, T2-weighted 
magnetic resonance imaging and Transrectal ultrasonography); studies directly comparing two or more 
tests (see Studies directly comparing tests); combinations of tests (see Studies reporting combinations 
of tests) and indirect comparison of tests (see Indirect comparison). Meta-analyses are included where 
appropriate and feasible, and patient- and biopsy-level analyses are reported separately. Information on 
false-positives is provided in False-positive results and information on the detection of clinically significant 
disease is provided in Detection of clinically significant disease. The section Results: assessment of non-
diagnostic outcomes provides information on non-diagnostic outcomes, followed by a chapter summary 
(see Summary).
Quantity of research available
Number and type of studies included
Appendix 4 lists the 51 studies, published in 65 reports (41 full-text papers57,74–113 and 24 abstracts114–137) 
that were included in the review of diagnostic accuracy. Figure 3 shows a flow diagram outlining the 
screening process, with reasons for exclusion of full-text papers.
4478 titles and abstracts screened
3671 excluded 
742 reports excluded: 
Participant no previous biopsy or unclear
Diagnostic outcomes not reported
Invalid study design
Invalid test(s)
Reference standard not appropriate
Retained for background
Not available
431
158
97
28
3
12
13
Included
65 reports of 51 studies
Selected for full-text assessment
807 reports
FIGURE 3 Screening process.
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Number and type of studies excluded
A list of full-text papers that were excluded along with the reasons for their exclusion is given in 
Appendix 5. These reports were excluded because they failed to meet one or more of the inclusion criteria 
in terms of the type of study, participants, test, reference standard or outcomes reported.
Characteristics of the included studies
Appendix 6 displays the characteristics of the 51 included studies. Table 4 presents summary information 
for the included studies. There were 39 full-text papers.57,74–84,86–93,95–113 Twenty-seven studies involved 
consecutive samples.57,74,76,78,79,81,84,86,87,89–93,95,97,100,101,104–106,108,111,112,118,127,133 Twenty-four studies did 
not report this information.75,77,80,82,83,88,96,98,99,102,103,107,109,110,113,115–117,120,126,130,134,136,137 There were 
41 prospective studies57,74–76,79–84,86,88–90,92,93,95,99–101,103–106,108,109,111–113,115–118,120,126,127,130,133,134,136,137 and 
10 retrospective studies.77,78,87,91,96–98,102,107,110
Fourteen studies included a follow-up in the reference standard: Campodonico et al.77 and Ukimura et 
al.107 did not report the length of follow-up; Hoeks et al.87 reported follow-up of 5 months; Lin et al.91 
reported a total follow-up of 18 months with only the initial 12 months taken into account for the present 
review; Lopez-Corona et al.92 reported follow-up of up to 97 months; Pepe et al.97 reported follow-up 
of up to 22 months; Philip et al.98 reported follow-ups of 3 and 6 months; Quinlan et al.102 reported 
follow-up of up to (a mean of) 50 months; Yanke et al.110 reported a mean period of 30 months between 
first and last biopsy. Djavan et al., Keetch et al., Pinsky et al., Roehl et al. and Zackrisson et al. reported 
population-based screening studies in which participants with negative biopsies were followed up every 
6 or 8 weeks, 6 months, 12 months, 6 months and 2 years, respectively.81,88,99,103,113
Eighteen studies74,76,79,84,95,100,101,104–106,108,111,115,117,118,120,130,134 reported diagnostic test accuracy 
for MRS (alone or in combination with other tests). Twelve studies78,84,86,87,89,90,95,100,104,105,109,133 
reported diagnostic test accuracy for DCE-MRI (alone or in combination with other tests). Eleven 
studies84,86,87,89,96,100,104,109,116,126,133 reported diagnostic test accuracy for DW-MRI (alone or in combination 
with other tests). Twenty-six studies57,74,76,78,79,82,84,86,87,89,90,100,104,106,108,109,112,116–118,126,127,130,134,136,137 
reported diagnostic test accuracy for T2-MRI (alone or in combination with other tests). Twenty-two 
studies57,75,77,80,81,83,88,91–93,96–99,102,103,107,110,111,113,120,136 reported diagnostic test accuracy for TRUS (alone or in 
combination with other tests).
Seven studies82,84,86,87,104,108,109 involved MRI-guided biopsies and 44 
studies57,74–81,83,88–93,95–103,105–107,110–113,115–118,120,126,127,130,133,134,136,137 involved TRUS-guided biopsies.
Of the 18 studies84,104,112,115,117,120,130 that involved MRS, seven did not report a threshold for a positive test. 
Four studies74,79,100,118 reported a threshold of the CC/C ratio of > 0.86. Two studies95,105 used a threshold of 
CC/C > 0.80. Two studies101,106 reported a threshold of CC/C ratio more than three standard deviations (SDs) 
above the mean healthy value. Bhatia et al.76 reported using the mean healthy CC/C to adjust a primary 
score to obtain a final voxel score. Wefer et al.134 reported abnormal metabolism as areas with four or 
more voxels with a CC/C ratio more than two SDs. Wetter et al.108 used a threshold of CC/C > 0.6.
Twelve studies were undertaken in the USA,75,88,90,92,99,103,107,110,127,130,134,136 eight in Italy,77,79,95,97,105,106,118,133  
six in Germany,57,82,84,89,104,108 four each in France74,78,100,137 and the Netherlands,80,86,87,109 three in Republic 
of Korea,96,116,126 two each in Singapore,111,112 Spain115,117 and Turkey83,93 and one each in Brazil,101 
Ireland,102 Sweden,113 Taiwan, Province of China,91 Thailand,76 Islamic Republic of Iran120 and the UK.98 One 
multicentre study was undertaken in Austria, Belgium, France and Poland.81
The 51 diagnostic studies enrolled 92,588 participants, with 10,264 included in the analysis. In 
18 studies, the number of participants analysed was less than the number of participants enrolled. Of 
these, six81,88,97,99,103,113 were large-scale screening studies in which only some of the participants matched 
the inclusion criteria of this review and were reported separately. The differences between the numbers 
enrolled (86,749) and the much smaller numbers matching the inclusion criteria for this review (5771) 
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TABLE 4 Summary of the characteristics of the diagnostic accuracy studies
Characteristic No. No. of studies
Patients
Enrolleda 92,588 50
Analysed 10,264 51
Age (years) 
Median (range) of means 63.5 (60.3 to 68.1) 24 (47%)
Median (range) of medians 66 (62 to 69) 7 (14%)
Other format/not reported – 20 (39%)
Baseline PSA (ng/ml)
Median (range) of means 10.8 (6.4 to 16) 17 (33%)
Median (range) of medians 10 (5.5 to 19.5) 8 (16%)
Other format/not reported – 26 (51%)
Participants at initial biopsy with
ASAP 217 (2%) 4 (8%)
HGPIN 199 (2%) 5 (10%)
Test results reported
MRS 772 (8%) 18 (35%)
DCE-MRI 1094 (11%) 12 (23%)
DW-MRI 1021 (10%) 11 (22%)
T2-MRIb 1615 (16%) 26 (51%)
TRUS 8105 (79%) 22 (43%)
Biopsy guidance
T2-MRI 538 (5%) 7 (14%)
TRUS 9726 (95%) 44 (86%)
Prostate size (cc)
Median (range) of means 53.9 (42.5 to 59.3) 4 (8%)
Median (range) of medians 54.9 (41 to 67) 3 (6%)
Other format/not reported – 44 (86%)
a No. of participants enrolled not reported by Comet-Batlle.
b Studies that used T2-MRI in combination with other MRI modalities, but did not report results for T2-MRI not 
included in these totals.
in these six studies81,88,97,99,103,113 largely accounted for the difference in numbers between those enrolled 
and those analysed shown in Table 4. In five studies,57,105,108,127,136 not all participants had a previous 
negative biopsy (those with a previous negative biopsy were reported separately). Two studies84,86 involved 
participants withdrawing because of comorbidities. The study by Destefanis et al.118 was an ongoing 
study in which not all enrolled participants had reached the point of analysis. Hoeks et al.87 analysed only 
participants who underwent a follow-up MR-guided biopsy. The study by Panebianco et al.95 involved 
analysing urine samples, not all of which were successful. In the study by Testa et al.,106 data from four 
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participants were not analysed because of poor MRS quality. Yakar et al.109 analysed only participants in 
whom scanning revealed cancer-suspicious regions.
Across 24 studies reporting mean age,57,74–76,78–82,86,92,93,95,96,98–100,105–107,112,120,136,137 the median (range) of 
means was 63.5 years (60.3 to 68.1 years). Seven studies84,87,90,101,104,108,109 reported median values for age 
and the median (range) of medians was 66 years (62 to 69 years). Eight studies77,83,89,97,102,111,126 reported 
age in other formats. Twelve studies88,91,103,113,115–118,127,130,133,134 did not report this information.
Across 17 studies57,74–76,78,79,81,82,92,93,95,96,100,101,106,120,136 reporting mean baseline PSA, the median 
(range) of means was 10.8 ng/ml (6.4 to 16 ng/ml). Eight studies80,84,86,87,90,104,108,109 reported median 
baseline PSA levels, the median (range) of medians being 10 ng/ml (5.5 to 19.5 ng/ml). Eleven 
studies83,88,89,97,99,102,105,110,111,112,126 reported baseline PSA in other formats. The remaining 15 studies did not 
report baseline PSA levels.
At initial biopsy, four studies75,90,110,118 reported a total of 217 participants with ASAP and five 
studies75,79,83,90,110 reported a total of 199 participants with HGPIN. In the study by Destefanis et al.,118 all 
participants had been diagnosed with ASAP on enrolment.118 One study96 included three participants (out 
of 43 participants analysed) with a history of radiation therapy for PC.
Four studies75,78,81,106 reported mean prostate size, with the median (range) of means being 53.9 cc 
(42.5 to 59.3 cc). Three studies87,90,104 reported median prostate size, with the median (range) of medians 
being 54.9 cc (41 to 67 cc). Seven studies79,80,83,126,105,110,111 reported prostate size in other formats. The 
remaining 37 studies did not report prostate size.
Eight studies57,76,82,88,91,103,108,113 reported six or fewer cores taken in the previous biopsy 
scheme. Eleven studies74,77,80,81,86,93,96,97,105,116,126 reported between 8 and 12 cores taken in 
the previous biopsy scheme. Eskicorapci et al.83 and Yuen et al.111 reported six or 10 cores, 
and Yanke et al.110 reported 6 or 12 cores taken in the previous biopsy scheme. Twenty-nine 
studies75,78,79,84,87,89,90,92,95,98–102,104,106,107,109,112,115,117,118,120,127,130,133,134,136,137 did not report this information.
Risk of bias of the included studies
All 39 full-text papers were assessed using a modified version of the QUADAS-2 tool containing 14 items. 
Figure 4 presents a summary of the results for the risk of bias and concerns for applicability QUADAS-2 
domains across the 39 full-text papers. Appendix 7 presents results of risk of bias and applicability 
concerns for the individual studies.
The majority of studies were considered to have a low risk of bias for the patient selection (74%, 29/39), 
index test (100%, 39/39) and flow and timing (92%, 36/39) domains. The 10 studies for which risk of 
bias for patient selection was unclear did not report exclusion criteria or whether or not the sample was 
consecutive.75,77,82,83,88,96,98,102,103,110 Three studies (8%) were considered at high risk of bias for the flow and 
timing domain; patients did not all receive a reference standard and all patients were not included in the 
analysis.57,87,109 In two studies (5%) patients did not all receive the same reference standard.87,109
In the reference standard domain, the majority of studies (64%, 25/39) were considered at high risk 
of bias, although the risk of bias for the remaining 14 (36%) studies was considered unclear. All 25 
studies were classed as high risk of bias in this domain owing to having no follow-up included in the 
reference standard.57,74–76,78–80,82–84,86,89,90,93,95,96,100,101,104–106,108,109,111,112 Five of these studies78,83,89,93,101 also 
involved the reference standard not being interpreted without knowledge of the index test. None of the 
14 studies77,81,87,88,91,92,97–99,102,103,107,110,113 that did include a follow-up in the reference standard reported 
whether or not the reference standard was interpreted without knowledge of results of the index test. In 
addition, 13 (33%) studies77,81,88,91,92,97–99,102,103,107,110,113 did not report whether or not the reference standard 
was interpreted by an experienced person.
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All 39 studies had low concern for applicability for the reference standard domain and the majority had 
low concerns for applicability for the patient selection domain (95%, 37/39). The study by Labanaris et 
al.89 was classed as high concern for applicability for patient selection due to specification of the inclusion 
criteria as ‘one of the following’ (p. 66), which may have resulted in some participants having a suspicious 
DRE but not a raised PSA level.89 The study by Yanke et al.110 was also classed as high concern in this 
domain as patient preference was one of the inclusion criteria. Thus, patients with normal PSA levels and 
DRE may have opted to have a biopsy, albeit all had undergone a previous negative biopsy.110
A majority of studies had low concern for applicability for the index test domain (87%, 34/39). One 
study76 was classed as unclear in this domain as both normal and equivocal index tests were categorised 
as negative for malignancy.76 There was therefore the possibility that some test results classed as equivocal 
may ultimately have been positive. Four studies79,100,101,111 for which there was high concern for applicability 
for the index test did not report findings relating to the entire prostate; three studies79,100,111 involved the 
PZ only and one study101 did not include the central gland.
Results: assessment of diagnostic accuracy
Individual study results are presented in Appendix 8.
0
0
20 40 60 80
20 40 60 80
100
Patient selection
Patient selection
Index test
Index test
Reference standard
Reference standard
Flow and timing
Proportion of studies with low, high or unclear
risk of bias (%)
Q
U
A
D
A
S-
2 
D
o
m
ai
n
Q
U
A
D
A
S-
2 
D
o
m
ai
n
Low
High
Unclear
100
Proportion of studies with low, high or unclear
concerns regarding applicability (%)
Low
High
Unclear
FIGURE 4 Summary of risk of bias and applicability domains.
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Magnetic resonance spectroscopy
Patient-level analysis
Ten studies74,76,79,101,105,106,108,112,115,120 involving 438 patients reported the diagnostic accuracy of MRS and 
provided sufficient information for inclusion in a meta-analysis. All used a (10- or 12-core) TRUS-guided 
approach plus additional targeted cores on MRS equivocal or suspicious areas, apart from the study by 
Wetter et al.,108 which used a MRI-guided approach. Four studies reported the CC/C ratio used as the 
cut-off for a positive test result, which ranged from > 0.6108 to > 0.86.79
Across the studies the median (range) prevalence of PC was 34.5% (9.5% to 48.9%). The number of 
previous biopsy sessions the participants had undergone ranged from one105 to two to six.101 Most studies 
reported that participants had undergone one to three, or one to four, previous biopsy sessions. The 
number of cores extracted in the previous biopsy session ranged from six76,108 to (a mean of) 16.106
The studies were judged to have low risk of bias for the patient selection, index test and flow of timing 
domains. All studies were judged to have a high risk of bias for the reference standard domain owing to 
a lack of follow-up. All studies were judged to have low applicability concerns for the patient selection, 
index test and reference standard domains, apart from, for the index test domain, Cirillo et al.79 (only PZ 
assessed) and Prando et al.101 (central gland not assessed).
Figure 5 shows the sensitivity and specificity of the individual studies, pooled estimates and SROC curve. 
The pooled (95% CI) estimates for sensitivity and specificity were 92% (86% to 95%) and 76% (61% to 
87%), respectively.
All of the studies reported sensitivity of ≥ 88% apart from Yuen et al.112 (71%). Yuen et al.112 suggested 
that contributory factors to the low sensitivity reported might have been (1) difficulties in ensuring the 
correspondence of TRUS biopsy spatial accuracies to suspicious areas on MRS and (2) that MRS did not 
cover the entire PZ of the gland. The studies by Prando et al.101 and Testa et al.106 reported low specificity 
(both 44%). Prando et al.101 reported results either when a voxel score of 4 or 5, or just 5, was used as 
a cut-off for a positive test result. The results using the cut-off of 4 or 5 were included in the pooled 
estimates. However, if the results using a cut-off of just 5 had been used this would have increased the 
specificity to 84% but reduced the sensitivity from 100% to 70.6%. Testa et al.106 suggested that the low 
specificity in their study was probably determined by the lower CC/C ratio used (actual value not reported) 
compared with cut-offs used by other studies.
A sensitivity analysis comparing pooled estimates of the results of earlier studies (pre 2007) with those 
of studies published more recently (2007 onwards) found no significant differences between the two 
subgroups. The pooled (95% CI) estimates for sensitivity and specificity were pre 2007, 93% (80% to 98%) 
and 71% (43% to 89%); 2007 onwards, 91% (84% to 95%) and 79% (60% to 90%) (see Appendix 9).
Biopsy-level analysis
Six studies76,79,100,101,106,112 reported the diagnostic accuracy of MRS at biopsy or other non-patient-level 
analysis and provided sufficient information for inclusion in a meta-analysis. Figure 6 shows the sensitivity 
and specificity of the individual studies, pooled estimates and SROC curve. The units of analyses reported 
by the studies included biopsy,76 site,79 segment,100 region106 and core.112 The pooled (95% CI) estimates for 
sensitivity and specificity were 66% (46% to 82%) and 89% (86% to 92%), respectively.
Testa et al.106 also reported region-based analysis separately for the PZ (sensitivity 64.9%, specificity 85.8%) 
and the TZ (sensitivity 72.2%, specificity 93.2%).
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Dynamic contrast-enhanced magnetic resonance imaging
Patient-level analysis
Three studies78,90,105 involving 209 patients reported the diagnostic accuracy of DCE-MRI and provided 
sufficient information for inclusion in a meta-analysis. All used a (10-core or at least 12-core) TRUS-guided 
approach plus additional targeted cores from suspicious areas on the imaging test.
Across the studies the median (range) prevalence of PC was 48.9% (24.7% to 53.8%). The number of 
previous biopsy sessions the participants had undergone ranged from one105 to one to twelve.90 The 
number of cores extracted in the previous biopsy session was 10,105 and (a mean of) 12.6,78 although 
this information was not reported by Lattouf et al.90 The studies were judged to have low risk of bias and 
applicability concerns for all domains, apart from the reference standard domain where all three were 
judged to be at high risk of bias due to a lack of follow-up.
Figure 7 shows the sensitivity and specificity of the individual studies, pooled estimates and SROC curve. 
The pooled (95% CI) estimates for sensitivity and specificity were 79% (69% to 87%) and 52% (14% 
to 88%), respectively. Compared with the other two studies, the study by Sciarra et al.105 reported high 
specificity (91%). This study actually reported sensitivity of 84.6% and specificity of 82.3%; however, 
using the actual 2 × 2 data presented in the paper led to a calculation of 79.5% for sensitivity and 91.3% 
for specificity, and these were the data used in the pooled estimates. However, there was no obvious 
explanation for the large difference in specificity values between this study and the other two studies.
Biopsy-level analysis
Four studies78,100,105,133 reported the sensitivity and/or specificity of DCE-MRI at biopsy or other non-patient-
level analysis (Table 5). Across these studies the median (range) sensitivity and specificity was 64.0% 
(29.3% to 80.0%) and 83.5% (76.7% to 93.5%), respectively.
Diffusion-weighted magnetic resonance imaging
Patient-level analysis
One study, by Park et al.,96 reported a patient-level analysis for DW-MRI. This study, involving 43 patients, 
employed an MRI-directed, TRUS-guided approach, with at least two cores from suspicious DW areas 
followed by a 6-, 8- or 10-core biopsy. The study reported a sensitivity of 100% (specificity not reported).
Biopsy-level analysis
Three studies reported DW-MRI at biopsy or other non-patient-level analysis.96,100,133 The study by Portalez 
et al.100 used a 12- to 34-core TRUS-guided approach plus two biopsies of suspicious MRI areas. In a 
segment level analysis (n = 408) they reported a sensitivity of 39.0% and specificity of 96.0%. Valentini et 
al.133 used a 24-core TRUS/Bx (transperineal) approach plus additional biopsies of suspicious MRI areas. In 
a biopsy-level analysis (number of biopsies not stated) they reported a sensitivity of 60% (specificity not 
reported). In the study by Park et al.96 reporting a core level analysis (number of cores not stated), from the 
information provided it was possible to calculate PPV (78.9%) but not sensitivity or specificity.
T2-weighted magnetic resonance imaging
Patient-level analysis
Fifteen studies57,74,76,78,79,84,90,101,106,108,112,128,134,136,137 involving 620 patients reported the diagnostic accuracy 
of T2-MRI and provided sufficient information for inclusion in a meta-analysis. All used a (mostly 10- or 
12-core) TRUS-guided approach plus additional targeted cores on T2-MRI equivocal or suspicious areas, 
apart from the studies by Franiel et al.84 and Wetter et al.,108 which used a MRI-guided approach.
Across the studies the median (range) prevalence of PC was 35.7% (9.5% to 53.8%). The number of 
previous biopsy sessions the participants had undergone ranged from 1108 to 1–12.90 Most studies reported 
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that participants had undergone somewhere in the region of between one to six previous biopsy sessions. 
The number of cores extracted in the previous biopsy session ranged from 4 or 657 to (a mean of) 12–14.112
The studies were judged to have low risk of bias for the patient selection, index test and flow of timing 
domains, apart from, for the flow and timing domain, Beyersdorff et al.57 (not all patients were included in 
the analysis).57 All studies were judged to have a high risk of bias for the reference standard domain owing 
to a lack of follow-up. All studies were judged to have low applicability concerns for the patient selection, 
index test and reference standard domains, apart from, for the index test domain, Bhatia et al.76 (both 
normal and equivocal results were classed as negative), Cirillo et al.79 (only PZ assessed) and Prando et al.101 
(central gland not assessed).
Figure 8 shows the sensitivity and specificity of the individual studies, pooled estimates and SROC curve. 
The pooled (95% CI) estimates for sensitivity and specificity were 86% (74% to 93%) and 55% (44% to 
66%), respectively.
Four studies74,78,108,112 reported sensitivity of 60% or lower. There was no obvious explanation for this in 
the studies by Amsellem-Ouazana et al.74 or Cheikh et al.78 In the study by Wetter et al.108 only six patients 
had undergone a previously negative biopsy and this study also extracted biopsies transgluteally.108 Yuen 
et al.112 suggested that contributory factors to the low sensitivity reported might have been (1) difficulties 
in ensuring the correspondence of TRUS biopsy spatial accuracies to suspicious areas on MRS and (2) that 
MRS did not cover the entire PZ of the gland. Four studies57,84,90,101 reported specificity of 35% or lower. 
There was no obvious explanation for this in the studies by Franiel et al.84 and Prando et al.101 Beyersdorff 
et al.57 reported results either when suspicious and inconclusive, or just suspicious, were used as a cut-
off for a positive test. The results using the cut-off of suspicious and inconclusive were included in the 
pooled estimates. However, if the results using a cut-off of just suspicious had been used this would have 
increased the specificity to 61.5% but reduced the sensitivity from 100% to 83.3%. The study by Lattouf et 
al.90 reported sensitivity of 40% and specificity of 69.5%; however, using the actual 2 × 2 data presented 
in the paper led to a calculation of 92.9% for sensitivity and 16.7% for specificity, and these were the data 
used in the pooled estimates.90
A sensitivity analysis comparing pooled estimates of the results of earlier studies (pre 2007) with those 
of studies published more recently (2007 onwards) found no significant differences between the two 
subgroups. The pooled (95% CI) estimates for sensitivity and specificity were pre 2007, 83% (63% to 94%) 
and 56% (39% to 71%) and 2007 onwards, 88% (72 to 95%) and 55% (41 to 69%) (see Appendix 10).
Biopsy-level analysis
Eight studies57,76,78,79,84,100,106,112 reported the diagnostic accuracy of T2-MRI at biopsy or other non-patient-
level analysis and provided sufficient information to be included in a meta-analysis. Figure 9 shows the 
sensitivity and specificity of the individual studies, pooled estimates and SROC curve. The units of analyses 
reported by the studies included biopsy,57,76 sector,78 site,79 region,84,106 segment100 and core.112 The 
TABLE 5 Dynamic contrast-enhanced MRI: individual study results (biopsy-level analysis)
Study ID Level of analysis No. analysed Sensitivity (%) Specificity (%)
Cheikh 200978 Sector 670 52.3 83.5
Portalez 2010100 Segment 408 29.3 93.5
Sciarra 2010105 Core NR 75.6 76.7
Valentini 2010133 Biopsy NR 80.0 NR
NR, not reported.
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pooled (95% CI) estimates for sensitivity and specificity were 54% (42% to 66%) and 87% (75% to 94%), 
respectively.
Testa et al.106 also reported region-based analysis separately for the PZ (sensitivity 27.0%, specificity 95.8%) 
and the TZ (sensitivity 61.1%, specificity 98.9%).
Transrectal ultrasonography
Patient-level analysis
Twenty-one studies57,75,77,80,81,83,88,91–93,96–99,102,103,107,110,111,113,120 involving 8393 patients reported the sensitivity 
and/or specificity of systematic TRUS-guided biopsies. See Appendix 11 for the individual study results.
Eleven of these studies57,75,80,81,83,92,93,96,103,107,111 included the use of TRUS as an imaging test, of which 
six,57,75,80,83,93,111 involving 782 patients, provided sufficient information for inclusion in a meta-analysis. The 
number of cores extracted ranged from 8 or 1280 to 15.93
Across the six studies57,75,80,83,93,111 the median (range) prevalence of PC was 26.5% (14.4% to 31.6%). 
The number of previous biopsy sessions the participants had undergone ranged from 180,93 to 1–6.57 The 
number of cores extracted in the previous biopsy session ranged from 4 or 657 to 12.93
Most studies were judged to have low risk of bias for the patient selection, index test and flow of timing 
domains. The study by Babaian et al.75 was judged to be of unclear risk of bias for patient selection (did 
not report whether or not participant sample was consecutive or provide exclusion criteria) and for the 
index test (did not report whether or not the test was interpreted by an experienced person). The study 
by Eskicorapci et al.83 was also judged to be of unclear risk of bias for patient selection (did not report 
whether or not participant sample was consecutive or provide exclusion criteria). The study by Beyersdorff 
et al.57 was judged to be at high risk of bias for the flow and timing domain (not all participants received 
a reference standard and not all were included in the analysis). All studies were judged to have a high 
risk of bias for the reference standard domain owing to a lack of follow-up. All studies were judged to 
have low applicability concerns for the patient selection, index test and reference standard domains, apart 
from, for the index test domain, Yuen et al.,111 which was judged to have high applicability concerns (only 
PZ assessed).
Figure 10 shows the sensitivity and specificity of the individual studies, pooled estimates and SROC curve. 
The pooled (95% CI) estimates for sensitivity and specificity were 27% (16% to 42%) and 81% (77% to 
85%), respectively.
Six large-scale population screening studies enrolling 86,749 participants provided information on the 
performance of systematic biopsies using a TRUS-guided approach on a subset of their populations who 
had a previously negative biopsy (n = 5771).81,88,97,99,103,113 The number of cores taken ranged from 4–688,103 
to 16–21.97 It was not possible to calculate specificity because the procedure merely extracted cores for 
histopathological assessment and therefore there were no positive or negative test results as such. It was 
possible to calculate sensitivity on the basis that, for participants with a first negative biopsy, cores taken 
during the second biopsy session and assessed histopathologically as positive were considered true-
positive. For those patients negative on the second biopsy, cores taken during subsequent biopsy sessions 
and assessed histopathologically as positive were considered to be false-negative on the second biopsy 
session, thereby allowing sensitivity to be calculated. Across these studies the median (range) sensitivity 
was 72.5% (60.6% to 96.3%). In effect these studies provided an indication of the sensitivity of the 
reference standard, which is influenced by the method by which tissue samples are obtained. Across all of 
the 10 non-imaging TRUS/Bx studies,77,88,91,97–99,102,110,113,120 the median (range) sensitivity was 72.5% (59.3% 
to 96.3%). The number of cores taken ranged from 4–688 to 16–21.97
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Mowatt et al. under the terms of a commissioning contract issued by the Secretary of State for 
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17200 HealtH tecHnOlOgy assessment 2013 VOl. 17 nO. 20
33
Se
n
si
ti
vi
ty
 a
n
d
 s
p
ec
if
ic
it
y 
– 
in
d
iv
id
u
al
 s
tu
d
y 
re
su
lt
s 
Po
o
le
d
 e
st
im
at
es
 (
95
%
 C
I)
SR
O
C
 c
u
rv
e
Se
n
si
ti
vi
ty
Sp
ec
if
ic
it
y 
D
O
R
LR
+
LR
–
0.
27
 (
0.
16
 t
o
 0
.4
2)
0.
81
 (
0.
77
 t
o
 0
.8
5)
1.
61
 (
0.
70
 t
o
 3
.7
1)
1.
44
 (
0.
77
 t
o
 2
.6
9)
0.
90
 (
0.
73
 t
o
 1
.1
1)
St
u
d
y
B
ab
ai
an
 2
00
07
5
B
ey
er
sd
o
rf
f 
20
02
57
d
e 
la
 R
o
se
tt
e 
20
09
80
Es
ki
co
ra
p
ci
 2
00
78
3
O
zd
en
 2
00
59
3
Y
u
en
 2
00
41
11
39 4 2 10 7 2
32 3 31 34 8 3
42 8 18 44 9 13
16
4 23 88 12
3 36 39
0.
48
 (
0.
37
 t
o
 0
.6
0)
0.
33
 (
0.
10
 t
o
 0
.6
5)
0.
10
 (
0.
01
 t
o
 0
.3
2)
0.
19
 (
0.
09
 t
o
 0
.3
1)
0.
44
 (
0.
20
 t
o
 0
.7
0)
0.
13
 (
0.
02
 t
o
 0
.4
0)
0.
84
 (
0.
78
 t
o
 0
.8
9)
0.
88
 (
0.
70
 t
o
 0
.9
8)
0.
74
 (
0.
65
 t
o
 0
.8
2)
0.
78
 (
0.
71
 t
o
 0
.8
5)
0.
82
 (
0.
67
 t
o
 0
.9
2)
0.
93
 (
0.
81
 t
o
 0
.9
9)
TP
FP
FN
TN
Se
n
si
ti
vi
ty
Sp
ec
if
ic
it
y
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
0.
0 1
.0
0.
9
0.
8
0.
7
0.
6
0.
5
0.
4
0.
3
0.
2
0.
1
Sp
ec
if
ic
it
y
Sensitivity
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Se
n
si
ti
vi
ty
(9
5%
 C
I)
Sp
ec
if
ic
it
y
(9
5%
 C
I)
Su
m
m
ar
y 
cu
rv
e
St
u
d
y 
p
o
in
t
Su
m
m
ar
y 
p
o
in
t
FI
G
U
R
E 
10
 T
ra
ns
re
ct
al
 u
lt
ra
so
no
gr
ap
hy
 –
 p
at
ie
nt
-le
ve
l a
na
ly
si
s:
 s
en
si
ti
vi
ty
, s
pe
ci
fic
it
y,
 p
oo
le
d 
es
ti
m
at
es
 a
nd
 S
RO
C
 c
ur
ve
.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
assessment Of DIagnOstIc accuracy
34
Biopsy-level analysis
No studies reported sensitivity or specificity at a biopsy or other non-patient-level analysis. In the study 
by Lee et al.,126 from the information provided it was possible to calculate PPV (3.5%) but not sensitivity 
or specificity. This study did not report the number of cores taken per patient but did report the overall 
number of cores sampled (n = 903 from 87 patients, average of 10 cores per patient).
Studies directly comparing tests
Seventeen studies57,74,76,78,79,84,90,96,100,105,106,108,112,120,133,134,136 directly compared two or more tests (see 
Appendix 12 for details of which studies reported which tests).
Magnetic resonance spectroscopy compared with T2-weighted magnetic 
resonance imaging
Six studies74,76,79,106,108,112 involving 201 patients reported MRS compared with T2-MRI and provided 
sufficient information for inclusion in a meta-analysis. All used a (10- or 12-core) TRUS-guided approach 
plus additional targeted cores on MRS/T2-MRI equivocal or suspicious areas, apart from the study by 
Wetter et al.,108 which used a MRI-guided approach.108 Three studies reported the CC/C ratio used as a 
cut-off for a positive test result for MRS, which ranged from > 0.6108 to > 0.86.79
Across the studies the median (range) prevalence of PC was 32.4% (9.5% to 40.7%). The number of 
previous biopsy sessions the participants had undergone ranged from 1108 to 1–4.74,106 The number of 
cores extracted in the previous biopsy session ranged from 676,108 to (a mean of) 12–14.112 The studies were 
judged to have low risk of bias for the patient selection, index test and flow of timing domains. All studies 
were judged to be at high risk of bias for the reference standard domain owing to a lack of follow-up. 
All studies were judged to have low applicability concerns for patient selection, index test and reference 
standard domains, apart from, for the index test domain, Bhatia et al.76 (unclear concern for applicability: 
both normal and equivocal test results categorised as negative) and Cirillo et al.79 (high concern for 
applicability: only PZ assessed).
For the HSROC analysis, we made the assumption that the underlying shape parameter varies with the 
threshold and accuracy parameters. This is because using the original assumption of a common underlying 
shape made our models unstable. We provide the results of a sensitivity analysis with the original 
assumption in Appendix 13.
Figure 11 shows the sensitivity and specificity of the individual studies, pooled estimates and SROC plot 
with 95% confidence region. The pooled (95% CI) estimates for sensitivity and specificity were 89% (79% 
to 95%) and 71% (51% to 85%) for MRS, and 77% (55% to 90%) and 68% (59% to 75%) for T2-MRI.
Magnetic resonance spectroscopy compared with dynamic contrast-enhanced 
magnetic resonance imaging
Two studies100,105 involving 158 patients reported MRS compared with DCE-MRI (Table 6). Portalez et al.100 
reported segment-level but not patient-level analysis, whereas Sciarra et al.105 reported both patient- and 
core-level analysis.105 In the study by Portalez et al.100 the sensitivity of the tests was similar but low, 
whereas specificity was also similar but high. In the study by Sciarra et al.105 MRS had higher sensitivity 
TABLE 6 Studies comparing MRS with DCE-MRI
Study ID Unit of analysis No. analysed
MRS DCE
Sensitivity Specificity Sensitivity Specificity
Portalez 2010100 Segment 408 29.3 90.2 29.3 93.5
Sciarra 2010105 Patient 90 88.6 93.5 79.5 91.3
Core NR 83.3 72.7 75.6 76.7
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than DCE-MRI at both patient- and core-level analysis, with broadly similar specificity, which was higher 
for patient-level analysis compared with core-level analysis. With regard to the low sensitivity reported by 
Portalez et al.,100 the authors stated that in order to visualise the early phase of cancer enhancement and 
retain spatial resolution, they resorted to the shortest possible time with their MRI unit, which proved to 
yield adequate specificity but suboptimal sensitivity.100
Dynamic contrast-enhanced magnetic resonance imaging compared with 
T2-weighted magnetic resonance imaging
Three studies78,90,100 involving 187 patients compared DCE-MRI with T2-MRI (Table 7). In the two studies 
reporting patient-level analysis,78,90 DCE-MRI had higher sensitivity and lower specificity than T2-MRI 
in one, with lower sensitivity and higher specificity in the other. Cheikh et al.78 reported low specificity 
for DCE-MRI, whereas Lattouf et al.90 reported low specificity for both DCE-MRI and T2-MRI. The test 
combination ‘DCE-MRI or T2-MRI’ resulted in similar or increased sensitivity compared with the individual 
tests but reduced specificity, whereas the combination ‘DCE-MRI and T2-MRI’ reduced sensitivity with 
a moderate increase in specificity. In the two studies reporting non-patient-level analysis, DCE-MRI had 
higher sensitivity and slightly lower specificity than T2-MRI in one and lower sensitivity and slightly higher 
specificity in the other.
Dynamic contrast-enhanced magnetic resonance imaging compared with 
diffusion-weighted magnetic resonance imaging
Two studies100,133 involving 79 patients compared DCE-MRI with DW-MRI (Table 8). Both reported non-
patient-level analysis. DCE-MRI had higher sensitivity than DW-MRI in one study133 and lower sensitivity100 
in the other, whereas the sensitivity reported for both DCE-MRI and DW-MRI was much higher in the study 
by Valentini et al.133 than it was in the study by Portalez et al.100 Portalez et al.100 reported similarly high 
specificity for both tests.
Studies reporting combinations of tests
The following combinations of tests were reported:
 z MRS or T2-MRI (eight studies)
 z MRS and T2-MRI (five studies)
 z MRS or DCE-MRI (two studies)
 z MRS and DCE-MRI (one study)
 z MRS or DCE-MRI or T2-MRI (one study)
 z MRS or DW-MRI or T2-MRI (one study)
 z MRS or DCE-MRI or DW-MRI or T2-MRI (one study)
 z DCE-MRI or T2-MRI (three studies)
 z DCE-MRI and T2-MRI (two studies)
 z DCE-MRI or DW-MRI (one study)
 z DCE-MRI or DW-MRI or T2-MRI (four studies)
 z DCE-MRI and DW-MRI and T2-MRI (one study)
 z DW-MRI or T2-MRI (three studies).
No studies reported MRS combined with DW-MRI.
In combinations linked by ‘or’ only one of the tests has to be positive for the result of the combination 
to be considered positive, while in combinations linked by ‘and’ all tests in the combination have to be 
positive before the result for the combination is considered positive. Combinations linked by ‘or’ generally 
result in higher sensitivity and lower specificity compared with the individual tests while the reverse is the 
case for combinations linked by ‘and’.
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Magnetic resonance spectroscopy or T2-weighted magnetic resonance imaging
Patient-level analysis
Eight studies74,79,84,106,108,112,118,130 involving 316 patients reported the diagnostic accuracy of MRS or T2-MRI 
and provided sufficient information for inclusion in a meta-analysis. All used a (mostly 10- or 12-core) 
TRUS-guided approach plus additional targeted cores on MRS/T2-MRI equivocal or suspicious areas, apart 
from Franiel et al.84 and Wetter et al.,108 who used a MRI-guided approach. In the study by Destefanis 
et al.118 all participants (n = 26) had ASAP. Four studies reported the CC/C ratio used as the cut-off for a 
positive test result, which ranged from > 0.6108 to > 0.86.79,118
Across the studies the median (range) prevalence was 35.2% (29.2% to 40.7%). The number of previous 
biopsy sessions the participants had undergone ranged from 1108,118 to 1–6.84 The number of cores 
extracted in the previous biopsy session ranged from 6108 to (a mean of) 16.106
The studies were judged to have low risk of bias for the patient selection, index test and flow of timing 
domains. All studies were judged to be at high risk of bias for the reference standard domain owing to 
a lack of follow-up. All studies were judged to have low applicability concerns for the patient selection, 
index test and reference standard domains, apart from, for the index test domain, Cirillo et al.79 (only 
PZ assessed).
Figure 12 shows the sensitivity and specificity of the individual studies, pooled estimates and SROC curve. 
The pooled (95% CI) estimates for sensitivity and specificity were 96% (90% to 98%) and 31% (21% to 
42%), respectively.
Biopsy-level analysis
Three studies79,84,106 reported MRS or T2-MRI and provided sufficient information for inclusion in a meta-
analysis. The units of analyses reported by the studies included site79 and region.84,106 Figure 13 shows the 
sensitivity and specificity of the individual studies, pooled estimates and SROC curve. The pooled (95% 
CI) estimates for sensitivity and specificity were 79% (71% to 86%) and 74% (45% to 90%), respectively. 
Testa et al.106 also reported region-based analysis separately for the peripheral and TZs. For the PZ (540 
regions analysed), sensitivity was 70.3% and specificity 83.3%, whereas for the TZ (108 regions analysed) 
sensitivity was 72.2% and specificity 92.2%.
Magnetic resonance spectroscopy and T2-weighted magnetic resonance imaging
Patient-level analysis
Five studies76,106,108,112,134 involving 129 patients reported the diagnostic accuracy of MRS and T2-MRI and 
provided sufficient information for inclusion in a meta-analysis. All used a (mostly 10- or 12-core) TRUS-
guided approach plus additional targeted cores on MRS/T2-MRI equivocal or suspicious areas, apart from 
Wetter et al.,108 which used a MRI-guided approach and extracted cores transgluteally. None of the studies 
reported the CC/C ratio value used as the cut-off for a positive test result.
TABLE 8 Studies comparing DCE-MRI with DW-MRI
Study ID Unit of analysis No. analysed
DCE-MRI DW-MRI
Sensitivity Specificity Sensitivity Specificity
Portalez 2010100 Segment 408 29.3 93.5 39.0 96.0
Valentini 2010133 Biopsy NR 80.0 NR 60.0 NR
NR, not reported.
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Across the studies the median (range) prevalence was 33.3% (9.5% to 41.7%). The number of previous 
biopsy sessions the participants had undergone ranged from 1108 to 1–4.106 The number of cores extracted 
in the previous biopsy session ranged from 676,108 to (a mean of) 16.106
The studies were judged to have low risk of bias for the patient selection, index test and flow of timing 
domains. All studies were judged to be at high risk of bias for the reference standard domain owing to a 
lack of follow-up. All studies were judged to have low applicability concerns for the patient selection, index 
test and reference standard domains, apart from, for the index test domain, Bhatia et al.76 (normal and 
equivocal tests were categorised as negative for malignancy).
Figure 14 shows the sensitivity and specificity of the individual studies and pooled estimates (this analysis 
required to be undertaken without random effect parameters as otherwise the model would not converge 
and consequently it was not possible to produce a ROC curve). The pooled (95% CI) estimates for 
sensitivity and specificity were 60% (46% to 75%) and 74% (65% to 84%), respectively.
Biopsy-level analysis
Two studies reported the diagnostic accuracy of MRS and T2-MRI at biopsy or other non-patient-level 
analysis.76,106 In a biopsy-level analysis (n = 290), Bhatia et al.76 reported sensitivity of 64.3% and specificity 
of 91.7%, whereas in a region-based analysis (n = 648) Testa et al.106 reported sensitivity of 34.5% and 
specificity of 98.8%, as well as region-based analysis separately for the PZ and TZ.106 For the PZ (540 
regions analysed), sensitivity was 21.6% and specificity 98.6%, whereas for the TZ (108 regions analysed) 
sensitivity was 61.1% and specificity 100%.
Magnetic resonance spectroscopy or dynamic contrast-enhanced magnetic 
resonance imaging
Patient-level analysis
Two studies involving 131 patients reported MRS or DCE-MRI.95,105 Panebianco et al.95 reported sensitivity 
of 92.9% and specificity of 86.6%, whereas Sciarra et al.105 reported sensitivity of 93.2% and specificity of 
91.3%. No studies reported biopsy-level analysis.
FIGURE 14 Magnetic resonance spectroscopy and T2-MRI patient-level analysis: sensitivity, specificity and pooled 
estimates.
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Magnetic resonance spectroscopy and dynamic contrast-enhanced magnetic 
resonance imaging
Patient-level analysis
One study, by Sciarra et al.105 involving 90 patients reported sensitivity of 75% and specificity of 93.5% for 
MRS and DCE-MRI.
Biopsy-level analysis
Sciarra et al.105 reported sensitivity of 89.7% and specificity of 80.4% for core-level analysis.
Other combinations involving magnetic resonance spectroscopy
Franiel et al.84 reported other combinations of tests involving MRS, both at patient-level (n = 54) and 
region-level (n = 178) analysis (Table 9).
In the study by Roethke et al.104 reporting MRS or T2-MRI or DCE-MRI or DW-MRI (n = 100), from the 
information provided it was possible to calculate PPV (52%), but not sensitivity or specificity.
Dynamic contrast-enhanced magnetic resonance imaging or T2-weighted 
magnetic resonance imaging
Patient-level analysis
Three studies78,84,90 involving 173 patients reported the diagnostic accuracy of DCE-MRI or T2-MRI and 
provided sufficient information for inclusion in a meta-analysis. The studies by Cheikh et al.78 and Lattouf 
et al.90 used a 12-core TRUS-guided approach plus additional targeted cores from suspicious areas on the 
imaging tests.78,90 The study by Franiel et al. used a MRI-guided approach.84
Across the studies the median (range) prevalence of PC was 38.9% (24.7% to 53.8%). The number of 
previous biopsy sessions the participants had undergone ranged from 1–578 to 1–12.90 Only Cheikh et 
al.78 reported the number of cores extracted in the previous biopsy session (mean of 12.6). The studies 
were judged to have low risk of bias and applicability concerns for all domains apart from the reference 
standard domain, for which all three were judged to be at high risk of bias owing to a lack of follow-up.
Figure 15 shows the sensitivity and specificity of the individual studies, pooled estimates and SROC curve. 
The pooled (95% CI) estimates for sensitivity and specificity were 88% (80% to 96%) and 14% (8% to 
20%), respectively.
Biopsy-level analysis
Two studies78,84 reported DCE-MRI or T2-MRI. Cheikh et al.,78 in a sector-based analysis (n = 670), reported 
sensitivity of 52.3% and specificity of 83.1%, whereas Franiel et al.,84 in a region-based analysis (n = 178), 
reported sensitivity of 83.0% and specificity of 33.6%.
TABLE 9 Other combinations of tests involving MRS
Study ID Test combination
Patient-level analysis Region-level analysis
Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
Franiel 
201184
MRS or DCE or T2-MRI 95.2 9.1 90.6 14.4
MRS or DW or T2-MRI 100.0 3.0 94.3 19.2
MRS or DCE or DW or T2-MRI 100.0 0.0 100.0 0.0
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Dynamic contrast-enhanced magnetic resonance imaging and T2-weighted 
magnetic resonance imaging
Patient-level analysis
Two studies78,90 involving 119 patients reported the diagnostic accuracy of DCE-MRI and T2-MRI; Cheikh 
et al.78 reported sensitivity of 47.8% and specificity of 51.4%, whereas Lattouf et al.90 reported sensitivity 
of 64.3% and specificity of 33.3%.
Biopsy-level analysis
One study, by Cheikh et al.,78 in a sector-based analysis (n = 670), reported sensitivity of 31.8% and 
specificity of 92.3%.78
Dynamic contrast-enhanced magnetic resonance imaging or diffusion-weighted 
magnetic resonance imaging
Biopsy-level analysis
No study reported a patient-level analysis of DCE-MRI combined with DW-MRI. Valentini et al.,133 in a 
study involving 11 patients, reported a biopsy-level analysis (number of biopsies not reported) for DCE-MRI 
or DW-MRI. This study used a TRUS-guided approach (24 cores plus additional biopsies of suspicious 
MRI areas). From the information provided in the study it was possible to calculate PPV (17.2%) but not 
sensitivity or specificity.
Dynamic contrast-enhanced magnetic resonance imaging or diffusion-weighted 
magnetic resonance imaging or T2-weighted magnetic resonance imaging
Patient-level analysis
Four studies84,86,87,109 involving 395 patients reported DCE-MRI or DW-MRI or T2-MRI. Franiel et al.84 
reported sensitivity of 100% and specificity of 0%. However, from the information provided in the other 
three studies86,87,109 it was possible to calculate PPV (100%,86 40.9%,87 55.6%109) but not sensitivity 
or specificity.
Biopsy-level analysis
Three studies84,87,109 reported DCE-MRI or DW-MRI or T2-MRI at a region-level analysis. However, only the 
study by Franiel et al.84 reported sensitivity (94.3%) and specificity (16.0%). From the information provided 
in the other two studies87,109 it was possible to calculate PPV (33.4%,87 46.2%109) but not sensitivity 
or specificity.
Dynamic contrast-enhanced magnetic resonance imaging and diffusion-
weighted magnetic resonance imaging and T2-weighted magnetic 
resonance imaging
Patient-level analysis
One study, by Labanaris et al.89 involving 260 patients reported sensitivity of 88.1% and specificity of 
62.4% for DCE-MRI and DW-MRI and T2-MRI. No studies reported biopsy-level analysis.
Diffusion-weighted magnetic resonance imaging or T2-weighted magnetic 
resonance imaging
Patient-level analysis
Two studies84,126 involving 141 patients reported DW-MRI or T2-MRI at a patient-level analysis. The study by 
Franiel et al.84 used a MRI-guided approach. Franiel et al.84 reported sensitivity of 100% and specificity of 
3.0%, whereas Lee et al.126 reported sensitivity of 95.7% and specificity of 7.3%.
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Biopsy-level analysis
Three studies84,116,126 reported DW-MRI or T2-MRI at a biopsy or other non-patient-level analysis. Chung et 
al.116 reported sensitivity of 82.8% and specificity of 68.9%, whereas Franiel et al.84 reported sensitivity of 
84.9% and specificity of 36.8%. From the information provided in the study by Lee et al.54 it was possible 
to calculate PPV (12.7%) but not sensitivity or specificity.126
Indirect comparison
Table 10 shows the results of the indirect comparison (see also Appendix 13).
Patient-level analysis
For the patient-level estimates of tests with three or more studies, comparing T2-MRI against all the other 
tests showed statistically significant differences (p < 0.001). Compared with DCE-MRI, T2-MRI was observed 
to have lower sensitivity and significantly higher specificity. Sensitivity (95% CI) for DCE-MRI was 87% (74% 
to 94%) compared with 83% (75% to 89%) for T2-MRI (p = 0.499). Specificity (95% CI) for DCE was 40% 
(25% to 56%) compared with 57% (47% to 67%) for T2-MRI (p = 0.041).
Magnetic resonance spectroscopy was observed to have higher sensitivity and specificity than T2-MRI. 
Sensitivity for MRS was 93% (87% to 97%) compared with 83% (75% to 89%) for T2-MRI (p = 0.008). 
Specificity for MRS was 64% (52% to 75%) compared with 57% (47% to 67%) for T2-MRI (p = 0.194).
When T2-MRI was used in combination with MRS (‘T2-MRI and MRS’, both tests had to be suspicious for 
the combination to be considered positive) T2-MRI used alone was observed to have higher sensitivity but 
significantly lower specificity. Sensitivity for ‘T2-MRI and MRS’ was 71% (50% to 85%) compared with 83% 
(75% to 89%) for T2-MRI (p = 0.172). Specificity for ‘T2-MRI and MRS’ was 73% (58% to 85%) compared 
with 57% (47% to 67%) for T2-MRI (p = 0.011).
TABLE 10 Results of the indirect comparison (patient-level analysis)
Parameter Estimate
95% CI
Ratio (95% CI) p-valueLower Upper
Sensitivity for T2-MRI 83 75 89 1
Sensitivity for DCE 87 74 94 1.04 (0.93 to 1.17) 0.499
Sensitivity for MRS 93 87 97 1.12 (1.03 to 1.22) 0.008
Sensitivity for T2-MRI and MRS 71 50 85 0.85 (0.67 to 1.07) 0.172
Sensitivity for T2-MRI or DCE 92 81 97 1.10 (1.00 to 1.21) 0.046
Sensitivity for T2-MRI or MRS 97 91 99 1.16 (1.07 to 1.26) 0.001
Sensitivity for TRUS 24 13 39 0.28 (0.16 to 0.50) < 0.001
Specificity for T2-MRI 57 47 67 1
Specificity for DCE 40 25 56 0.70 (0.49 to 0.98) 0.041
Specificity for MRS 64 52 75 1.12 (0.95 to 1.32) 0.194
Specificity for T2-MRI and MRS 73 58 85 1.28 (1.06 to 1.55) 0.011
Specificity for T2-MRI or DCE 24 13 39 0.42 (0.26 to 0.68) < 0.001
Specificity for T2-MRI or MRS 34 23 46 0.59 (0.44 to 0.78) < 0.001
Specificity for TRUS 88 79 94 1.54 (1.27 to 1.86) < 0.001
DCE, dynamic contrast enhanced.
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When T2-MRI was used in combination with DCE-MRI (‘T2-MRI or DCE-MRI’, if either test is suspicious 
the combination is considered positive), T2-MRI used alone was observed to have lower sensitivity but 
significantly higher specificity. Sensitivity for ‘T2-MRI or DCE-MRI’ was 92% (81% to 97%) compared with 
83% (75% to 89%) for T2-MRI (p = 0.046). Specificity for ‘T2-MRI or DCE-MRI’ was 24% (13% to 39%) 
compared with 57% (47% to 67%) for T2-MRI (p < 0.001).
When T2-MRI was used in combination with MRS (‘T2-MRI or MRS’, if either test is suspicious the 
combination is considered positive), this combination had significantly higher sensitivity than T2-MRI 
alone but significantly lower specificity. Sensitivity for ‘T2-MRI or MRS’ was 97% (91% to 99%) compared 
with 83% (75% to 89%) for T2-MRI (p = 0.001). Specificity for ‘T2-MRI or MRS’ was 34% (23% to 46%) 
compared with 57% (47% to 67%) for T2-MRI (p < 0.001).
Compared with TRUS used as an imaging test, T2-MRI was observed to have significantly higher sensitivity 
but significantly lower specificity. Sensitivity for TRUS was 24% (13% to 39%) compared with 83% (75% 
to 89%) for T2-MRI (p < 0.001). Specificity for TRUS was 88% (79% to 94%) compared with 57% (47% to 
67%) for T2-MRI (p < 0.001).
These differences are based on between-study comparisons, so may have been due to differences between 
the studies rather than true differences between the tests.
For the estimates comparing T2-MRI with other tests, in terms of relative sensitivity, the direction of effect 
favoured (1) MRS; (2) ‘T2-MRI or DCE’; and (3) ‘T2-MRI or MRS’ over T2-MRI, while favouring T2-MRI 
over (1) DCE-MRI; (2) ‘T2-MRI and MRS’; and (3) TRUS, although the only results that were statistically 
significant were for ‘T2-MRI or MRS’ compared with T2-MRI (‘T2-MRI or MRS’ better) and T2-MRI 
compared with TRUS (T2-MRI better). See Appendix 13.1 for further details.
In terms of relative specificity the direction of effect favoured (1) MRS; (2) ‘T2-MRI and MRS’; and (3) 
TRUS over T2-MRI, while favouring T2-MRI over (1) DCE-MRI; (2) ‘T2-MRI or DCE-MRI’; and (3) ‘T2-MRI 
or MRS’, although the only results that were statistically significant were for ‘T2-MRI and MRS’ compared 
with T2-MRI (‘T2-MRI and MRS’ better), T2-MRI compared with TRUS (TRUS better), ‘T2-MRI or DCE-MRI’ 
compared with T2-MRI (T2-MRI better) and ‘T2-MRI or MRS’ compared with T2-MRI (T2-MRI better). See 
Appendix 13.1 for further details.
Biopsy-level analysis
The highest sensitivity (95% CI) was for the combination ‘T2-MRI or MRS’ at 75% (61% to 86%), whereas 
the highest specificity was for T2-MRI at 87% (78% to 93%), with MRS also reporting a similarly high 
specificity at 84% (72% to 91%). See Appendix 13.2 for further details.
For the estimates comparing T2-MRI with other tests, in terms of relative sensitivity both (1) MRS and 
(2) ‘T2-MRI or MRS’ had statistically significantly higher sensitivity than T2-MRI, whereas for specificity 
the direction of effect favoured T2-MRI over both (1) MRS and (2) ‘T2-MRI or MRS’, although only the 
comparison with ‘T2-MRI or MRS’ was statistically significant. See Appendix 13.2 for further details.
False-positive results
Eleven studies57,74,76,78,79,101,106,108,109,133,137 provided further information on the MR-imaging false-positive 
results in their studies (see Appendix 14 for individual study details). The false-positive rate for patient-level 
analysis (six studies74,76,79,101,108,137) ranged from 2.4%74 to 100%108 and for biopsy or other non-patient-
level analysis (five studies57,78,106,109,133) ranged from 13.0%106 to 46.2%.57 High-grade PIN and prostatitis 
accounted for a substantial proportion of the false-positive results.109 Cirillo et al.79 presented this 
information separately for MRS and T2-MRI. For MRS (11 false-positives), there was PIN in six (54.5%), 
fibrosis in four (36.4%) and normal prostatic tissue in one (9.1%); for T2-MRI (13 false-positives), there 
was PIN in three (23.0%), fibrosis in five (38.5%) and normal prostatic tissue in five (38.5%).79 Beyersdorff 
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et al.57 concluded that the T2-MRI technique used in their study did not enable reliable differentiation of 
PC from prostatitis, fibrosis or PIN.
Detection of clinically significant disease
Twenty-nine studies74,76,78–80,82,84,86,87,90,91,95,96,104–106,108,109,111,112,136 reported the Gleason score based on the 
biopsy results of patients diagnosed with PC (see Appendix 15 for individual study details). Most studies 
reported a median Gleason score of ≥ 6. The percentage of patients diagnosed with PC who had a Gleason 
score of ≥ 7 ranged from 20.3%86 to 66.7%.109 In 13 studies74,80,81,83,87,91,96–98,102,111,113,136 it was not possible 
to calculate this information.
Six MRI studies reported a median Gleason score of > 6 (Table 11). In these studies the percentage of 
patients diagnosed with PC who had a Gleason score of ≥ 7 ranged from 50.0%90,108 to 66.7%.109
Results: assessment of non-diagnostic outcomes
Altered treatment as a result of the tests
No studies reported information on altered treatment as a result of the tests.
Acceptability of the tests
No studies provided information on the acceptability of the tests used.
Interpretability of the tests
Three studies78,101,106 reported the interpretability of the tests used. Cheikh et al.,78 in a study using T2-MRI 
and DCE-MRI, reported that in 1 (1.1%) of 93 patients analysed, DCE images could not be interpreted 
because of inadequate quality due to artefacts induced by a hip prosthesis. This patient was 1 of 23 
diagnosed with cancer.
In a study that employed T2-MRI and MRS, Prando et al.101 stated that suitable spectroscopic voxels were 
rated as optimal, fair or poor on the basis of spectral quality (Table 12).101 They reported that, out of 42 
patients analysed, the quality of spectral data was rated as optimal in 23 (55%), fair in 10 (24%) and poor 
in 9 (21%).
Testa et al.,106 in a study using T2-MRI and MRS, reported that 4 (7%) of 58 patients were excluded 
because more than one-third of the prostate was not included in the MRI volume of interest, or more than 
TABLE 11 Studies reporting a median Gleason score of > 6
Study ID Test(s)
No. 
analysed
No. 
with PC
Prevalence 
(%)
Median (range) 
Gleason score
Percentage with 
Gleason score ≥ 7
Amsellem-Ouazana 
200574
T2-MRI/MRS 42 15 35.7 6.6 (5 to 9) NR
Lattouf 200790 T2-MRI/DCE 26 14 53.8 6.5 (5 to 9) 50.0
Park 200896 DW-MRI 43 17 39.5 7 (6 to 9) NR
Roethke 2012104 T2-MRI/MRS/DCE-
MRI/DW-MRI
100 52 52.0 7 (5 to 9) 59.7
Wetter 2005108 T2-MRI/MRS 6 2 33.3 (6, 7) 50.0
Yakar 2011109 T2-MRI/DCE-MRI/
DW-MRI
9 5 55.6 7 (6 to 8) 66.7
NR, not reported.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
assessment Of DIagnOstIc accuracy
48
one-third of spectroscopic voxels were not interpretable owing to lipid contamination or presented low 
spectral resolution. Out of the remaining 54 patients included in the analysis, in 18 (3%) of 648 regions 
MRS imaging was not interpretable (corresponding to six patients) and these regions were excluded from 
the analysis. None of these 18 regions was in the TZ.106
Effect of testing on quality of life
No studies reported the effects of the tests on QoL.
Adverse effects of testing
Ten studies57,76,81,82,86,87,89,109,111,112 reported adverse events, all of which appeared to be related to TRUS-
guided biopsies, with one of the most frequently reported adverse events being transient haematuria (see 
Appendix 16 for individual study details). Of the other more serious adverse events reported, Beyersdorff 
et al.57 reported that two patients (5%) experienced haemorrhage in the prostate; Djavan et al.81 reported 
that 1.4% experienced moderate to severe vasovagal episodes, 0.5% experienced severe haematuria and 
0.1% major rectal bleeding (numbers of patients not reported); Hoeks et al.87 reported that one patient 
(0.4%) experienced sepsis with hospitalisation and four (1.5%) experienced a vasovagal reaction; Labanaris 
et al.89 reported that 190 patients (73%) experienced macroscopic haematuria; Yuen et al.111 reported that 
three patients (1.4%) experienced macroscopic haematuria, five (2.3%) experienced fever and five (2.3%) 
experienced acute retention of urine (all 13 treated conservatively as inpatient), while one patient (0.5%) 
experienced rectal bleeding, requiring admission to hospital. None of the studies provided information on 
injuries resulting from multiple biopsies over time. Neither did any study report the extremely rare adverse 
event of biopsy leading to disease seeding along needle tracks.
Summary
Sixty-five reports of 51 studies met the inclusion criteria (39 full text, 12 abstracts). The majority of studies 
were considered to have a low risk of bias for the patient selection (74%, 29/39), index test (100%, 39/39) 
and flow and timing (92%, 36/39) domains. In the reference standard domain, the majority of studies 
(64%, 25/39) were considered at high risk of bias due to a lack of follow-up. All 39 studies had low 
concern for applicability for the reference standard domain and the majority also had low concerns for 
applicability for the patient selection (95%, 37/39) and index test (87%, 34/39) domains.
The sensitivity and specificity of the tests (patient-level analysis) are summarised in Table 13 (results of the 
meta-analyses for the individual tests, combinations of tests and for those studies directly comparing MRS 
with T2-MRI), Table 14 (results for the tests and combinations of tests for which it was not considered 
appropriate or feasible to include in a meta-analysis) and Table 15 (pooled estimates for the individual tests 
and combinations of tests included in the indirect comparison).
In the meta-analyses for the individual tests, sensitivity was highest for MRS (92%), followed by T2-MRI 
(86%) and DCE-MRI (79%), whereas specificity was highest for TRUS (used as an imaging test) (81%), 
followed by MRS (76%). TRUS used as an imaging test had poor sensitivity (27%). In the pooled estimates 
for combinations of tests, sensitivity was highest for ‘MRS or T2-MRI’ (96%) followed by ‘DCE-MRI or 
TABLE 12 Voxel rating system used by Prando et al.101
Spectral quality Definition
Optimal Signal–noise ratio of all metabolites > 10, all metabolic resonances well resolved, no baseline 
distortions due to residual water or lipids 
Fair Signal–noise ratio of all metabolites 8–10, all metabolic resonances reasonably well resolved, or 
minimal baseline distortions owing to residual water or lipids 
Poor Lower signal–noise ratios and substantial lipid contamination
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TABLE 13 Summary of meta-analysis results (patient-level analysis)
Test(s) No. of studies
No. of 
participants
Sensitivity: pooled 
estimate, % (95% CI)
Specificity: pooled 
estimate, % (95% CI)
Individual tests
MRS 10 438 92 (86 to 95) 76 (61 to 87)
DCE-MRI 3 209 79 (69 to 87) 52 (14 to 88)
T2-MRI 15 620 86 (74 to 93) 55 (44 to 66)
TRUS (imaging test) 6 782 27 (16 to 42) 81 (77 to 85)
Combinations of tests
MRS or T2-MRI 8 316 96 (90 to 98) 31 (21 to 42)
MRS and T2-MRI 5 129 60 (46 to 75) 74 (65 to 84)
DCE-MRI or T2-MRI 3 173 88 (80 to 96) 14 (8 to 20)
Studies directly comparing MRS with T2-MRI
MRS
6 201
89 (79 to 95) 71 (51 to 85)
T2-MRI 77 (55 to 90) 68 (59 to 75)
TABLE 14 Descriptive summary of results for tests/combinations not included in meta-analysis (patient-level analysis)
Test(s) No. of studies
No. of 
participants Sensitivity (%) Specificity (%)
DW-MRI 1 43 100 NR
MRS or DCE 2 131 93, 93 87, 91
MRS and DCE 1 90 75 94
MRS or DCE-MRI or T2-MRI 1 54 95 9
MRS or DW-MRI or T2-MRI 1 54 100 3
MRS or DCE-MRI or DW-MRI or T2-MRI 1 54 100 0
DCE-MRI and T2-MRI 2 119 48, 64 51, 33
DCE-MRI or DW-MRI or T2-MRI 1 54 100 0
DCE-MRI and DW-MRI and T2-MRI 1 260 88 62
DW-MRI or T2-MRI 2 141 96, 100 7, 3
TABLE 15 Indirect comparison (patient-level analysis)
Test(s) Sensitivity: pooled estimate, % (95% CI) Specificity: pooled estimate, % (95% CI)
MRS 93 (87 to 97) 64 (52 to 75)
DCE-MRI 87 (74 to 94) 40 (25 to 56)
T2-MRI 83 (75 to 89) 57 (47 to 67)
MRS or T2-MRI 97 (91 to 99) 34 (23 to 46)
MRS and T2-MRI 71 (50 to 85) 73 (58 to 85)
DCE-MRI or T2-MRI 92 (81 to 97) 24 (13 to 39)
TRUS (imaging test) 24 (13 to 39) 88 (79 to 94)
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T2-MRI’ (88%), whereas specificity was highest for ‘MRS and T2-MRI’ (74%). The gain in sensitivity from 
MRS as a single test (92%) to the combination ‘MRS or T2-MRI’ (96%) was offset by a large decrease in 
specificity from 76% to 31%.
In the meta-analysis of the six studies74,76,79,106,108,112 directly comparing MRS with T2-MRI, sensitivity and 
specificity for MRS was 89% and 71%, respectively, compared with 77% and 68% for T2-MRI.
Only one small study96 involving 43 patients reported DW-MRI, with sensitivity of 100% (specificity not 
reported). A number of other combinations of tests were reported, mostly by single studies.
The results of the indirect comparison broadly reflected those of the meta-analyses of the individual 
tests and combinations of tests. In the indirect comparison, the highest sensitivity reported was for the 
combination of ‘MRS or T2-MRI’ (97%), followed by MRS (93%) and ‘DCE-MRI or T2-MRI’ (92%). TRUS as 
an imaging test had poor sensitivity (24%). However, TRUS had the highest specificity (88%), followed by 
the combination of ‘MRS and T2-MRI’ (73%) and MRS (64%).
Six large-scale population screening studies81,88,97,99,103,113 provided information on the performance of 
systematic biopsies using a (non-imaging) TRUS-guided approach on a subset of their patient populations 
with a previous negative biopsy (n = 5771). Across these studies the median (range) sensitivity was 72.5% 
(60.6% to 96.3%). Across all of the 10 non-imaging TRUS/Bx studies,77,88,91,97–99,102,110,113,120 the median 
(range) sensitivity was 72.5% (59.3% to 96.3%).
Eleven studies57,74,76,78,79,101,106,108,109,133,137 provided information on the MR-imaging false-positive results, 
with the false-positive rate for patient-level analysis (six studies74,76,79,101,108,137) ranging from 2.4% to 
100%. High-grade PIN and prostatitis accounted for a substantial proportion of the false-positive 
results. Twenty-nine studies74,76,78–84,86,87,90,91,95–98,102–106,108–113,136 reported the Gleason score based on the 
biopsy results of patients diagnosed with PC, with most reporting a median Gleason score of ≥ 6. The 
percentage of patients diagnosed with PC that had a Gleason score of ≥ 7 ranged from 20.3% to 66.7%. 
Ten studies57,76,81,82,86,87,89,109,111,112 reported adverse events related to TRUS-guided biopsies, with one of the 
most frequently reported adverse events being transient haematuria.
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Chapter 5 Assessment of cost-effectiveness
The purpose of this chapter is to assess the cost-effectiveness of utilising different MRI sequences to direct prostate biopsy following a previous negative biopsy.
The specific economic objectives are to estimate:
 z the costs of standard practice (i.e. repeated TRUS/Bx) and the alternative, directed biopsies in the form 
of T2-MRI, MRS, DCE-MRI and DW-MRI techniques in the diagnosis of prostate abnormalities
 z the cost-effectiveness of T2-MRI, MRS, DCE-MRI and DW-MRI in comparison with standard practice in 
men with suspected PC.
Structured review of cost-effectiveness studies
Although a systematic literature review of cost-effectiveness studies was not included as part of the 
protocol for this study, a systematic search was undertaken to locate studies considering the cost-
effectiveness of MRS and enhanced MRI techniques for aiding the localisation of prostate abnormalities for 
biopsy. A broader search for health-state utility data and existing economic modelling studies in the area of 
PC, to inform subsequent cost-effectiveness modelling, was conducted simultaneously. Databases searched 
included the NHS Economic Evaluation Database (NHS EED) (November 2011), the IDEAS Economics and 
Finance Research database (November 2011), MEDLINE, the NHS Economic Evaluation Database (NHS 
EED), and the Cost-effectiveness Analysis Registry (CEA Registry) (specifically for health utilities). Details of 
the full search strategies used are given in Appendix 2.
Efforts were made to identify papers reporting full economic evaluations on the use of MRS/MRI 
techniques to direct/guide prostate biopsies. A total of 1315 titles and abstracts were screened for 
possible relevance but only one non-English-language paper was found comparing both the costs and 
consequences of alternatives of interest. From review of the available English-language abstract of the 
latter paper, this study used modelling techniques to assess the cost-effectiveness of using MRI (type not 
specified) to determine and direct prostate biopsies compared with the standard practice of systematic 
TRUS/Bx for all patients.138 The authors reported their results in terms of a hypothetical cohort of 100,000 
patients, and concluded that although the use of MRI could prevent the need for 64,000 unnecessary 
biopsies, it would result in increased costs to the health insurer for only a small increase in quality-adjusted 
life-years (QALYs). They concluded that their estimates did not permit a clear recommendation for or 
against the use of MRI in the diagnosis of PC. The abstract also stated that the use of MRI was being 
evaluated in the context of patients undergoing their first biopsy, so the results are not directly applicable 
to the decision problem being addressed in this report.
Independent economic assessment
Based on consideration of existing economic modelling studies and trial-based evidence, a de novo 
economic model was developed to assess the cost-effectiveness of using alternative MRS/MRI sequences to 
direct TRUS-guided biopsies, compared with the standard practice of relying on systematic TRUS-guided 
biopsies (in patients with a previous negative biopsy). The alternative diagnostic pathways were embedded 
in a Markov model simulating the progression of undiagnosed cancer and the downstream impact of 
diagnosis and treatment on survival and health-related QoL.
After considering a number of existing economic models of treatment and screening strategies for 
PC,9,139–145 we chose to adopt a Markov cohort approach similar to that used in a model developed to 
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inform NICE clinical guidance on prostatectomy for localised cancer.9 However, we included a greater 
number of states so as to capture the risk stratified natural history of localised PC, associated treatment 
effects, and treatment complications. Costs incorporated in the model included the costs associated with 
obtaining the final diagnosis (cancer/no cancer), management of biopsy complications, cancer staging, 
cancer treatment, and the management of complications resulting from cancer treatment.
Survival benefits of diagnosis were captured through the application of relative risk parameters reflecting 
the effects of appropriately targeted radical treatment by stage of underlying cancer. It was assumed that 
via a risk targeted approach, the observed benefits of radical treatment over observation could be achieved 
for diagnosed cohorts without the need to treat all patients immediately. Limited, high-quality randomised 
evidence was identified for the effect of radical treatment compared with observation in men with 
localised PC. A recently updated Cochrane review on prostatectomy compared with watchful waiting146 
identified only two randomised trials for inclusion: the VACURG trial,147 which was judged to be of poor 
quality, and the SPCG-4 trial,148 which was judged to be of good quality. The SPCG-4 trial,148 carried out 
in Sweden, provides up to 15 years’ follow-up on 695 men with localised PC randomised to either radical 
prostatectomy (n = 347) or watchful waiting (n = 348). It recruited patients prior to the widespread 
introduction of PSA screening, and, as such, uncertainty exists regarding its applicability to men with 
localised disease identified through PSA screening. However, as systematic PSA screening is not policy in 
the UK, and as no more contemporary randomised data on the effect of radical prostatectomy compared 
with watchful waiting were available at time of model development, we based our modelled progression 
risks and relative treatment effects (post diagnosis) on this trial. Late in our study period, the PIVOT trial149 
published preliminary results on the effect of radical prostatectomy compared with watchful waiting in 
men with localised disease identified through PSA screening.149 As such, we also performed a sensitivity 
analysis with the model recalibrated to the progression rates and treatment effects observed in this more 
recent study.
Health-state utilities associated with cancer stage and the occurrence of treatment complications were 
incorporated in the model to estimate QALYs. Experimental strategies were compared incrementally with 
standard practice in terms of their incremental cost per life-year (LY) and QALY gained. For each cost per 
QALY analysis, the strategy with the highest net monetary benefit (NMB) was identified using the formula: 
NMB = (E × rc) – C, where NMB is the net monetary benefit of a strategy, E is the mean effect (in terms of 
QALYs), rc represents decision-makers’ maximum willingness to pay for a QALY, and C is the mean cost of 
the strategy. A value of £30,000 was applied for rc.
Methods
Relevant patient population
The modelled cohorts consisted of men with suspected PC with a prior negative/inconclusive biopsy, 
with indications for repeat biopsy (i.e. sustained suspicion of PC as a result of clinical and/or pathological 
findings).40 We carried out several analyses applying cancer prevalence rates consistent with those observed 
in the literature for different subgroups defined by factors that influence disease prevalence at repeat 
biopsy. The base-case analysis was carried out using a prevalence of 24%, which is consistent with cancer 
detection rate (with 24-core saturation biopsy) reported for a cohort of patients with a previous benign 
biopsy result but persistently elevated PSA (> 4 ng/ml) and/or abnormal DRE.38 Further analyses were 
carried out, with the prevalence of underlying cancer set at a higher level consistent with that reported for 
patients with ASAP or percentage free to total PSA level of < 10% (i.e. 50%). Further, we also set the cancer 
prevalence at the lower level of 10% to represent a lower risk cohort selected for repeat biopsy.
Analyses were conducted separately for men aged 60 years and men aged 70 years at time of repeat 
biopsy, as age influences the cost-effectiveness of diagnosing and treating PC. It was assumed that a 
PC diagnosis would not be aggressively pursued in men aged 75 years and over. Men with cancer were 
initially spread across the undiagnosed cancer states in the model (Table 16), based on the reported 
Gleason scores of tumours detected during the studies included in the systematic review, and other 
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available data on the clinical and/or pathological stages/grades of cancers detected at second biopsy.2,37,38 
Although the frequency of higher grade cancer may increase with age and underlying prevalence, data 
limitations precluded adjustment of the proportions by selection criteria for repeat biopsy. As such, results 
of subgroup analyses (by age and prevalence) should be treated with caution. If a higher proportion of 
older men have more advanced or higher risk tumours, this would serve to improve the cost-effectiveness 
of more sensitive strategies in comparison with the base-case estimates we provide for 70-year-old men.
Diagnostic strategies to be evaluated
The experimental strategies chosen for evaluation were selected based on the availability of data from 
the systematic review of diagnostic accuracy (Table 17). It was not possible to obtain comparable pooled 
sensitivity/specificity estimates for all sequences of clinical interest. Further, the majority of studies included 
in the diagnostic accuracy review assessed the accuracy of MRI sequences for directing TRUS-guided 
biopsies, rather than for directly guiding the biopsy. Thus, the economic analysis focused on evaluating the 
use of MRS/MRI in this context, i.e. using it to identify areas of the prostate for targeting in a subsequent 
TRUS/Bx. As the patient-level sensitivities obtained from the diagnostic accuracy meta-analysis reflect 
detection rates achieved when both targeted cores and a number of systematic cores (8 to 12) are 
taken from patients with positive findings on MRS/MRI, we modelled targeted biopsies to proceed in 
this same manner in the economic model. Insufficient data were available to ascertain how patient-level 
sensitivity would be affected if only targeted cores were obtained from patients positive on imaging. 
As a consequence, we assumed that MRI/imaging prior to biopsy would not alter the cost of the biopsy 
procedure in the base-case analysis. We also assumed that patients with no visible pathology on MRS/MRI 
would not proceed to biopsy. The model was specified to simulate the use of MRS/MRI in the index repeat 
TABLE 16 Cohort information
Parameter
Proportion (ranges 
across studies) Sources (references)
Cancer prevalence 0.24 (0.10 to 0.50) Stewart 2001,2 Campos-Fernandez 2009,37 Scattoni 201138 (assumptions)
Localised disease 0.878 (0.767 to 0.938) Stewart 2001,2 Campos-Fernandez 2009,37 Scattoni 201138 (assumptions)
Risk status of localised disease
Low 0.540 (0.330 to 1.000) Bhatia 2007,76 Cheikh 2009,78 Cirrillo 2008,79 Engelhard 2006,82 Franiel 
2011,84 Hambrock 2008,85 Lattouf 2007,90 Testa 2010,106 Wetter 2005,108 
Yakar 2011,109 Yuen 2004,112 Panebianco 2011,95 Roethke 2012,104 Sciarra 
2010105
Intermediate 0.301 (0.000 to 0.500)
High 0.159 (0.000 to 0.330)
Locally advanced 0.122 (0.052 to 0.233) Stewart 2001,2 Campos-Fernandez 2009,37 Scattoni 201138 (assumptions)
TABLE 17 Diagnostic accuracy of strategies evaluated in the economic model
Strategy Sensitivity Specificity Source 
Systematic extended-core TRUS/Bx 0.832 (0.78 to 0.88) 1.00 Scattoni 201138
T2-MRI 0.86 (0.74 to 0.93) 0.55 (0.44 to 0.66) Systematic review
MRS 0.92 (0.86 to 0.95) 0.76 (0.61 to 0.87) Systematic review
DCE-MRI 0.79 (0.69 to 0.87) 0.52 (0.14 to 0.88) Systematic review
T2-MRI or MRS 0.96 (0.90 to 0.98) 0.31 (0.21 to 0.42) Systematic review
T2-MRI or DCE-MRI 0.88 (0.80 to 0.96) 0.14 (0.08 to 0.20) Systematic review
Note: reference standard differs for extended-cores TRUS/Bx and MRI methods. A 24-core TRUS-guided saturation biopsy 
serves as the gold standard for the extended-cores estimate, whereas MRI methods are validated on histopathology of 
any targeted cores and a varying number of additional cores taken under TRUS guidance.
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biopsy only. It was assumed that any patients missed by the index repeat biopsy (false-negatives), would 
have persistently elevated PSA level, which would trigger the offer of a saturation biopsy (> 24 cores) 
12 months later, and that acceptance would be high (assumption based on attitudes to repeat biopsy 
reported by Rosario et al.150). These conservative assumptions, which favour less-sensitive cancer detection 
strategies, were subjected to sensitivity analysis.
A systematic TRUS-guided extended-cores (14–16 cores) biopsy for all, carried out in an outpatient 
setting, was selected as the base comparator against which to assess the cost-effectiveness of using 
MRS/MRI (see Table 17). A limitation of the available literature is that no existing studies have directly 
assessed the relative sensitivity/specificity of MRI-directed biopsies in comparison with systematic biopsy 
sampling schemes with different numbers of cores. Thus, in modelling the comparison we were forced to 
rely on diagnostic accuracy data for the comparator and index tests derived from different sources using 
different reference standards. The sensitivity of the systematic extended-cores biopsy was derived from a 
study assessing the proportion of cancers detected by systematic biopsy schemes with variable numbers 
of cores,38 using the results of a TRUS-guided saturation biopsy as the reference standard. The MRS/MRI 
sensitivities/specificities were derived from the systematic review (see Chapter 4), where the reference 
standard was histopathological assessment of biopsied tissue but the number of cores taken varied 
from study to study. Sensitivity analysis was performed to assess the sensitivity of findings to variation in 
these parameters.
How care pathways were determined and modelled, including an illustration of 
the model
The diagnostic and care pathways were determined based on a review of guidelines, expert opinion, 
and the availability of data. A schematic review of the diagnostic pathways was provided in Chapter 1 
(see Figure 2). Figure 16 shows the tree structure used to model the index repeat biopsy within the 
economic model.
The diagnostic pathways were embedded in a Markov model developed to simulate the progression 
of diagnosed (treated) and undiagnosed PC (Figure 17). Seven basic states were used to model the 
natural history of PC: (1) no or undetectable cancer; (2) localised (T1–T2) PC (low risk); (3) localised PC 
(intermediate risk); (4) localised PC (high risk); (5) locally advanced cancer (T3); (6) metastatic cancer; and 
(7) PC death. Patients with localised and locally advanced disease were modelled to progress towards 
metastatic disease based on age, tumour risk status, and whether or not their cancer was diagnosed and 
appropriately treated. To begin with, patients with suspected PC following a first negative biopsy were 
spread across the undiagnosed states (using the proportions in Table 16). In the first cycle of the model, 
all patients were modelled to undergo their repeat biopsy, either by standard means or directed by one 
of the MRS/MRI sequences. Patients with underlying cancer (undetected) identified by the second biopsy 
as having disease, as determined by the sensitivity of the biopsy procedure, were modelled to transit to 
the appropriate diagnosed cancer state for the subsequent model cycle. Those with undetected cancer 
missed by the second negative biopsy remained in the appropriate undiagnosed state. Those remaining 
undiagnosed faced a higher risk of progression to metastases (based on progression rates observed for 
patients under watchful waiting), whereas those detected were modelled to progress at rates observed for 
patients receiving radical treatments. The model was cycled on a 3-monthly basis, such that probabilities of 
progression and costs of treatment and monitoring were expressed in terms of this constant cycle length.
Patients remaining in an undiagnosed cancer state after the index repeat biopsy were modelled to have 
their PSA levels monitored on a 6-monthly basis. An assumption was made that these patients would 
have persistently elevated PSA level and would therefore be selected for a further biopsy 12 months later. 
It was assumed that a saturation biopsy (≥ 24 cores) would be offered at this stage, that there would be 
90% uptake,150 and that the biopsy would have 98% sensitivity for detecting the remaining undiagnosed 
cancers (based on clinical opinion within the team). For patients without underlying PC, it was assumed 
that no further biopsies would be indicated unless incident PCs developed. These assumptions were 
subjected to sensitivity analysis.
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For every biopsy undertaken, modelled patients also faced an associated risk of complications (bleeding, 
infection, urinary retention). Patients crossing to the diagnosed states were modelled to receive 
appropriate staging, treatment and monitoring. In addition, patients receiving treatment faced a risk of 
experiencing complications, which incurred further health service costs and quality-of-life decrements. 
Following treatment for localised disease, a proportion of the cohort was modelled to experience tumour 
recurrence, triggering further treatment and costs.
Costs associated with biopsy procedures, PSA monitoring, staging, treatment and disease monitoring were 
incorporated into the model based on the application of unit costs to procedures and treatment protocols 
(derived from expert opinion and current guidelines). Utilities associated with the different cancer states 
were used to quality adjust the time spent by patients in each state, and utility decrements associated with 
complications arising from treatment were also applied. Thus the model enabled cumulative costs, LYs 
and QALYs to be tracked over the lifetime of modelled cohorts under alternative diagnostic strategies. The 
model captures the potential trade-offs between increased short-term costs associated with incorporating 
MRI sequencing into the care pathways and any cost savings and potential survival gains resulting from 
fewer repeat biopsies and earlier cancer treatment. The model also accounts for the fact that treatment 
may have a detrimental impact on patients’ health-related QoL.
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FIGURE 16 Diagnostic pathways for index re-biopsy. The base-case analysis assumed that all patients negative on MRS/
MRI would not proceed to biopsy, but we also assessed the impact of assuming these patients would proceed to an 
extended-cores TRUS/Bx. FN, false-negative; FP, false-positive; sens, sensitivity; spec, specificity; TN, true-negative; TP, 
true-positive.
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Complications of biopsy
The occurrence of biopsy complications was modelled on the basis of two data sources: the ProtecT trial150 
and a cohort study reported by Nam et al.151 The resultant probabilities are provided in Table 18. Costs 
associated with these complication events were estimated and incorporated into the model.
Risk of cancer progression (undiagnosed and diagnosed patients)
A simplifying assumption of the model was that all men in a cancer state are at risk of disease progression, 
and that men progress towards metastatic disease. It was also assumed that all cancer-related deaths 
occur following transition to metastatic disease. Given a lack of comparable data on the rate of transition 
from localised to locally advanced disease, and from locally advanced to metastatic disease (and the 
relative effect of diagnosis and treatment on these transitions), the model structure was simplified such 
that progression from localised disease to metastases was modelled in a single step (using a Weibull 
function fitted to observed published data for this transition).
Men were initially spread across the ‘no cancer’, ‘localised cancer’ and ‘locally advanced cancer’ states 
(see Table 16). They were then modelled to progress according to their cancer and diagnostic status using 
observed follow-up data on the cumulative incidence of metastatic disease combined with estimates of 
relative treatment effects (i.e. baseline transition risks were adjusted downwards to reflect the impact 
of appropriate treatment in those receiving a diagnosis). The progression risk for localised cancer was 
modelled based on data reported by Bill-Axelson et al.148 whereas the progression risk for men starting in 
the locally advanced state was modelled based on data from a European Organisation for Research and 
Treatment of Cancer (EORTC) study reported by Bolla et al.152
No cancer
Negative biopsy
Biopsy
+
+
+–
–
–
Localised
cancera
Locally
advanced
Metastatic
cancer
Localised
cancera
Extraprostatic
cancer
Metastatic
cancer
Prostate cancer
death
Diagnosed positive
Biopsy
Prop
recurrence
Biopsy
Biopsy
Other-cause
mortality
FIGURE 17 Model structure. a, Patients with localised cancer were risk stratified by cancer grade (low, intermediate 
and high) and modelled to progress to metastatic disease at different rates. Prop recurrence, proportion with local 
recurrence following treatment.
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Regression methods153 were used to fit Weibull functions to the observed metastases-free survival 
probabilities reported for men receiving watchful waiting over a 15-year follow-up period;148 separate 
functions were fitted for men of < 65 years of age and men aged ≥ 65 years. The estimated parameters 
of the Weibull functions were then used to derive 3-monthly transition probabilities for the risk of 
developing metastatic disease from undiagnosed localised cancer. In order to risk-stratify the probabilities 
of progression, separate functions were determined for patients with low-, moderate- and high-risk 
localised cancer. This was achieved by adjusting the rate parameters of the Weibull functions to yield the 
cumulative incidence of metastases or PC mortality observed for cohorts with low-148 and high-risk154 
localised cancer. The cumulative incidence rates of metastatic disease reported for the two age-specific 
cohorts (< 65/≥ 65) as a whole by Bill-Axelson et al. were taken to represent the risk of progression for 
moderate risk patients in each respective modelled age group. Transition probabilities for developing 
metastatic disease following diagnosis and treatment were estimated by multiplying the rate parameters 
of the Weibull functions by published relative risk estimates associated with radical prostatectomy.148 
The resultant modelled cumulative incidence of metastases in treated and untreated patients is shown in 
Figure 18 compared with the observed values derived from published sources. As a sensitivity analysis, we 
calibrated the model transition rates to yield the PC-specific survival probabilities (by risk status) observed 
for patients (> 12 years of follow-up) in the control group of a recently published randomised controlled 
TABLE 18 Risks of complications following prostate biopsy 
Event Probability (95% CI) Distribution for PSA Source
Biopsy complication
0.117 (0.100 to 0.137) Beta Rosario 2012150
Alpha: 134
Beta: 1013
Probability of hospital admission given biopsy complication
0.112 (0.069 to 0.176) Beta Rosario 2012150
Alpha: 15
Beta: 119
Reasons for hospital admission
Dirichlet Nam 2010151
Urinary infection related 0.716 (0.675 to 0.738) Alpha: 556
Urinary bleeding related 0.194 (0.166 to 0.221) Alpha: 151
Urinary obstruction related 0.090 (0.081 to 0.124) Alpha: 79
Biopsy-related consultation given complication
0.888 (0.824 to 0.931) Beta Rosario 2012150
Alpha: 119
Beta: 15
Location of consultation
Dirichlet Rosario 2012150
GP 0.773 (0.690 to 0.839) Alpha: 92
Urology department nurse 0.118 (0.071 to 0.188) Alpha: 14
Other – NHS Direct 0.109 (0.065 to 0.178) Alpha: 13
GP, general practitioner.
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trial of radical prostatectomy compared with observation for localised disease.149 In addition, we applied 
the corresponding relative risk estimates obtained from this trial.
For those starting the model in the locally advanced cancer stage, a similar approach as above was 
used to model the risk of progression to metastatic disease. However, given the lack of contemporary 
data on the risk of developing metastases from untreated locally advanced disease, we applied the 
metastases-free survival data reported for a cohort of patients treated with EBRT alone. These rates were 
then adjusted downwards for diagnosed patients using the relative risk reduction associated with EBRT 
combined with adjuvant hormone therapy.152 All of the relative risk parameters applied in the model are 
presented in Table 19.
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FIGURE 18 Modelled and observed cumulative incidence of metastases. WW, watchful waiting; RP, radical 
prostatectomy.
TABLE 19 Relative risk parameters applied to diagnosed patients in the model
Parameter Value (95% CI) Distribution for PSA Source
Localised disease
Relative risk of metastases (< 65 years, 
low risk)
0.41 (0.18 to 0.95) Log-normal;
Ln mean: –0.8916
Ln SE: 0.424364
Bill-Axelson et al. 2011148
Relative risk of metastases (< 65 years, 
intermediate/high risk)
0.47 (0.32 to 0.70) Log-normal:
Ln mean: –0.75502
Ln SE: 0.199684
Bill-Axelson et al. 2011148
Relative risk of metastases (≥ 65 years, 
low risk)
0.46 (0.19 to 1.11) Log-normal:
Ln mean: –0.77653
Ln SE: 0.450278
Bill-Axelson et al. 2011148
Relative risk of metastases (≥ 65 years, 
intermediate/high risk)
0.77 (0.51 to 1.15) Log-normal:
Ln mean: –0.026136
Ln SE: 0.207425
Bill-Axelson et al. 2011148
Locally advanced disease
Relative risk of metastases 0.28 (0.18 to 0.46) Log-normal:
Ln mean: –1.27297
Ln SE: 0.239354
Bolla et al. 2002152
SE, standard error.
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For those with metastatic disease, a constant 3-monthly risk of death from PC was estimated from English 
observational data155 and applied in the model. The age-specific risk of death from other causes was also 
incorporated based on age- and sex-specific interim UK life tables.156
Resource use and unit cost estimation
All costs were estimated based on resource-use inputs and unit costs for the 2009–10 financial year.
Standard transrectal ultrasound-guided biopsy
The cost of a TRUS-guided needle biopsy was taken from the NHS reference costs41 using the appropriate 
HRG (LB27Z). There is some uncertainty as to how hospitals in England and Wales are, or would be, 
reimbursed for repeat biopsies using the systematic extended-cores or MRI-/MRS-directed approach. 
Although both approaches can be carried out as outpatient procedures without general anaesthetic, it is 
likely that at least some organisations commission these as day-case procedures. As a result of outpatient 
procedure coding being non-mandatory, it is not possible to accurately ascertain the proportion of 
procedures carried out in each care setting, and this is likely to vary from trust to trust. Thus, adopting a 
conservative approach in favour of less sensitive less costly diagnostic strategies, we initially assumed that 
all index repeat biopsies would be carried as outpatient procedures, incurring an average cost of £212.
Note, however, that although this tariff-based cost should reflect the budget impact on NHS primary care 
trusts of commissioning such procedures, it might not fully capture the opportunity cost that hospitals 
face in delivering the procedure, particularly for extended-cores biopsies that can substantially increase 
pathology time over standard TRUS/Bx (10–12 cores). We therefore assessed the impact of increasing this 
cost through sensitivity analysis.
In the base case we also made the conservative assumption that the use of MRS/MRI would not influence 
the cost of the biopsy procedure itself. This was due to a lack of certainty as to how the patient-level 
pooled sensitivity estimates obtained for MRS/MRI imaging (from the systematic review) would be affected 
if only targeted cores were taken in the subsequent biopsy. However, we explored the impact of increasing 
the cost of extended-cores biopsies, but not the cost of MRI-/MRS-targeted biopsies.
For patients with underlying cancer missed by the index re-biopsy, we assumed that a saturation biopsy 
(≥ 24 cores) would be indicated at 12 months, and applied the day-case NHS reference cost for all these 
procedures (£447). We also explored the impact of increasing this cost to reflect potential underestimation 
of histopathology costs associated with obtaining larger numbers of cores (for further deterministic 
scenario analyses, see Results, below).
Magnetic resonance imaging sequences for guiding biopsy
The costs of performing alternative MRI sequences to guide prostate biopsy were estimated using a 
bottom-up approach. Radiographer and radiologist time associated with the performance of different 
sequences was estimated by asking all of the radiologists involved in the project to provide estimates of 
time inputs they deemed to be representative of standard practice. Within these estimates, allowance 
was made for preparation (getting the patient into the machine) and scanning time (two radiographers) 
and reading/reporting time (one consultant radiologist). The average reported time inputs for sequences 
included in the economic model are outlined in Table 20. Unit costs obtained from the Unit Costs of 
Health and Social Care157 were applied to these resource-use inputs. These unit costs included salaries, 
on-costs (employer superannuation and national insurance contributions) and an apportionment of 
capital space and overhead costs to capture the opportunity cost of space and overheads attributable to 
the alternative procedures. Capital equipment required for the alternative MRI sequences was costed by 
applying current market prices obtained from NHS Grampian. These initial outlay costs were annuitised 
over the useful working lifespan of the piece of equipment in question, applying an annual discount rate 
of 3.5% to account for the opportunity cost of the investment over time. The equivalent annual cost of 
each piece of equipment was divided through by its estimated running time to give a cost per minute 
estimate. The scanning time estimates associated with alternative MRI sequences were then multiplied 
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TABLE 20 Summary of MRS/MRI procedure cost estimates
Sequence
Grade/
band
Patient 
preparation 
time (minutes)
Time per 
patient 
(minutes)
Cost per 
hour (£)
Staff cost 
per patient 
(£)
Equipment 
cost per 
patient (£)
Total 
cost per 
patienta (£)
T2-MRI
Radiographer 1 6 + 7 + 7 10.00 14.33 48.33 19.60
Radiographer 2 7 10.00 14.33 50.00 20.28
Radiologist Consultant 5.00 162.00 13.50
Totals 53.38 46.90 106.29
DW-MRI (+ T2-MRI)
Radiographer 1 6 + 7 + 7 10.00 21.33 48.33 25.24
Radiographer 2 7 10.00 21.33 50.00 26.11
Radiologist Consultant 8.67 162.00 23.40
Totals 74.75 60.65 141.30
DCE-MRI (+ T2-MRI)
Radiographer 1 6 + 7 + 7 12.00 22.67 48.33 27.93
Radiographer 2 7 12.00 22.67 50.00 28.89
Radiologist Consultant 10.00 162.00 27.00
Totals 83.81 71.21 189.71
MRS (+ T2-MRI)
Radiographer 1 6 + 7 + 7 10.00 27.33 48.33 30.07
Radiographer 2 7 10.00 27.33 50.00 31.11
Radiologist Consultant 16.67 162.00 45.00
Totals 106.19 73.93 185.68
T2-MRI + DW-MRI + DCE-MRI
Radiographer 1 6 + 7 + 7 12.00 31.33 48.33 34.91
Radiographer 2 7 12.00 31.33 50.00 36.11
Radiologist Consultant 16.67 162.00 45.00
Totals 116.02 88.42 239.06
T2-MRI + DW-MRI + MRS
Radiographer 1 6 + 7 + 7 10.00 37.67 48.33 38.40
Radiographer 2 7 10.00 37.67 50.00 39.72
Radiologist Consultant 20.33 162.00 54.90
Totals 133.02 94.61 233.18
T2-MRI + DCE-MRI + MRS
Radiographer 1 6 + 7 + 7 12.00 37.33 48.33 39.74
Radiographer 2 7 12.00 37.33 50.00 41.11
Radiologist Consultant 21.67 162.00 58.50
Totals 139.35 101.71 275.34
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Mowatt et al. under the terms of a commissioning contract issued by the Secretary of State for 
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17200 HealtH tecHnOlOgy assessment 2013 VOl. 17 nO. 20
61
by the appropriate equipment cost per minute estimates to give estimates of the capital equipment costs 
attributable to each different MRI sequence. Costs of equipment used only for DCE-MRI (pump) or MRS 
(MRS software) were only allocated to sequences involving these procedures. The annual equivalent costs 
of these items were divided through by the number of uses per year (Dr Lutfi Kurban, Aberdeen Royal 
Infirmary, March 2012, personal communication; Dr Anwar Padhani, Mount Vernon Cancer Centre, April 
2012, personal communication) to give cost per use estimates, which were then applied to sequences 
incorporating these procedures. Finally, consumables associated with DCE-MRI (contrast, pump pack, 
others) were costed using unit prices provide by NHS Grampian.
As the MRI costs represent the opportunity costs to hospitals of providing alternative scan sequences, 
they are well suited to assessing the relative cost-effectiveness of using alternative sequences. However, 
the estimated costs for some of the simpler scans may underestimate the costs of commissioning such 
activity. This makes them somewhat less comparable with the tariff-based cost estimate for TRUS/Bx. 
However, we did not adjust these costs further in the base-case analysis given the concurrent conservative 
approach to costing TRUS/Bx. As a sensitivity analysis we adjusted the costs of sequences by setting the 
cost of T2 + DCE-MRI equal to the NHS reference cost for HRG RA03Z (Magnetic Resonance Imaging Scan, 
one area, pre and post contrast) (£229)41 and maintained the incremental differences in cost between 
sequences as estimated from the bottom-up calculations.
Biopsy complication costs
Standard practice for repeat biopsy in the UK is systematic TRUS-guided extended-cores or saturation 
biopsy. The incidence of adverse events post biopsy was determined from the literature150,151 and 
categorised into hospital admissions or biopsy-related consultations (see Table 18). A risk of death from 
biopsy complications was experienced only by patients who developed an infection (p = 0.0009) and all 
other patients were assumed to recover after initial treatment.
Hospital admissions resulting from biopsy complications were reported by Nam151 and Rosario150 as being 
due to one of three urological diagnoses: urinary infection; urinary bleeding (haematuria); or urinary 
obstruction (Table 21). For inpatient admissions due to urinary tract infection (UTI) we applied the NHS 
reference cost for HRG LA04G (Kidney or Urinary Tract Infections with length of stay 1 day or less) (£401). 
Admission for haematuria was assumed to require insertion of a haematuria catheter for bladder irrigation 
HRG LB18Z (Attention to Suprapubic Bladder Catheter) at a cost of £567 per patient.41 Urinary retention 
was assumed to be temporary and was modelled to incur the cost of inserting and subsequently removing 
a urethral catheter: day-case HRGs LB09Z (Ureter Intermediate Endoscopic Procedures) and LB15E (Bladder 
Minor Procedure 19 years and over) at £652 and £368, respectively.41 It was further assumed that the 
NHS would incur the daily cost of an overnight catheter bag and the weekly cost of a leg bag (apart 
from in the first week when two leg bags would be required) over the course of 1 month (£6.47 and 
£12.61, respectively).
Sequence
Grade/
band
Patient 
preparation 
time (minutes)
Time per 
patient 
(minutes)
Cost per 
hour (£)
Staff cost 
per patient 
(£)
Equipment 
cost per 
patient (£)
Total 
cost per 
patienta (£)
T2-MRI + DW-MRI + DCE-MRI + MRS
Radiographer 1 6 + 7 + 7 12.00 46.00 48.33 46.72
Radiographer 2 7 12.00 46.00 50.00 48.33
Radiologist Consultant 25.33 162.00 68.40
Totals 163.46 118.92 316.60
a Total costs also include estimates of administration and consumable costs per scan.
TABLE 20 Summary of MRS/MRI procedure cost estimates (continued)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
assessment Of cOst-effectIVeness
62
Rosario et al.150 also reported the 35-day incidence of consultations with general practitioners, urology 
department nurses, and ‘other sources of medical advice’ (e.g. NHS Direct). The cost associated with a 
general practitioner (GP) consultation was derived from the Unit Costs of Health and Social Care.157 The 
average duration of a GP consultation is 11.7 minutes157 at a cost of £3.10 per surgery minute,157 giving 
a unit cost of £36.27 per consultation. The cost of a consultation with a urology department nurse was 
derived from the relevant NHS tariff – non-consultant-led follow-up attendance, non-admitted, face to 
face – at cost of £70.41 The cost per NHS direct contact was derived from the NHS Direct National Health 
Service Trust Annual Report and Accounts 2009–10, and was based on the total reported staff wages 
divided by the number of calls logged, giving a cost of £20.98 per call.
Prostate cancer treatment costs for localised disease
Potential treatment pathways by cancer stage were derived from the current NICE guidance.9 The costs 
associated with implementing alternative treatment pathways, on an ongoing 3-monthly basis, were 
estimated using data from a variety of sources including the Department of Health NHS reference costs,41 
the Unit Costs of Health and Social Care,157 and a recently completed technology assessment report 
(TAR) evaluating the cost-effectiveness of robotic radical prostatectomy compared with laparoscopic 
prostatectomy144 for localised PC. Clinical opinion was relied upon to enable an appropriate estimation of 
timelines for treatment pathways.
It is typical practice in the UK to monitor PSA level for the duration of the patient’s life post treatment; 
every 3 months for the first 2 years and then every 6 months thereafter (based on clinical opinion within 
the research team). The cost of PSA level monitoring was thus estimated, based on a consultation with a 
practice nurse (£12)157 plus £5.91 for laboratory services,144 and included in the model (Table 22).
Patients with localised PC were modelled to follow one of three alternative treatment pathways: (1) active 
surveillance; (2) radical prostatectomy followed by PSA level monitoring; or (3) EBRT followed by PSA level 
TABLE 21 Unit costs associated with biopsy complications
Procedure
Unit 
cost (£) Assumptions
Lower/higher estimates 
(distribution) Source
Hospital admissions
Gamma
UTI 401 HRG LA04G (Kidney or Urinary 
Tract Infections with length of stay 
1 day or less)
£286/£466
(Alpha: 8.91; beta: 45.00)
Department of Health 
201141
Urinary bleeding 
(haematuria)
567 HRG LB18Z (Attention to 
Suprapubic Bladder Catheter)
£293/£635
(Alpha: 4.94; beta: 114.88)
Department of Health 
201141
Urinary 
obstruction 
1039.08 HRG LB09Z (Ureter Intermediate 
Endoscopic Procedures) and LB15E 
(Bladder Minor Procedure 19 years 
and over) + cost of catheter bags
£595/£1225
(Alpha: 4.88; beta: 212.73)
Department of Health 
2011;41 Ramsay et al. 
2012144
Biopsy-related consultations
GP visit 36.27 11.7 minutes for surgery 
consultation
Curtis 2011157
Urology 
department 
nurse visit
70 £46/£85
(Alpha: 5.78; beta: 12.10)
Department of Health 
201141
Call to NHS 
Direct
20.98 Applied deterministically
GP, general practitioner.
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monitoring. The proportion of patients receiving each management strategy, by D’Amico Risk category,31 
was derived from routine Scottish health episode data (Dr Karina Laing, MSc in Surgical Sciences thesis, 
University of Edinburgh, May 2012, personal communication). It was assumed that the alternative 
treatment modalities would be applied appropriately based on the risk of progression and that, as such, 
the observed risk reduction associated with radical prostatectomy 148 could be achieved at the level of the 
cohort as a whole.
The cost of active surveillance was estimated based on the cost of PSA testing (see Table 22) on a 
3-monthly basis, followed by a repeat TRUS/Bx41 at 12 months, and every 3 years thereafter (based on 
clinical opinion within the research team).
The cost of radical prostatectomy was taken as the NHS reference cost for HRG LB21Z (Bladder Neck Open 
Procedures – Male). Of the two most common approaches to radical surgery (open and laparoscopic 
radical prostatectomy) the overall activity reported for open procedures was higher,41 and, as such, the cost 
for this procedure was applied in the model.
The cost associated with a programme of EBRT was calculated on the basis of 37 sessions within a 
7.5-week time frame (expert opinion) at a cost per session of £129.41 EBRT treatment is generally 
accompanied by a course of androgen deprivation therapy. Although all patients with localised PC were 
modelled to receive 3 months of hormone therapy from commencement of EBRT, hormone therapy prior 
to EBRT treatment was assumed to occur only for those with intermediate- or high-risk disease. Before 
commencing EBRT, these patients were initially modelled to receive a 21-day course of bicalutamide 
(Casodex®, AstraZeneca: £96.00), followed by a 3-month course of the LHRH agonist triptorelin 
(Decapeptyl® SR, Ipsen: 11.25-mg 3-month injection) at a cost of £207.158 As localised low-risk patients do 
not generally receive hormone therapy prior to EBRT treatment, it was assumed that the costs of hormone 
treatment for these patients would be incurred in the first 3-month cycle following diagnosis, concurrently 
with the EBRT sessions. It was assumed in all cases that triptorelin would be administered by a practice 
nurse in a primary care setting, at a cost of £12 per visit.
Treatment costs associated with locally advanced disease
External beam radiotherapy with adjuvant hormone therapy was identified as the most appropriate 
treatment option for patients with locally advanced PC upon diagnosis.9 A small proportion of men were 
also modelled to receive radical prostatectomy. The cost streams and timelines for these treatments were 
assumed to be consistent with those outlined above for patients with moderate- to high-risk localised 
disease, with the exception that hormone therapy was continued to 2 years post EBRT.
Costs associated with local progression following treatment for localised disease
A proportion of the cohort was modelled to experience biochemical recurrence following radical 
treatment for localised cancer. These patients were modelled to receive either salvage EBRT or hormone 
therapy alone.
Salvage EBRT is delivered at lower gray, with fewer sessions (33 sessions within a 6.5-week time frame). 
As such, we applied the NHS reference cost (£107) for the appropriate HRG (SC22Z) to each treatment 
TABLE 22 Cost of PSA testing
Procedure Unit cost (£) Source
PSA test 5.91 Ramsay et al.144
Practice nurse 12 per consultation Unit Costs of Health and Social Care157
PSA unit cost 17.91
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session.41 In addition, hormone treatment for patients receiving salvage EBRT for biochemical recurrence 
was extended for a period of 2 years post EBRT treatment.
The 3-monthly cost of hormone therapy was assumed to correspond to the cost of hormone therapy 
administered pre and post EBRT (21-day course of bicalutamide, followed by 3-monthly injections of 
triptorelin). However, treatment was assumed to extend for the duration of the patient’s lifetime when 
initiated for biochemical relapse.
Costs associated with metastatic disease
Upon transiting to the metastatic disease state, it was initially assumed that all patients would be treated 
with hormone therapy, incurring a continuous 3-monthly cost of £219 (Table 23). Without explicitly 
modelling the initiation and impact of chemotherapy, we also assumed that 50% of patients developing 
metastatic disease would undergo a first-line docetaxel-based chemotherapy regimen (£10,450) and that 
70% of these patients would go on to receive a second-line abiraterone-based regimen (£24,670) prior to 
death, as per the assumptions used in the costing template for the NICE abiraterone technical appraisal.39
Costs of complications arising from treatment
Radical prostatectomy
Three common adverse events following radical prostatectomy were modelled: (1) bladder neck 
contracture; (2) urinary incontinence (UI); and (3) ED (Table 24). The probability of experiencing bladder 
neck contracture following surgery was taken from the systematic review of a recently completed 
TABLE 23 Unit cost estimates for treatment pathways
Procedure
Unit 
cost (£) Assumption
Lower/higher quartile 
(distributions) Source
Active surveillance
TRUS/Bx 212 HRG = LB27Z (outpatient) £137/£295
(Gamma; alpha: 3.23, 
beta: 65.58)
Department of Health 
201141
Radical treatment
Open radical 
prostatectomy
4614 HRG = LB21Z £3650/£5408
(Gamma; alpha: 12.37; 
beta: 373.04)
Department of Health 
201141
EBRT: 37 sessions 4773 HRG = SC23Z £129 × 37 £3848/£5439
(Gamma; alpha: 16.16; 
beta: 295.35)
Department of Health 
201141
Salvage treatment
EBRT: 33 sessions 3531 HRG = SC22Z £107 × 33 £2211/£4983
(Gamma; alpha: 2.91; 
beta: 1211.93)
Department of Health 
201141
Hormone therapy
A 21-day course of 
bicalutamide
96 50 mg per day Applied deterministically BNF 63158
Three months’ decapeptyl 219 Drugs + administration: 
£207 + £12
Applied deterministically BNF 63;158 Curtis 2011157
Two years’ hormones 1752 £219 × 8 Applied deterministically BNF 63;158 Curtis 2011157
BNF, British National Formulary.
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technology assessment review.144 All patients were assumed to recover from bladder neck contracture and 
incur the one-off inpatient admission cost for a bladder neck minor endoscopic procedure (HRG LB27Z). 
Increases in the proportions of patients suffering from ED and/or UI at different time points following 
radical prostatectomy were derived from cohort studies (Sacco et al.;159 Stanford et al.160). Patients 
experiencing UI were assumed to enter a continuous period of self-management using containment pads 
at a 3-monthly cost of £65.90.144 Additionally, 10% of patients experiencing UI were modelled to incur 
the cost of oxybutynin hydrochloride (Ditropan, Sanofi Aventis) (clinical opinion) at a 3-monthly cost 
of £36.66.158 Patients recovering urinary continence were modelled to receive no further management 
costs for this complication, whereas those remaining incontinent continued to incur the costs of 
containment pads.
Patients suffering from ED were modelled to receive sildenafil (Viagra®, Pfizer) (84%) or alprostadil (MUSE®, 
Astra) (16%). Proportions of patients using both were identified in the literature and the weighted 
average cost was applied to estimate the 3-monthly treatment cost. All of the unit costs for treatment 
complications are provided in Table 24.
TABLE 24 Long-term complications associated with radical prostatectomy and EBRT 
Long-term 
complications
Probability (95% CI) Distribution
Unit cost of 
treatment (£) Source< 65 years ≥ 65 years < 65 years ≥ 65 years
Radical prostatectomy
Urinary stricture 0.022 0.022 1112 (one-off) Ramsay144
Urinary incontinence
3 months 0.318 (0.289 
to 0.348)
0.318 (0.289 
to 0.348)
Alpha: 305
Beta: 653
65.90 (every 
3 months)
Sacco159
6 months 0.220 (0.195 
to 0.247)
0.220 (0.195 
to 0.247)
Alpha: 211
Beta: 747
12 months 0.131 (0.110 
to 0.154)
0.131 (0.110 
to 0.154)
Alpha: 125
Beta: 833
ED
Baseline 0.115 (0.094 
to 0.140)
0.262 (0.228 
to 0.300)
Alpha: 83
Beta: 640
Alpha: 149
Beta: 419
232.08 (every 
3 months)
Stanford160
12 months 0.763 (0.728 
to 0.794)
0.840 (0.802 
to 0.872)
Alpha: 488
Beta: 152
Alpha: 352
Beta: 67
24 months 0.656 (0.619 
to 0.692)
0.790 (0.748 
to 0.826)
Alpha: 420
Beta: 220
Alpha: 331
Beta: 88
EBRT (late toxicity)
Beta
Urinary stricture 0.072 (0.050 
to 0.102)
0.072 (0.050 
to 0.102)
Alpha: 27
Beta: 350
1112 (one-off) Ataman161
Urinary 
incontinence
0.053 (0.035 
to 0.081)
0.053 (0.035 
to 0.081)
Alpha: 20
Beta: 357
65.90 (every 
3 months)
Ataman161
Bowel problems 0.119 (0.090 
to 0.156)
0.119 (0.090 
to 0.156)
Alpha: 45
Beta: 332
18 (every 
3 months)
Ataman161
ED 0.45 0.45 Applied 
deterministically
232.08 (every 
3 months)
Heidenreich162
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External beam radiotherapy
Four common complications (see Table 24) following EBRT treatment were identified from the EUA 
Guidelines on Prostate Cancer:161,162 urinary stricture, UI, ED, and bowel problems. An identical assumption 
was made for patients diagnosed with urinary stricture as for those diagnosed with bladder neck 
contracture following radical prostatectomy; i.e. all patients were assumed to recover following a minor 
bladder neck endoscopic procedure carried out in an inpatient setting (£1112). The cost of managing UI 
following EBRT was assumed to correspond to that reported for radical prostatectomy, as were the costs of 
treating ED.
Health measurement and valuation
Cancer states
The model was used to estimate cumulative costs and LYs over the lifetime of the simulated cohorts. 
Attempts were then made to identify appropriate utility weights (Table 25) for the different cancer states, 
so as to enable the estimation of QALYs. A similar approach to the one taken in the Robotic report144 
was used to adjust time spent in PC health states. For localised cancer, we used the European Quality of 
Life-5 Dimensions (EQ-5D) utility weights reported for a cohort of patients undergoing prostatectomy at 
baseline, 6 months, 1 year and 4 years. We assumed that patients with no cancer or undiagnosed localised 
cancer would have the same health-state utility as prostatectomy patients at baseline. For PC found to be 
locally advanced upon diagnosis, and for local recurrence following initial treatment, we applied further 
utility weights reported by Korfage et al.163 for a cohort of patients undergoing EBRT. This cohort of 
patients was slightly older on average, with more advanced disease. For patients with metastatic disease, 
we applied the average of the time trade-off weights for metastatic and castration resistant metastatic 
disease – elicited from a sample of 45- to 70-year-old married males (with no history of PC) presenting at a 
primary care medical facility in the USA.144
Biopsy and treatment complications
The EQ-5D weights reported by Korfage et al.163 were the mean values reported for cohorts where a 
substantial proportion of patients experienced the main complications of prostatectomy or EBRT but 
nevertheless reported high levels of health-related QoL on the EQ-5D.163 As such in the base-case analysis 
we made no further adjustment to health-related QoL for those modelled to experience treatment 
complications. However, we did explore the impact of applying further disutilities for complications 
through sensitivity analyses.
In order to do this we applied utilities reflecting the presence of mild/moderate bowel problems,164 UI,9,165 
and ED9,165 in a multiplicative fashion, such that if a modelled patient had localised cancer and UI, then 
their overall utility pay-off was equal to the product of the utilities for localised cancer and UI.
Discount rate (costs and benefits)
Costs and benefits (LYs and QALYs) were discounted at the treasury recommended rate of 3.5% per 
annum.167 We also assessed the impact of discounting benefits at the rate of 1.5% per annum, while 
maintaining a discount rate of 3.5% for costs, as suggested by NICE in instances where treatment effects 
‘. . . are both substantial in restoring health and sustained over a very long period (normally at least 
30 years)’.167
List of assumptions
 z All patients were initially spread across the states: no cancer, localised cancer (low, intermediate, high 
risk) or locally advanced cancer.
 z Imaging test sensitivities were not adjusted by grade and stage of underlying cancer in the base-case 
analysis, but the observed correlation between MRS and DW-MRI test performance and tumour grade 
was explored through sensitivity analysis.
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 z All patients with cancer were modelled to be at risk of progression to metastatic disease based on 
their D’Amico risk status (low, intermediate, high).
 z All cancer deaths occurred through distant metastases.
 z Diagnosed patients experienced a reduction in the risk of progression to metastases in line with that 
observed for patients receiving radical prostatectomy (favours more sensitive strategies). Although 
not all patients with localised disease were modelled to receive radical treatment upon diagnosis, 
it was assumed that appropriate risk-based targeting of treatment could maintain the relative 
treatment effects observed for radical prostatectomy, without the need to implement radical treatment 
immediately for all patients.
 z Given the lack of contemporary data on the risk of progressing to metastatic disease from locally 
advanced disease without treatment, progression was modelled to occur at the rate observed for 
patients receiving EBRT alone. Progression in those diagnosed was modelled to occur at the rate 
observed for patients receiving EBRT with adjuvant hormone therapy.
 z The starting point for the model was the first repeat biopsy, and it was assumed that patients with 
cancer missed by this biopsy would have persistently elevated PSA level, which would trigger a further 
definitive saturation biopsy 12 months later (base case).
 z For patients without underlying cancer, the assumption was made that management beyond the 
first repeat biopsy would remain the same, regardless of which strategy was used for the first repeat 
biopsy. No further biopsies were modelled for this group in the base-case analysis, unless incident 
PC developed.
TABLE 25 Health-state utilities applied in the economic model
Health-state utility Utility value Distribution for PSA Source
Cancer states
Beta: mean (SEM)
Localised (undiagnosed) 0.89 0.89 (0.0133) Korfage 2005163
Localised (diagnosed) Korfage 2005163
< 6 months 0.89 0.89 (0.0133)
6–12 months 0.91 0.91 (0.014427)
12–51 months 0.90 0.90 (0.015328)
≥ 52 months 0.88 0.88 (0.018276)
Locally advanced (undiagnosed) 0.81 0.81 (0.014625) Korfage 2005163
Locally advanced (diagnosed) Korfage 2005163
< 6 months 0.81 0.81 (0.0146)
6–12 months 0.83 0.83 (0.0156)
12–51 months 0.82 0.82 (0.0149)
≥ 52 months 0.76 0.76 (0.0205)
Metastases 0.635 0.635 (0.04) Volk et al. 2004166
Treatment complications
Urinary incontinence 0.84 Applied deterministically Shimizu et al. 2008165
Bowel problems 0.83 Applied deterministically Krahn et al. 2003164
ED 0.88 Applied deterministically Shimizu et al. 2008165
SEM, standard error of mean.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
assessment Of cOst-effectIVeness
68
 z A TRUS-guided systematic extended 14- to 16-core biopsy scheme was used as the comparator 
against which the cost-effectiveness of MRI-/MRS-directed TRUS/Bx was assessed in the base case.
 z It was assumed in the base case that MRI-/MRS-directed biopsy would not reduce the cost of 
the biopsy procedure or the risk of biopsy-related complications relative to the TRUS-guided 
extended-cores biopsy.
Time horizon
Once it was established that the model made internally consistent predictions of cancer-related mortality 
over the period to which the observed input data related (15 years), the analysis proceeded over a 30-year 
time horizon. By this stage the majority of the modelled cohorts were dead and the additional QALYs per 
cycle had fallen to < 0.001.
Internal validation
To assess the internal validity of the model, Figures 19 and 20 show the Markov traces for treated and 
untreated patients with localised cancer (men aged 60 years) over a 15-year follow-up period. The 
modelled cumulative incidence of PC death does not match the data reported by Bill-Axelson et al.148 
exactly (23% vs 26% for untreated; 12% vs 16% for treated) owing to the application of UK age-specific 
rates of death from other causes and the application of a constant UK-specific risk of death from 
metastatic PC. However, the cumulative PC mortality rate is generally consistent with the data reported by 
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FIGURE 19 Markov trace for undiagnosed/untreated local cancer in patients aged 60 years.
FIGURE 20 Markov trace for diagnosed/treated local cancer for patients aged 60 years.
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Bill-Axelson and other similar cohorts; for example, Albertson et al.168 estimated prostate-specific mortality 
of ~20% at 15 years in men aged 60–64 years with a Gleason score of 6.168 However, our modelled rates 
are significantly higher than those reported in the recently published PIVOT trial,149 which identified men 
through PSA screening. As such, sensitivity analysis was undertaken to assess the impact of recalibrating 
the model to yield the PC mortality rates observed by Wilt et al.149
Analysis
The model was first of all analysed deterministically, and the impact of altering key parameters and 
structural assumptions was demonstrated using deterministic sensitivity analysis. A probabilistic analysis 
was also undertaken, whereby Monte Carlo simulation was used to randomly draw a value for each model 
parameter from its assigned probability distribution for each of 1000 runs. The NMB approach was used to 
generate cost-effectiveness acceptability curves (CEACs) using the output from this probabilistic sensitivity 
analysis. One thousand probabilistic iterations were found to produce stable CEACs. Although the mean 
values obtained from probabilistic sensitivity analysis provide a more appropriate estimate of expected 
costs and effects for non-linear models, the analysis was found to be too computationally intensive to 
demonstrate the impact of all deterministic uncertainties on the mean probabilistic results. For this reason, 
the mean results from probabilistic sensitivity analysis are presented for only the main base-case analyses in 
60- and 70-year-old men.
For the PSA, beta or Dirichlet distributions were used to represent uncertainty surrounding probabilities 
and proportions; beta distributions were assigned for health-state utilities, gamma distributions were 
used for costs, and log-normal distributions were assigned for relative risk parameters (see parameter 
tables, above – Tables 19, 21, 23, 24 and 25). To reflect the joint uncertainty surrounding the estimated 
sensitivity/specificity of each MRI sequence, the logit of the sensitivity/specificity of each sequence was 
modelled to follow a bivariate normal distribution (derived from the meta-analysis), with negative 
correlation specified between sensitivity and specificity on the logit scale. As insufficient data were 
available to estimate the correlation between sensitivity and specificity for each sequence, correlation 
(–0.3), obtained from the bivariate meta-analysis model for T2-MRI (the sequence with most information 
available for estimating correlation), was applied to all sequences. Underlying cancer prevalence and 
the initial proportional spread of the cohorts across cancer stages and risk strata were omitted from the 
PSA. This was due to uncertainty as to how the estimated variability of these parameters (see Table 16) 
reflected heterogeneity rather statistical impression. Instead, the impact of uncertainty surrounding these 
parameters was addressed using subgroup analysis and deterministic sensitivity analysis.
Results
Mean costs and mean effects, and incremental analysis
Tables 26 and 27 present the mean costs, mean LYs, and incremental cost per LY gained for each 
strategy in men aged 60 years at the time of repeat biopsy (based on deterministic and the probabilistic 
analyses, respectively), assuming a prevalence of underlying cancer of 24%. Tables 28 and 29 present 
the same analyses using QALYs as the measure of effect. A breakdown of strategy costs into diagnosis 
and pre-diagnosis monitoring costs, biopsy complication costs, and cancer treatment and treatment 
complication costs is provided in Appendix 17. Appendix 17 also provides a summary of the expected 
numbers of unnecessary and appropriate biopsies undertaken with each strategy. Figures 21 and 22 
present the findings of the cost per LY and cost per QALY analyses graphically on the cost-effectiveness 
plane. Strategies falling above and behind the lines plotted through the cost-effectiveness planes represent 
options that are more costly and less effective than other strategies or combinations of strategies. 
Strategies falling on the lines (the cost-effectiveness frontier) represent potentially cost-effective options, 
dependent on decision-makers’ willingness to pay per LY or QALY gained.
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TABLE 26 Incremental cost per LY gained from deterministic analysis (men aged 60 years; underlying cancer 
prevalence 24%) 
Strategy
Average 
cost (£)
Incremental 
costa (£) Average LYs Incremental LYsa
Incremental cost 
per LYa (£)
ICER vs common 
baseline (£)
Syst. TRUS 3895 – 14.16796 – – –
T2-MRI 3902 7 14.16890 0.00094 7447 7447
MRS 3952 49 14.17081 0.00191 25,849 19,796
DCE-MRI 3984 32 14.16669 –0.00412 Dominated Dominated
T2-MRI or 
MRS
4031 80 14.17203 0.00122 65,208 33,425
T2-MRI or 
DCE-MRI
4056 25 14.16949 –0.00254 Dominated 105,351
–, common baseline; Syst. TRUS, systematic TRUS-guided extended-cores (15) biopsy.
a Incremental costs and LYs are estimated in comparison with the next less costly non-dominated strategy.
TABLE 27 Incremental cost per LY gained from the probabilistic analysis (men aged 60 years; underlying cancer 
prevalence 24%)
Strategy
Average 
cost (£)
Incremental 
costa (£) Average LYs Incremental LYsa
Incremental 
cost per LYa (£)
ICER vs common 
baseline (£)
Syst. TRUS 3910 – 14.15935 – – –
T2-MRI 3916 7 14.16013 0.00078 8512 8512
MRS 3967 51 14.16189 0.00176 28,715 22,535
DCE 3999 32 14.15802 –0.00387 Dominated Dominated
MRI or 
MRS
4045 78 14.16313 0.00124 63,393 35,903
MRI or DCE 4069 23 14.16065 –0.00248 Dominated 122,575
–, common baseline; Syst. TRUS, systematic TRUS-guided extended-cores (15) biopsy.
a Incremental costs and LYs are estimated in comparison with the next less costly non-dominated strategy.
TABLE 28 Incremental cost per QALY gained from deterministic analysis (men aged 60 years; underlying cancer 
prevalence 24%)
Strategy
Average 
cost (£)
Incremental 
costa (£)
Average 
QALYs
Incremental 
QALYsa
Incremental cost 
per QALYa (£)
ICER vs common 
baseline (£)
Syst. TRUS 3895 – 12.48432 – – –
T2-MRI 3902 7 12.48498 0.00066 10,626 10,626
MRS 3952 49 12.48630 0.00132 37,382 28,502
DCE-MRI 3984 32 12.48346 –0.00285 Dominated Dominated
T2-MRI or MRS 4031 80 12.48714 0.00083 95,481 48,367
T2-MRI or DCE-MRI 4056 25 12.48538 –0.00175 Dominated 152,323
–, common baseline; Syst. TRUS, systematic TRUS-guided extended-cores (15) biopsy.
a Incremental costs and QALYs are estimated in comparison with the next less costly non-dominated strategy.
Note: bold text denotes the strategy with the highest NMB at a ceiling willingness-to-pay ratio of £30,000 per QALY.
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TABLE 29 Incremental cost per QALY gained from probabilistic analysis (men aged 60 years; underlying cancer 
prevalence 24%)
Strategy
Average 
cost (£)
Incremental 
costa (£)
Average 
QALYs
Incremental 
QALYsa
Incremental cost 
per QALYa (£)
ICER vs common 
baseline (£)
Syst. TRUS 3910 – 12.47303 – – –
T2-MRI 3916 7 12.47357 0.00054 12,315 12,315
MRS 3967 51 12.47478 0.00121 41,927 32,811
DCE-MRI 3999 32 12.47213 –0.00264 Dominated Dominated
T2-MRI or MRS 4045 78 12.47562 0.00084 92,865 52,378
T2-MRI or DCE-MRI 4069 23 12.47392 –0.00170 Dominated 178,746
–, common baseline; Syst. TRUS, systematic TRUS-guided extended-cores (15) biopsy.
a Incremental costs and QALYs are estimated in comparison with the next less costly non-dominated strategy.
Note: bold text denotes the strategy with the highest NMB at a ceiling willingness-to-pay ratio of £30,000 per QALY.
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FIGURE 21 Cost-effectiveness frontier based on the cost per LY analysis (men aged 60 years, underlying cancer 
prevalence 24%).
FIGURE 22 Cost-effectiveness frontier based on the cost per QALY analysis (men aged 60 years, underlying cancer 
prevalence 24%).
3880
3900
3920
3940
3960
3980
4000
4020
4040
4060
4080
12.483 12.484 12.485 12.486 12.487 12.488
C
o
st
 (
£)
Effectiveness (QALYs)
Systematic TRUS
MRI
MRS
MRI or MRS
DCE
MRI or DCE
Not dominated
NIHR Journals Library www.journalslibrary.nihr.ac.uk
assessment Of cOst-effectIVeness
72
The base-case results show systematic extended-core TRUS/Bx to be the least costly option. However, 
using T2-MRI to determine which patients to biopsy (and to subsequently direct the biopsy) increases the 
costs by only a very small margin, with corresponding very small survival and QALY gains. Although these 
differences are very small and insignificant, T2-MRI-directed biopsy does have a favourable incremental 
cost per LY and QALY gained in comparison with systematic TRUS/Bx.
Using MRS to determine and direct biopsies results in a further cost increase and survival gain over 
T2-MRI but its incremental cost-effectiveness ratios (ICERs) are somewhat less favourable; although 
the incremental cost per QALY gained with MRS compared with systematic TRUS/Bx is just < £30,000 
(deterministic analysis), it is > £30,000 in comparison with T2-MRI. Using positive findings on T2-MRI or 
MRS to determine and direct biopsies again increases costs, LYs and QALYs further. However, the ICERs 
(for LYs and QALYs) for using any visible abnormalities detected on T2-MRI or MRS, compared with only 
using abnormalities detected on MRS alone, are well above £30,000. This is due to a substantial loss of 
specificity associated with combined strategy, compared with using the findings on MRS alone to guide 
biopsy (31% for T2-MRI or MRS vs 76% for MRS alone), for only a small gain in sensitivity (96% vs 92%).
Tables 30 and 31 presents the incremental cost per LY analysis for men aged 70 years at the time of 
repeat biopsy, assuming a prevalence of underlying cancer of 24%. Tables 32 and 33 present the same 
analysis but use QALYs as the unit of outcome (see Appendix 17 for a breakdown of strategy costs by 
component categories). Figures 23 and 24 present the findings of the respective analyses graphically on 
the cost-effectiveness plane.
A similar pattern of results is observed as for the cohort of men aged 60 years, but the survival benefit 
associated with the more sensitive strategies is smaller in the older cohort, owing to there being a higher 
risk of death from other causes (a competing risk for death from PC) and a smaller relative risk reduction 
associated with radical treatment in older men. As a consequence, the additional costs per LY and QALY 
gained with T2-MRI, MRS, and ‘T2-MRI or MRS’, are higher. However, the ICERs for T2-MRI compared with 
systematic TRUS/Bx remain < £30,000 despite the very small survival/QALY benefits.
Differential results for subgroups according to disease prevalence
Although few data were available to ascertain how diagnostic accuracy parameters vary by risk status of 
the cohort and underlying prevalence of cancer, Tables 34 and 35 present the incremental cost per LY and 
TABLE 30 Incremental cost per LY gained from deterministic analysis (men aged 70 years; underlying cancer 
prevalence 24%)
Strategy
Average 
cost (£)
Incremental 
cost (£)a Average LYs Incremental LYsa
Incremental 
cost per LY (£)
ICER vs common 
baseline (£)
Syst. TRUS 3199 – 10.55176 – – –
T2-MRI 3206 7 10.55233 0.00057 12,569 12,569
MRS 3256 50 10.55347 0.00115 43,305 33,121
DCE-MRI 3287 31 10.55100 –0.00247 Dominated Dominated
T2-MRI or 
MRS
3336 80 10.55420 0.00073 109,800 55,916
T2-MRI or 
DCE-MRI
3360 25 10.55268 –0.00152 Dominated 175,340
–, common baseline; Syst. TRUS, systematic TRUS-guided extended-cores (15) biopsy.
a Incremental costs and LYs are estimated in comparison with the next less costly non-dominated strategy.
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TABLE 31 Incremental cost per LY gained from probabilistic analysis (men aged 70 years; underlying cancer 
prevalence 24%)
Strategy
Average 
cost (£)
Incremental 
cost (£)a Average LYs Incremental LYsa
Incremental 
cost per LY (£)
ICER vs common 
baseline (£)
Syst. TRUS 3187 – 10.54702 – – –
T2-MRI 3194 7 10.54748 0.00046 14,696 14,696
MRS 3245 51 10.54854 0.00105 48,305 38,088
DCE-MRI 3275 31 10.54624 –0.00229 Dominated Dominated
T2-MRI or 
MRS
3323 78 10.54926 0.00073 107,834 60,716
T2-MRI or 
DCE-MRI
3346 23 10.54780 –0.00147 Dominated 205,281
–, common baseline; Syst. TRUS, systematic TRUS-guided extended-cores (15) biopsy.
a Incremental costs and LYs are estimated in comparison with the next less costly non-dominated strategy.
Note: bold text denotes the strategy with the highest NMB at a ceiling willingness-to-pay ratio of £30,000 per QALY.
TABLE 32 Incremental cost per QALY gained from deterministic analysis (men aged 70 years; underlying cancer 
prevalence 24%)
Strategy
Average 
cost (£)
Incremental 
costa (£)
Average 
QALYs
Incremental 
QALYsa
Incremental cost 
per QALYa (£)
ICER vs common 
baseline (£)
Syst. TRUS 3199 – 9.30639 – – –
T2-MRI 3206 7 9.30677 0.00038 18,727 18,727
MRS 3256 50 9.30752 0.00075 65,825 50,010
DCE-MRI 3287 31 9.30590 –0.00162 Dominated Dominated
T2-MRI or MRS 3336 80 9.30799 0.00047 170,109 85,071
T2-MRI or DCE-MRI 3360 25 9.30699 –0.00100 Dominated 266,423
–, common baseline; Syst. TRUS, systematic TRUS-guided extended-cores (15) biopsy.
a Incremental costs and QALYs are estimated in comparison with the next less costly non-dominated strategy.
Note: bold text denotes the strategy with the highest NMB at a ceiling willingness-to-pay ratio of £30,000 per QALY.
TABLE 33 Incremental cost per QALY gained from probabilistic analysis (men aged 70 years; underlying cancer 
prevalence 24%)
Strategy
Average 
cost (£)
Incremental 
costa (£)
Average 
QALYs
Incremental 
QALYsa
Incremental cost 
per QALYa (£)
ICER vs common 
baseline (£)
Syst. TRUS 3187 – 9.29963 – – –
T2-MRI 3194 7 9.29993 0.00030 22,677 22,677
MRS 3245 51 9.30061 0.00068 74,586 58,798
DCE-MRI 3275 31 9.29914 –0.00147 Dominated Dominated
T2-MRI or MRS 3323 78 9.30108 0.00047 167,637 93,943
T2-MRI or DCE-MRI 3346 23 9.30013 –0.00095 Dominated 316,854
–, common baseline; Syst. TRUS, systematic TRUS-guided extended-cores (15) biopsy.
a Incremental costs and QALYs are estimated in comparison with the next less costly non-dominated strategy.
Note: bold text denotes the strategy with the highest NMB at a ceiling willingness-to-pay ratio of £30,000 per QALY.
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QALY findings for a high-prevalence cohort (50%) and low-prevalence cohort (10%) of men aged 60 and 
70 years, respectively (assumes patient-level sensitivities not influenced by cancer prevalence). The findings 
seem to indicate that, for the 60-year-old cohorts (see Table 34), the more sensitive, more costly strategies 
have a higher chance of being considered cost-effective if used to direct biopsies in groups at higher risk 
of harbouring PC (e.g. men with ASAP on first biopsy). In the lower prevalence cohort, the T2-MRI strategy 
dominates systematic TRUS/Bx as a result of its specificity taking on greater significance with the underlying 
cancer prevalence set at only 10%.
A similar pattern of results is observed for the older cohort (see Table 35), with the cost-effectiveness of 
MRS improving relative to systematic TRUS/Bx and T2-MRI in the high-prevalence cohort. However, the 
ICER for MRS does not drop below £30,000 per QALY in this cohort. Moreover, the cost-effectiveness of 
T2-MRI rises above £30,000 in this cohort owing to the lower influence of specificity with high cancer 
prevalence combined with only very small gain in sensitivity with T2-MRI compared with systematic TRUS/
Bx. Thus, none of the MRS/MRI sequences appears cost-effective in this older cohort.
For the 70-year-old low-prevalence cohort, the same finding is observed as for the low-prevalence 60-year-
old cohort, i.e. T2-MRI dominates systematic TRUS-guided extended-cores biopsy for all.
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FIGURE 23 Cost-effectiveness frontier based on the cost per LY analysis (men aged 70 years, underlying cancer 
prevalence 24%).
FIGURE 24 Cost-effectiveness frontier based on the cost per QALY analysis (men aged 70 years, underlying cancer 
prevalence 24%).
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TABLE 34 Incremental costs per LY and QALY by prevalence subgroup based on deterministic analysis (men aged 
60 years)
Strategy
Average 
cost (£)
Incremental 
cost (£)a
Average LYs/
QALYs
Incremental 
LYs/QALYsa ICER (£)
ICER vs common 
baseline (£)
Prevalence 50%; unit of effect LYs
Syst. TRUS 6372 – 13.82903 – – –
T2-MRI 6404 32 13.83091 0.00188 16,929 16,929
MRS 6472 68 13.83486 0.00395 17,086 17,035
DCE-MRI 6477 5 13.82631 –0.00855 Dominated Dominated
T2-MRI or MRS 6529 58 13.83746 0.00260 22,176 18,620
T2-MRI or DCE-MRI 6537 7 13.83220 –0.00527 Dominated 51,871
Prevalence 50%; unit of effect QALYs
Syst. TRUS 6372 – 12.06553 – – –
T2-MRI 6404 32 12.06683 0.00131 24,402 24,402
MRS 6472 68 12.06956 0.00273 24,757 24,642
DCE-MRI 6477 5 12.06366 –0.00590 Dominated Dominated
T2-MRI or MRS 6529 58 12.07135 0.00179 32,256 26,981
T2-MRI or DCE-MRI 6537 7 12.06772 –0.00363 Dominated 75,120
Prevalence 10%; unit of effect LYs
T2-MRI 2555 – 14.35089 – – –
Syst. TRUS 2561 6 14.35046 –0.00043 Dominated Dominated
MRS 2595 40 14.35170 0.00081 48,866 48,866
DCE-MRI 2641 47 14.34997 –0.00173 Dominated Dominated
T2-MRI or MRS 2686 91 14.35218 0.00048 191,367 101,707
T2-MRI or 2721 35 14.35111 –0.00107 Dominated 756,814
Prevalence 10%; unit of effect QALYs
T2-MRI 2555 – 12.71014 – – –
Syst. TRUS 2561 6 12.70983 –0.00031 Dominated Dominated
MRS 2595 40 12.71070 0.00056 70,309 70,309
DCE-MRI 2641 47 12.70950 –0.00120 Dominated Dominated
T2-MRI or MRS 2686 91 12.71102 0.00032 285,797 148,351
T2-MRI or DCE-MRI 2721 35 12.71028 –0.00074 Dominated 1,164,444
–, common baseline; Syst. TRUS, systematic TRUS-guided extended-cores (15) biopsy.
a Incremental costs and QALYs are estimated in comparison with the next less costly non-dominated strategy.
Note: bold text denotes the strategy with the highest NMB at a ceiling willingness-to-pay ratio of £30,000 per QALY.
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TABLE 35 Incremental costs per LY and QALY by prevalence subgroup based on deterministic analysis (men aged 
70 years)
Strategy
Average 
cost (£)
Incremental 
cost (£)a
Average 
LYs/QALYs
Incremental 
LYs/QALYsa ICER (£)
ICER vs common 
baseline (£)
Prevalence 50%; unit of effect LYs
Syst. TRUS 5287 – 10.36606 – – –
T2-MRI 5319 32 10.36719 0.00113 28,394 28,394
MRS 5388 68 10.36956 0.00237 28,791 28,662
DCE-MRI 5391 4 10.36444 –0.00512 Dominated Dominated
T2-MRI or MRS 5446 58 10.37111 0.00155 37,381 31,342
T2-MRI or DCE-MRI 5452 6 10.36796 –0.00315 Dominated 86,624
Prevalence 50%; unit of effect QALYs
Syst. TRUS 5287 – 9.06143 – – –
T2-MRI 5319 32 9.06218 0.00075 42,942 42,942
MRS 5388 68 9.06373 0.00155 43,891 43,583
DCE-MRI 5391 4 9.06037 –0.00336 Dominated Dominated
T2-MRI or MRS 5446 58 9.06474 0.00101 57,324 47,782
T2-MRI or DCE-MRI 5452 6 9.06268 –0.00207 Dominated 131,943
Prevalence 10%; unit of effect LYs
T2-MRI 2068 – 10.65202 – – –
Syst. TRUS 2075 6 10.65175 –0.00026 Dominated Dominated
MRS 2108 40 10.65250 0.00049 81,213 81,213
DCE-MRI 2154 46 10.65146 –0.00104 Dominated Dominated
T2-MRI or MRS 2199 91 10.65278 0.00028 326,605 170,521
T2-MRI or DCE-MRI 2234 35 10.65214 –0.00064 Dominated 1,321,142
Prevalence 10%; unit of effect QALYs
T2-MRI 2068 – 9.43847 – – –
Syst. TRUS 2075 6 9.43829 –0.00018 Dominated Dominated
MRS 2108 40 9.43879 0.00032 122,508 122,508
DCE-MRI 2154 46 9.43811 –0.00069 Dominated Dominated
T2-MRI or MRS 2199 91 9.43897 0.00018 522,072 262,608
T2-MRI or DCE-MRI 2234 35 9.43854 –0.00042 Dominated 2,219,778
–, common baseline; Syst. TRUS, systematic TRUS-guided extended-cores (15) biopsy.
a Incremental costs and QALYs are estimated in comparison with the next less costly non-dominated strategy.
Note: bold text denotes the strategy with the highest NMB at a ceiling willingness-to-pay ratio of £30,000 per QALY.
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Illustrative analysis incorporating diffusion-weighted-magnetic resonance 
imaging-directed biopsy
Although the lack of sensitivity/specificity estimates for DW-MRI in repeat biopsy cohorts precluded its 
incorporation in the base-case analysis, it was still felt to be a relevant alternative based on evidence 
from other cohorts coupled with its lower cost compared with MRS. As such, an illustrative analysis was 
undertaken to assess how it would compare in terms of cost-effectiveness if it could be demonstrated to 
have sensitivity at least equal to that of MRS (92%) and specificity at least equal to that of T2-MRI (55%). 
Table 36 presents the cost per QALY findings from this analysis for a 60-year-old cohort.
The findings indicate that if DW-MRI could be shown to achieve this level of diagnostic accuracy then it 
would be preferred on grounds of cost-effectiveness over MRS in this cohort of patients [see Table 32 
(scenario 1) and Figure 25]. Under this scenario, DW-MRI is also borderline cost-effective compared with 
T2-MRI (incremental cost per QALY gained: £30,298).
When the sensitivities of DW-MRI and MRS are adjusted by cancer grade so that all false-negatives arising 
with these strategies occur in patients with low-risk cancer – to reflect the observation from other cohorts 
that MRS and DW-MRI positivity is highly correlated with tumour Gleason score – the ICER for DW-MRI 
compared with MRI falls to £18,260 [see Table 32 (scenario 2) and Figure 26], i.e. below the £20,000–
£30,000 per QALY range often used to make judgements on cost-effectiveness. This analysis gives an 
TABLE 36 Cost-effectiveness of scenarios incorporating DW-MRI based on deterministic analysis (unit of 
outcome QALYs) 
Strategy
Average 
cost (£)
Incremental 
costa (£)
Average 
QALYs
Incremental 
QALYsa
Incremental 
cost per QALY 
(£)a
ICER vs common 
baseline (£)
Scenario 1. DW-MRI incorporated assuming sensitivity 0.92/specificity 0.55 
Syst. TRUS 3895 – 12.48432 – – –
T2-MRI 3902 7 12.48498 0.00066 10,626 10,626
DW-MRI 3943 41 12.48629 0.00130 31,061 24,221
MRS 3952 9 12.48630 0.00002 529,885b 28,502
DCE-MRI 3984 32 12.48346 –0.00285 Dominated Dominated
T2-MRI or MRS 4031 88 12.48714 0.00085 104,032 48,367
T2-MRI or DCE-MRI 4056 25 12.48538 –0.00175 Dominated 152,323
Scenario 2. DW-MRI incorporated assuming sensitivity 0.92/specificity 0.55 (and that all false-negatives with 
DW-MRI and MRS occur in individuals with low-risk cancer)
Syst. TRUS 3895 – 12.48432 – – –
T2-MRI 3902 7 12.48498 0.00066 10,626 10,626
DW-MRI 3947 45 12.48734 0.00236 19,008 17,186
MRS 3956 9 12.48736 0.00002 529,885 20,013
DCE-MRI 3984 28 12.48346 –0.00390 Dominated Dominated
T2-MRI or MRS 4031 75 12.48714 –0.00023 –334,729 48,367
T2-MRI or DCE-MRI 4056 100 12.48538 –0.00198 Dominated 152,323
–, common baseline; Syst. TRUS, systematic TRUS-guided extended-cores (15) biopsy.
a Incremental costs and QALYs are estimated in comparison with the next less costly non-dominated strategy.
b Strategy dominated by combinations of other strategies.
Note: bold text denotes the strategy with the highest NMB at a ceiling willingness-to-pay ratio of £30,000 per QALY.
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indication of sensitivity/specificity requirements for DW-MRI to be considered cost-effective for directing 
biopsies (holding all other model parameters constant at base-case values).
Deterministic sensitivity analysis scenarios (60-year-old cohort)
Several deterministic analyses were carried out to assess the sensitivity of the base-case cost per QALY 
findings to assumptions surrounding the incorporation of health-state utilities. We assessed the impact of 
applying a utility decrement of 0.035 (half of the disutility associated with having moderate anxiety rather 
than no anxiety on the EQ-5D) to patients with undiagnosed cancer, to reflect potential disutility resulting 
from raised anxiety associated with having a high PSA but no diagnosis. Further, we tested a multiplicative 
utility model whereby utility levels for diagnosed cancer states were set equal to the product of the cancer 
state utility and the utility of any treatment complications experienced. Finally, we assessed the impact of 
applying both of these modifications simultaneously. These deterministic sensitivity analyses were carried 
out only for the 60-year-old cohort, owing to there being a higher likelihood of changes to base-case 
assumptions affecting the cost-effectiveness of strategies in this group.
Table 37 shows the cost per QALY findings to be highly sensitive to these alterations. Under the first 
adjustment (utility decrement associated with undiagnosed cancer), the cost-effectiveness of MRS 
compared with T2-MRI improves substantially. However, applying the multiplicative model to further adjust 
utility for complications associated with radical treatment results in all of the MRS/MRI sequences having 
unfavourable incremental cost per QALY ratios in comparison with the less-sensitive systematic TRUS. 
FIGURE 25 Comparison with DW-MRI included (assuming 92% sensitivity, 55% specificity).
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FIGURE 26 Comparison with DW-MRI included (assuming 92% sensitivity, 55% specificity, and that DW-MRI and MRS 
miss only low-risk cancers).
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Applying both changes simultaneously (see Table 37, scenario 3) results in a pattern of findings more in 
keeping with the base-case analysis.
Further deterministic scenario analyses
The process of populating the model required a number of parameter and structural assumptions. To 
further assess the influence of these assumptions on findings, the following deterministic sensitivity 
analyses were undertaken:
1. Costs adjusted such that pathology costs for TRUS/Bx are increased by £86 to reflect a 25-minute 
increase in pathologist time for biopsies involving more than 10 cores, and MRI costs are adjusted to 
the NHS reference costs.
2. Sensitivity of MRS adjusted so that it misses only low-risk localised disease.
3. Comparator for MRS/MRI assumed to be a standard TRUS/Bx (10–12 cores) with sensitivity 60% (the 
lowest estimated sensitivity value obtained for systematic TRUS/Bx from studies assessed for inclusion 
in the systematic review) (see Appendix 11).
TABLE 37 Sensitivity of cost per QALY findings to health-state utility assumptions
Strategy
Average 
cost (£)
Incremental 
costa (£)
Average 
QALYs
Incremental 
QALYsa ICERa (£)
ICER vs common 
baseline (£)
Scenario 1. Additional utility decrement for persistently elevated PSA without a diagnosis
Syst. TRUS 3895 – 12.47968 – – –
T2-MRI 3902 7 12.48059 0.000914 7633 7633
MRS 3952 49 12.48246 0.001873 26,373 20,229
DCE-MRI 3984 32 12.47842 –0.00404 Dominated Dominated
T2-MRI or MRS 4031 80 12.48366 0.001201 66,262 34,098
T2-MRI or DCE-MRI 4056 25 12.48118 –0.00249 Dominated 107,510
Scenario 2. Multiplicative model to further adjust for adverse treatment effects
Syst. TRUS 3895 – 12.32446 – – –
T2-MRI 3902 7 12.32466 0.000202 34,521 34,521
MRS 3952 49 12.32501 0.000348 141,776 102,408
DCE-MRI 3984 32 12.32427 –0.00074 Dominated Dominated
T2-MRI or MRS 4031 80 12.32519 0.000185 429,592 184,823
T2-MRI or DCE-MRI 4056 25 12.32474 –0.00046 Dominated 575,872
Scenario 3. Combination of scenarios 1 and 2
Syst. TRUS 3895 – 12.31981 – – –
T2-MRI 3902 7 12.32027 0.00046 15,182 15,182
MRS 3952 49 12.32117 0.00090 54,886 41,468
DCE-MRI 3984 32 12.31923 –0.00193 Dominated Dominated
T2-MRI or MRS 4031 80 12.32172 0.00055 143,966 71,109
T2-MRI or DCE-MRI 4056 25 12.32053 –0.00119 Dominated 223,564
Syst. TRUS, systematic TRUS-guided extended-cores (15) biopsy.
a Incremental costs and QALYs are estimated in comparison with the next less costly non-dominated strategy 
(common baseline).
Note: bold text denotes the strategy with the highest NMB at a ceiling willingness-to-pay ratio of £30,000 per QALY.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
assessment Of cOst-effectIVeness
80
4. Application of the sensitivity/specificity estimates obtained from the indirect comparison (see 
Appendix 13.10).
5. Assumed a 14-core TRUS/Bx is £86 more costly than a MRI-/MRS-directed biopsy, and £112 more 
costly than obtaining a MRS scan.
6. Assumed that MRI-/MRS-directed biopsy reduces the risk of biopsy complications by 50% because 
fewer cores are obtained per patient.
7. Subsequent repeat biopsies (i.e. following a first repeat biopsy) have 95% sensitivity with 80% uptake 
(repeat offered every 12 months for those remaining with undiagnosed cancer).
8. Application of lower discount rate for health benefits (1.5% for QALYs vs 3.5% for costs).
9. Application of lower baseline risks of progression and less significant diagnosis treatment effects, 
based on new trial evidence on the effect of radical prostatectomy compared with watchful waiting.149
10. Assumed all patients who are negative on MRI proceed with an extended 14-core TRUS biopsy.
Table 38 presents the results of these scenarios using QALYs as the unit of outcome. Appendix 17, 
Table 43, presents the results for these same scenarios using LYs as the unit of outcome.
These analyses demonstrate that T2-MRI-directed biopsy dominates systematic TRUS/Bx under several 
scenarios; specifically, when the sensitivity and specificity of T2-MRI are set equal to the values obtained 
from the indirect comparison (see Table 38, scenario 3), and when it is assumed that T2-MRI direction 
reduces the cost of the subsequent biopsy procedure relative to the cost of an extended-cores biopsy 
(scenario 4). The ICER for MRS compared with systematic TRUS also remains at < £30,000 for most 
scenarios. The cost-effectiveness of MRS compared with T2-MRI appears less sensitive to scenarios 
presented in Table 38. The ICER for MRS-directed biopsy (relative to T2-MRI) falls below £30,000 when 
(1) the cost of all biopsies is increased (scenario 1); (2) when it is assumed that MRS misses only low-risk 
cancer (scenario 2); and (3) when the discount rate applied to health benefits is reduced to 1.5% (scenario 
7). Although increasing the costs of systematic extended-cores TRUS/Bx (but not MRI-/MRS-directed 
TRUS/Bx) results in both T2-MRI and MRS being more effective and less costly than systematic TRUS/
Bx, this specific scenario has little impact on the comparison between MRS and T2-MRI. Application of 
the sensitivity/specificity estimates obtained from the indirect comparison also undermines the cost-
effectiveness of MRS in relation to T2-MRI, owing to a substantial decline in the specificity of MRS.
The application of lower relative diagnosis/treatment effects and lower baseline cancer progression rates 
(scenario 8) undermine the cost-effectiveness of MRS compared with T2-MRI and systematic TRUS/Bx. The 
incremental cost per QALY gained with the most sensitive imaging strategy (positive on either T2-MRI or 
MRS) does not fall below £30,000 for any of the scenarios assessed. Further, none of the MRI strategies 
compares very favourably in terms of cost-effectiveness when it is assumed that all patients who are 
negative on MRI proceed to an extended-cores TRUS/Bx regardless (scenario 9).
In addition to the scenarios presented in Table 38, threshold analysis would suggests that MRS would 
dominate systematic extended-cores TRUS/Bx in contexts where the cost saving per biopsy averted is 
≥ ~£115 more than the cost of obtaining the MRS sequences to determine whether or not a biopsy 
should proceed.
Probabilistic sensitivity analysis
To assess the impact of joint uncertainty surrounding all model parameters and inputs, appropriate 
distributions were assigned and randomly sampled for each of 1000 iterations of the base-case analysis. 
The results were used to estimate the probability of each diagnostic strategy being preferred on grounds of 
cost-effectiveness for different values of decision-makers’ willingness to pay for a QALY. The resultant CEAC 
is displayed in Figure 27. The results indicate that under base-case parameter values and assumptions, 
none of the strategies demonstrates a high probability of being the preferred option at the threshold 
value of £30,000 per QALY gained. The cost-effectiveness acceptability frontier (Figure 28) displays the 
probability of the strategy with the highest NMB, at different values of decision-makers’ willingness to 
pay per QALY gained, being cost-effective. At a threshold ratio of £30,000 per QALY, T2-MRI provides the 
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TABLE 38 Deterministic sensitivity analysis scenarios using QALYs as unit of outcome (men aged 60 years; cancer 
prevalence 24%) 
Strategy
Average 
cost (£)
Incremental 
costa (£)
Average 
QALYs
Incremental 
QALYsa ICERa (£)
ICER vs common 
baseline (£)
Scenario 1. Biopsy costs inflated to account for additional pathology time associated with more than 10 
cores; MRS/MRI costs also adjusted to the NHS reference costs 
Syst. TRUS 4018 – 12.48432 – – –
T2-MRI 4024 7 12.48498 0.00066 10,271 10,271
MRS 4060 35 12.48630 0.00132 26,848 21,347
DCE-MRI 4108 49 12.48346 –0.00285 Dominated Dominated
T2-MRI or MRS 4169 109 12.48714 0.00083 130,497 53,719
T2-MRI or DCE-MRI 4205 37 12.48538 –0.00175 Dominated 177,295
Scenario 2. Sensitivity of MRS adjusted to miss only low-grade cancer
Syst. TRUS 3895 – 12.48432 – – –
T2-MRI 3902 7 12.48498 0.000656 10,626 10,626
MRS 3956 54 12.48736 0.00238 22,602 20,013
DCE-MRI 3984 28 12.48346 –0.0039 Dominated Dominated
T2-MRI or MRS 4031 75 12.48714 –0.00023 Dominated 48,367
T2-MRI or DCE-MRI 4056 100 12.48538 –0.00198 Dominated 152,323
Scenario 3. Sensitivity of comparator reduced to 60%
Syst. TRUS 3882 – 12.47825 – – –
T2-MRI 3899 16 12.48395 0.00571 2858 2858
MRS 3948 49 12.48527 0.00132 37,399 9353
DCE-MRI 3981 32 12.48243 –0.00285 Dominated 23,455
T2-MRI or MRS 4028 80 12.48611 0.00083 95,498 18,490
T2-MRI or DCE-MRI 4053 25 12.48435 –0.00175 Dominated 27,926
Scenario 4. Application of sensitivity/specificity estimates obtained from the indirect comparison (T2-MRI 
sensitivity 0.84/specificity 0.58; MRS sensitivity 0.92/specificity 0.65)
Syst. TRUS 3895 – 12.48432 – – –
T2-MRI 3895 0 12.48455 0.00022 240 240
MRS 3970 75 12.48629 0.00175 42,903 38,052
DCE-MRI 3986 16 12.48346 –0.00284 Dominated Dominated
T2-MRI or MRS 4029 59 12.48735 0.00106 55,218 44,066
T2-MRI or DCE-MRI 4052 23 12.48669 –0.00066 Dominated 66,176
continued
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Strategy
Average 
cost (£)
Incremental 
costa (£)
Average 
QALYs
Incremental 
QALYsa ICERa (£)
ICER vs common 
baseline (£)
Scenario 5. Biopsy costs uplifted for systematic TRUS (assumes 14-core TRUS biopsy is £86 more costly than 
MRI-/MRS-directed biopsy, and £112 more costly than MRS)
T2-MRI 3907 – 12.48498 – – –
MRS 3955 48 12.48630 0.00132 36,200 36,200
DCE-MRI 3991 36 12.48346 –0.00285 Dominated Dominated
Syst. TRUS 3991 36 12.48432 –0.00198 Dominated Dominated
T2-MRI or MRS 4034 79 12.48714 0.00083 94,233 58,653
T2-MRI or DCE-MRI 4061 27 12.48538 –0.00175 Dominated £382,270
Scenario 6. MRI reduces the risk of biopsy complications by 50%
Syst. TRUS 3895 – 12.48432 – – –
T2-MRI 3899 4 12.48501 0.00068 6063 6063
MRS 3949 50 12.48632 0.00131 38,173 27,182
DCE-MRI 3981 32 12.48348 –0.00284 Dominated Dominated
T2-MRI or MRS 4027 78 12.48717 0.00085 91,288 46,354
T2-MRI or DCE-MRI 4052 25 12.48543 –0.00175 Dominated 142,198
Scenario 7. Subsequent repeat biopsy offers have 80% uptake (repeat offer every 12 months for those 
remaining with undiagnosed cancer)
Syst. TRUS 3888 – 12.483 – – –
T2-MRI 3895 8 12.48377 0.00077 9753 9753
MRS 3946 51 12.48534 0.00157 32,261 24,839
DCE-MRI 3976 30 12.48196 –0.00338 Dominated Dominated
T2-MRI or MRS 4026 80 12.48634 0.00100 80,567 41,506
T2-MRI or DCE-MRI 4050 24 12.48425 –0.00208 Dominated 129,183
Scenario 8. QALYs discounted at 1.5% per annum
Syst. TRUS 3895 – 15.13056 – – –
T2-MRI 3902 7 15.13138 0.000815 8553 8553
MRS 3952 49 15.13302 0.001643 30,052 22,923
DCE-MRI 3984 32 15.12948 –0.00354 Dominated Dominated
T2-MRI or MRS 4031 80 15.13406 0.001038 76,676 38,882
T2-MRI or DCE-MRI 4056 25 15.13188 –0.00218 Dominated 122,465
Scenario 9. Disease progression calibrated to PC mortality rates observed in the PIVOT trial149
Syst. TRUS 3751 – 12.57939 – – –
T2-MRI 3758 7 12.57969 0.000303 23,054 23,054
MRS 3808 49 12.58026 0.000563 87,749 65,132
DCE-MRI 3840 32 12.57906 –0.0012 Dominated Dominated
T2-MRI or MRS 3887 80 12.58059 0.000328 242,585 113,923
T2-MRI or DCE-MRI 3913 25 12.57984 –0.00074 Dominated 356,787
TABLE 38 Deterministic sensitivity analysis scenarios using QALYs as unit of outcome (men aged 60 years; cancer 
prevalence 24%) (continued)
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Strategy
Average 
cost (£)
Incremental 
costa (£)
Average 
QALYs
Incremental 
QALYsa ICERa (£)
ICER vs common 
baseline (£)
Scenario 10. Use extended-cores biopsy for all patients negative on MRS/MRI
Syst. TRUS 3895 – 12.48432 – – –
T2-MRI 4007 112 12.48747 0.003144 35,561 35,561
MRS 4087 80 12.48769 0.000219 362,957b 56,913
DCE-MRI 4087 80 12.48783 0.000366 218,506 54,618
T2-MRI or MRS 4090 3 12.48721 –0.00062 Dominated 67,370
T2-MRI or DCE-MRI 4090 3 12.48754 –0.00029 Dominated 60,667
– common baseline; Syst. TRUS, systematic TRUS-guided extended-cores (15) biopsy.
a Incremental costs and QALYs are estimated in comparison with the next less costly non-dominated strategy.
b Strategy dominated by combinations of other strategies.
Note: bold text denotes the strategy with the highest NMB at a ceiling willingness-to-pay ratio of £30,000 per QALY.
TABLE 38 Deterministic sensitivity analysis scenarios using QALYs as unit of outcome (men aged 60 years; cancer 
prevalence 24%) (continued)
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FIGURE 27 Cost-effectiveness acceptability curves under base-case assumptions.
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FIGURE 28 Cost-effectiveness acceptability frontier under base-case assumptions.
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option with the highest NMB but with only a 34% probability. The expected value of perfect information at 
this threshold (i.e. of eliminating uncertainty) is £27.30 per patient.
In order to assess the sensitivity of the probabilistic analysis findings to several base-case assumptions, 
the analysis was repeated with the biopsy costs inflated to account for the possibility of higher pathology 
time requirements and the MRS/MRI costs were adjusted to the reference cost for direct access DCE-MRI 
(see Table 38, scenario 1). Further, DW-MRI was incorporated under the assumption that it could achieve 
sensitivity equal to that of MRS and specificity equal to that of T2-MRI. In addition, it was assumed that 
MRS and DW-MRI would miss only low-risk cancer (see Table 38, scenario 2). Under this specification, 
there is 74% probability of either DW-MRI or MRS being cost-effective at a willingness-to-pay threshold 
of £30,000 per QALY gained (Figure 29). MRS in fact retains the higher probability of being cost-effective 
in this scenario because, with biopsy costs set at a higher level, the superior specificity of MRS (over the 
assumed specificity of DW-MRI, which was set at 55% purely for illustrative purposes) outweighs the 
additional cost of running the sequence.
Discussion
Summary of key results
The results of the deterministic economic modelling suggest that, when considering LYs as the unit of 
outcome, the use of T2-MRI, to determine and direct biopsies, may be cost-effective in comparison with 
systematic TRUS-guided extended-cores biopsy. This results from its modest implementation cost and 
slightly improved sensitivity over systematic extended-cores TRUS/Bx (14–16 cores). At the same time 
its specificity would suggest that it could avert the need for 55% of patients without cancer having to 
undergo a biopsy. The base-case incremental cost per QALY estimates for the more sensitive enhanced 
MRS/MRI techniques are somewhat less favourable (i.e. are > £30,000 per QALY gained in comparison with 
the next less costly option). However, the ICER for MRS compared with T2-MRI does fall below £30,000 in 
the high-prevalence (50%) 60-year-old cohort. In the lower-prevalence (10%) cohorts, T2-MRI was found 
to dominate systematic TRUS/Bx (i.e. be less costly and more effective) owing to its specificity, resulting in 
more biopsies being averted in this group.
Moreover, the deterministic sensitivity analysis shows the cost-effectiveness of MRS compared with T2-MRI 
(and systematic TRUS/Bx) to be particularly sensitive to two key parameters. The ICER for MRS falls below 
£30,000 when (1) the cost of biopsies is increased to £298 and (2) when MRS is modelled to detect all 
moderate- and high-risk cancer (only missing low-risk disease). The latter assumption is in keeping with 
data from case series, which suggest high levels of correlation between MRS positivity and tumour Gleason 
scores.52,54 The cost-effectiveness of MRS also improves considerably when the accuracy of and compliance 
with subsequent repeat biopsies decreases. Thus, our findings would suggest that the use of MRS may well 
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FIGURE 29 Cost-effectiveness acceptability curves, assuming DW-MRI has sensitivity equal to that of MRS and 
specificity equal to that of T2-MRI, and that MRS and DW-MRI miss only low-risk cancer.
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be cost-effective in certain contexts, for example in settings where the cost of TRUS/Bx exceeds the cost of 
obtaining a MRS sequence by ~£115. It is likely that practice and costs will vary substantially locally.
Unfortunately, there were insufficient data on the diagnostic accuracy of DW-MRI in the population of 
interest, and as such we did not include it as a comparator in the base-case analysis. With its lower cost 
in comparison with MRS, our modelling suggests it could represent a cost-effective approach if it could 
be shown to have sensitivity similar to that of MRS and specificity similar to that of T2-MRI. At these 
levels of sensitivity/specificity, however, it might also need to be able to discriminate between low-risk and 
moderate/high-risk disease (so that false-negatives would be concentrated in the low-risk cases) to be 
cost-effective in comparison with T2-MRI alone. Evidence from other case series suggest it may be able to 
do this.169,170
By the same token, changes to some of the model assumptions also undermine the cost-effectiveness of 
strategies that improve cancer detection rates at increased costs over standard practice and T2-MRI. These 
include reductions in the baseline risk of disease progression and reductions in the relative risk reductions 
associated with diagnosis and treatment.
Considering the probabilistic sensitivity analysis, when parameter distributions are centred on the base-case 
point estimates and all of the strategies are compared simultaneously, none of the strategies achieves a 
high probability of being preferred on grounds of cost-effectiveness (see Figure 27) at the threshold ceiling 
ratio of £30,000 per QALY gained. Although the point estimate of the ICER of T2-MRI compared with 
systematic TRUS/Bx is favourable, its probability of being cost-effective at £30,000 per QALY is only ~60% 
in comparison with TRUS/Bx and only 34% considering all strategies simultaneously (see Figure 28).
However, Figure 29 demonstrates how the uncertainty surrounding the relative cost-effectiveness of 
strategies reduces if the average cost of biopsies is increased to £300 (the upper quartile reference cost 
reported for biopsies carried out in an outpatient setting) and MRS and DW-MRI are modelled to miss 
low-risk cancer only. Under this alternative model specification, the choice between strategies becomes 
one between MRS and DW-MRI above a willingness-to-pay threshold of ~£20,000 per QALY gained. 
Note this still assumes disease progression rates and relative diagnosis/treatment effects in line with 
Bill-Axelson et al.148
Generalisability of results
In developing the model we have attempted to use data applicable to the UK setting as far as possible. 
However, many of the data on disease progression and relative treatment effects were derived from a 
European cohort identified in the pre-PSA era.148 Although we have tried as far as possible to model the 
risk of progression by clinical grade (low, intermediate, high), it is possible that the progression rates 
observed for low-risk patients in this pre-PSA cohort are higher than would be observed for low-risk 
patients identified in clinical practice in the UK today. This is potentially important as reducing progression 
rates and treatment effects for low-risk patients reduces the cost-effectiveness of more sensitive and more 
costly diagnostic strategies, and further emphasises the potential importance of further research to assess 
the sensitivity of alternative imaging sequences by tumour grade in cohorts of patients undergoing biopsy. 
The ongoing PROMIS trial may help address this question.171
The modelling also relied on health-state utility data from a number of sources outwith the UK. Attempts 
were made to identify EQ-5D data from UK cohorts for the modelled states and treatment complications 
of interest, but limited data were identified. A decision was made to use the EQ-5D utilities observed for 
a European cohort post diagnosis and at varying time points post treatment with radical prostatectomy or 
EBRT. As these average utilities were obtained from cohorts with proportions experiencing complications, 
we chose not to further adjust utility for modelled treatment complications in the base-case analysis. Given 
a lack of EQ-5D-based utility estimates for metastatic and castration resistant metastatic disease, for men 
modelled to progress to metastatic disease we applied the average time trade-off values elicited for these 
states from a sample of US men.166
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Although there is uncertainty surrounding the wider applicability of some of the progression rates, 
treatment effects and utility values applied in the model, the cost inputs were based on the estimation 
of resource use in UK settings according to current guidelines. National average unit costs were applied 
to resource-use estimates wherever possible, making individual cost inputs generalisable across the UK. 
However, there is uncertainty as to how hospitals are reimbursed for TRUS-guided biopsies at the local 
level and also the true opportunity cost of TRUS/Bx compared with that of running MRS/MRI sequences. It 
would be useful if future prospective studies could estimate these more accurately using patient-level data.
Strengths and limitations of the analysis
Strengths
Attempts have been made to use the best available evidence to model both the diagnostic pathways and 
subsequent treatment pathways and outcomes. The model provides a flexible framework allowing the 
comparison of many different diagnostic strategies in the context of the patient’s lifetime. It captures the 
trade-off between the increased upfront costs of imaging and the reduction in subsequent biopsies, and 
also the trade-off between earlier diagnosis and potential utility decrements associated with treatment 
side-effects. Further, the model is risk stratified to allow for comparison of strategies that vary in their 
ability to differentiate between tumours of different stage and grade. The model can easily be updated to 
incorporate new, more detailed evidence as it becomes available.
Limitations
The modelling was hampered by limited availability of data on the diagnostic accuracy of alternative 
diagnostic strategies, comparable cost estimates for alternative procedures, the natural history of cancer 
detected at repeat biopsy, and also the impact of diagnosis and treatment on disease progression.
The systematic review uncovered limited data on the relative sensitivity (cancer detection rates) of MRI-/
MRS-targeted biopsy techniques and systematic TRUS-guided approaches. In particular, there were no 
identified studies providing head-to-head comparisons of MRI-/MRS-targeted approaches and systematic 
sampling schemes based on different numbers of cores. Further, it was not possible to obtain pooled 
estimates for the sensitivity/specificity of alternative MRS/MRI sequences by grade of tumour, which is 
potentially an important parameter for informing cost-effectiveness. There is therefore a need for a large 
comparative study assessing the sensitivity of systematic approaches and MRS/MRI sequences for detecting 
cancer by D’Amico risk strata.
A high degree of uncertainty also exists regarding the impact of a false-negative result at repeat biopsy 
on the time to final diagnosis, and also on the impact of any delay on disease progression. The base-case 
analysis relied on the assumption that all patients experience a relative risk reduction for progression 
to metastatic disease upon referral, but recent data suggest that risk reductions associated with radical 
treatment for low-risk patients (and even moderate-risk patients) may be small and insignificant.149 If this 
is the case it will undermine the cost-effectiveness of strategies that increase cancer detection rates over 
standard practice.
The more sensitive and more costly enhanced imaging techniques were found to be associated with small 
cost increases, for even smaller survival and QALY gains compared with T2-MRI and systematic TRUS/Bx. 
This results in the incremental cost per QALY ratios being very sensitive to the baseline risks of progression 
and relative treatment effects. Recent data suggest that the underlying risk of progression for low-risk 
cancer, identified in the PSA era, may be lower than reported for the low-risk subgroup identified by 
Bill-Axelson et al.148 However, the above point also highlights the potential benefit of utilising a pre-biopsy 
imaging test that could differentiate between low-, moderate- and high-risk cancer, so that only those 
patients in the latter categories could be targeted for biopsy. Our modelling suggests that if DW-MRI 
or MRS could be shown to provide such discrimination in the cohort of patients with elevated PSA but 
previously negative biopsy, these tests could achieve levels of cost-effectiveness considered acceptable. 
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More detailed studies are required to assess the diagnostic accuracy of different sequences by stage/grade 
of cancer in order to address this question.
Finally, a further issue contributing to the uncertainty surrounding the cost-effectiveness of alternative 
diagnostic approaches, and indeed the cost-effectiveness of radical treatment,9 is the impact of treatment 
on health-related QoL. In our base-case specification we have applied utility values that suggest that 
radical treatment complications do not impact heavily on health-related QoL as measured by the 
EQ-5D.163 However, the incremental cost per QALY findings are highly sensitive to changes to the applied 
utility assumptions. When health-state utilities are adjusted downwards for those patients experiencing 
treatment complications, the cost-effectiveness of strategies that improve cancer detection rates decreases 
substantially. This highlights the potential importance of risk stratifying treatment appropriately, so that 
only those patients likely to experience a significant survival benefit receive radical treatments. However, 
current data suggest that a substantial proportion of low-risk patients still elect for radical treatment, 
which undermines the cost-effectiveness of diagnostic strategies that result in more low-risk patients 
being diagnosed.
Summary/conclusions
To summarise, the level of uncertainty surrounding model inputs and structural assumptions makes it 
difficult to arrive at a definitive conclusion on the cost-effectiveness of using MRS/MRI techniques to aid 
the localisation of prostate abnormalities for biopsy. However, our modelling shows that under certain 
circumstances T2-MRI may be considered cost-effective in comparison with TRUS/Bx, and if MRS and 
DW-MRI can be shown to have high sensitivity for picking up moderate/high-risk cancer, while negating 
the need for patients with no cancer or low-risk disease to undergo biopsy, then their use could represent 
a cost-effective approach to diagnosis. Data from subgroup analysis would also suggest that the use of 
more sensitive and more expensive sequences is more likely to be cost-effective in subgroups of patients 
who are more likely to be harbouring cancer. Future research should focus on generating comparable 
estimates of (1) the sensitivity of MRI-/MRS-directed and systematic approaches to TRUS/Bx; (2) the 
sensitivity/specificity of MRS/MRI sequences for detecting different grades of localised disease in the repeat 
biopsy cohort; and (3) the full economic costs of MRI sequences and systematic approaches to TRUS/Bx 
based on different numbers of cores.
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Chapter 6 Assessment of factors relevant to the 
NHS and other parties
The introduction of MRS and other MRI techniques (T2-MRI, DCE-MRI, DW-MRI) for evaluation of men with a TRUS-guided negative biopsy but in whom there remains suspicion of cancer would have a range 
of implications for the NHS, patients and other parties. These arise primarily because of a shift in the test–
treatment pathway for this group. This shift is caused by changes in the method of making the diagnosis 
and changes the options and timings of treatments, complications and outcomes of patients. There are 
consequential effects on service delivery, health-care professionals and wider society.
Factors relevant to the NHS
Increased sensitivity and specificity of the diagnostic pathway would lead to more patients being correctly 
diagnosed with PC and diagnosed at an earlier stage and fewer patients wrongly diagnosed as having no 
cancer. This would result in a shift in the numbers and stages of patients diagnosed with PC. For the NHS 
this change in distribution of disease would have implications for service configuration, cost and training.
Service reconfiguration, including the purchase of high-end MRI scanners, would be needed to ensure 
that radiology departments have sufficient capacity and the means to offer high-quality MRI testing 
within adequate timescales. Local diagnostic pathways would require updating to ensure compliance with 
national targets because of the persistent suspicion of undiagnosed cancers in these subjects. Occasional 
local disruptions may occur if MRI equipment suffers technical failures although most scanners have 
up-times of > 95%.
The requirements of urological and/or radiological services to undertake targeted biopsies of MRS/
MRI-suspicious regions will reduce the number of patients undergoing repeat biopsies. However, there 
would need to be extra provision for undertaking targeted biopsies, whether MRS/MRI guided (within MRI 
scanners under direct visualisation as an outpatient procedure) or MRI/MRS directed (outside MRI scanner 
using MRS/MRI information fused to ultrasound images). The latter could be undertaken as outpatient 
procedures if only a few targeted biopsies were undertaken (per rectally) or an inpatient procedure if the 
template transperineal route was chosen. MRI-/MRS-targeted or -directed biopsy will require the purchase 
of a new generation of hardware equipment and software to enable accurate biopsies to be obtained 
from all regions of the prostate (particularly from commonly missed anterioapical areas). This equipment 
is capable of operating within MRI scanners or can be used for biopsy via the transperineal or transrectal 
routes and is beginning to appear in the marketplace. In the future, the move towards targeted biopsy 
may reduce the number of biopsy cores taken per biopsy session (approximately two to five cores per 
session) and this will likely result in cost savings especially when compared with saturation or template 
biopsies (often 20–30 cores per session).
Earlier positive diagnosis of patients who would also be more accurately staged and whose risk 
stratification was more definitively known would have the benefit of them being appropriately triaged 
to several therapy options. It is likely that MRS/MRI will identify more patients with localised disease with 
intermediate and high risk of progression and this would increase the number of patients who would 
be eligible for radical therapies (including prostatectomy, brachytherapy and external beam therapy). 
Therefore, surgical and radiation therapy services may require more resources. Furthermore, MRI would 
provide more accurate preoperative imaging, which may alter the type of radical therapy being undertaken 
(e.g. the decision to resect or preserve neurovascular bundles at surgery). Preoperative imaging might 
prevent positive resection margins around large tumours and might also prevent unnecessary morbidity 
by predicting the preservation of neurovascular bundles if cancer foci locations permitted this. MRS/MRI 
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may identify fewer patients with low risk of progression, which would help the problem of over-diagnosis 
of indolent PCs. More accurate and confident diagnoses of patients with low risk of progression disease 
will increase the proportion of patients likely to undergo ‘active surveillance’ programmes. This would have 
implications for the follow-up of these patients including increased utilisation of repeated PSA-testing, 
repeated interval biopsies and follow-up clinics (much of this work could be nurse practitioner led). Taken 
together, earlier, more accurate diagnoses and treatment of PC may improve survival and reduce the 
requirements on end-of-life and palliative care services.
There will be cost implications of these service reconfigurations and for changes in treatment patterns 
mentioned above. There will be significant cost implications for procuring and maintaining new MRI 
equipment. Although some centres may already have access to the high-end equipment required for 
this purpose, other centres may have to upgrade, purchase or rent new equipment because of access 
considerations. There are several other costs associated with implementing MRI testing, which are outlined 
in the cost-effectiveness chapter.
Implementation would result in the need for further training for radiology staff. Radiographers and 
radiologists would require additional training to ensure adequate technical skills for performing these tests 
and diagnostic skills to read the MRS/MRI scans. There is a learning curve effect for all staff when more 
sophisticated MRS/MRI techniques are being implemented; this is particularly true for MRS and DCE-MRI. 
Adequate quality control and quality assurance programmes would be needed in order to maintain 
high standards of data acquisition and reporting. However, these new skills and equipment would be 
transferable for future use in other PC subgroups (e.g. staging of known PC, therapy planning and 
suspected relapsed disease), and to other pathologies for which MRS/MRI are known to be useful.
Factors relevant to patients and other parties
Many men find themselves in the difficult situation of having a persistently raised serum PSA level but a 
negative biopsy. They and their physicians know that there is a substantial risk of an undiagnosed, perhaps 
life-threatening, PC that has not yet been found and as a consequence cannot be treated. This can cause 
anxiety for patients and their family. The anxiety and stress may substantially reduce an individual’s QoL 
with many men seeking clarity about their status in order to be able to move forward. Increased certainty 
of diagnosis influences an individual’s decision-making about life choices, such as employment, insurance 
and family issues. Any test that improves the diagnostic certainty in this group of men may reduce anxiety. 
Additionally, patients may feel more reassured if they have different tests that point to the same diagnosis. 
Although earlier diagnosis may reduce the anxiety of uncertainty, it may also cause psychological harm 
if effective treatments are unavailable or if the discovered cancer is indolent and unlikely to cause 
health deterioration over the course of an individual’s life. DW-MRI and MRS may be better at detecting 
intermediate and high risk of progression cancers, which may have a positive effect in this regard. Active 
surveillance programmes for patients with indolent cancer types can have high dropout rates, partly 
because many patients find it difficult to have a diagnosis of cancer without commencing disease-limiting 
or curative treatment. If more evidence were to become available that allowed the discrimination between 
low-risk/less aggressive cancer and intermediate- and high-risk cancer, then urologists would not need to 
treat asymptomatic men with clinically insignificant cancer, curing them from a disease that might never 
have harmed them, with collateral morbidity as a result. Perhaps over time clinically insignificant PC may 
also come to be more accepted by the patient.
Magnetic resonance imaging techniques may reduce the number of patients undergoing several repeat 
biopsies, avoiding the discomfort, side effects and possible complications of this. Patients who have chosen 
not to undergo repeat biopsy, because of the unpleasantness of the procedure, may find MRI investigation 
more acceptable. However, some patients who suffer from claustrophobia may find MRI more 
unacceptable than repeat biopsy. Patient refusal to undergo MRI scanning is likely to decrease in the future 
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with the increasing availability of wider, short-bore scanners. MRI cannot always be used in patients who 
have metallic foreign objects in their bodies or in those with implanted non-MRI compatible pacemakers.
Patients and carers may need to travel further to access appropriate MRI testing in scanners that have 
the appropriate high levels of sophistication capable of performing high-quality MRS/MRI (T2-MRI, 
DW-MRI and DCE-MRI) examinations. Inequalities in access may arise as services undergo reconfiguration 
at different rates, depending on pre-existing equipment age and capability as well as operator and 
interpretation expertise. If MRI technologies are not implemented across the NHS, income inequalities may 
arise as some patients seek investigations through private health-care companies. Private UK providers are 
already preparing to provide this service with some providing MRI detection only and others offering MRI 
detection and biopsy services. These patients may then re-present to the NHS for their further care.
Health professionals are likely to prefer the increased certainty, reproducibility and anatomic capability 
of diagnoses made with MRS/MRI. Subsequently, medical staff would be more confident about negative 
diagnoses, knowing that an intermediate or high risk of progression cancer is unlikely to be present.
Earlier treatment may result in greater medical and societal success and improved patient functioning 
[physiological (urinary, rectal, erectile) and psychological]. These may, in turn, reduce the requirements on 
end-of-life and social care.
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Chapter 7 Discussion
Diagnostic accuracy
Statement of principal findings
The included diagnostic studies reported sensitivity, specificity or predictive values for the index tests of 
MRS, DCE-MRI and DW-MRI and the comparator tests of T2-MRI and TRUS against a reference standard 
of histopathological assessment of biopsied tissue. Studies that reported true/false-positive and true/
false-negative results or provided information that allowed these data to be calculated were considered 
for inclusion in the pooled estimates (meta-analyses). Meta-analyses were performed at both patient and 
biopsy level. In addition to the meta-analyses models of the diagnostic accuracy of the individual tests, 
combinations of tests and also of six studies directly comparing MRS with T2-MRI, an indirect comparison 
of all tests was also undertaken.
In terms of methodological quality, the majority of the 39 full-text studies were considered to have a low 
risk of bias for the patient selection (29/39, 74%), index test (39/39, 100%) and flow and timing (36/39, 
92%) domains. Three studies (8%) were considered at high risk of bias for the flow and timing domain. 
In the reference standard domain, 25 studies (64%) were considered at high risk of bias because of a lack 
of follow-up, and in 14 (36%) the risk of bias was considered unclear. In terms of the applicability of the 
studies to the review question, all studies had low concern for applicability for the reference standard 
domain, whereas the majority had low concern for applicability for the patient selection (37/39, 95%) and 
index test (34/39, 87%) domains.
Although biopsy-level analysis was reported by a number of studies, patient-level data are more useful 
in determining management, and more clinically relevant. Most studies took multiple biopsies from 
participants, leading to clustering within participants. We were unable to account for this clustering in 
the biopsy-level analysis and therefore estimates from the biopsy-level analysis will be to some extent 
artificially precise.
In the patient-level pooled estimates for the individual tests, although both sensitivity and specificity (95% 
CI) of MRS [92% (86% to 95%), 76% (61% to 87%)] were higher than that of T2-MRI [86% (74% to 93%), 
55% (44% to 66%)], the difference was greater for specificity. However, the reverse was the case in the 
meta-analysis of the six studies that directly compared the two tests, where the sensitivity and specificity of 
MRS was 89% (95% CI 79% to 95%) and 71% (95% CI 51% to 85%) compared with 77% (95% CI 55% 
to 90%) and 68% (95% CI 59% to 75%) for T2-MRI, with the difference being greater for sensitivity. There 
was statistical evidence (p = 0.004) that accuracy varied with threshold for the direct comparison analysis 
of T2-MRI and MRS; however, to make inferences on how these two tests compared with each other 
would require the assumption that accuracy did not vary with threshold.
A sensitivity analysis for MRS and T2-MRI comparing the pooled estimates for earlier studies (pre 2007) 
with those published more recently (2007 onwards) found no significant differences between the two time 
periods for either test (see Appendices 9 and 10).
Combining the two tests so that a positive result for either was considered a positive result for the 
combination led to an increase in sensitivity [96% (95% CI 90% to 98%)] but at the expense of a large 
decrease in specificity [31% (95% CI 21% to 42%)]. In a meta-analysis of three studies reporting DCE-MRI, 
the pooled estimates for both sensitivity [79% (95% CI 69% to 87%)] and specificity [52% (95% CI 14% to 
88%)] were lower than that reported for either MRS or T2-MRI. DW-MRI was reported only by one small 
study96 involving 43 patients, and only for sensitivity, although this was 100%. In pooled estimates for six 
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studies reporting TRUS as an imaging test,57,75,80,82,93,111 sensitivity and specificity were 27% (95% CI 16% to 
42%) and 81% (95% CI 77% to 85%), respectively.
Across six large-scale population screening studies81,88,97,99,103,113 that provided information on the 
performance of systematic biopsies using a TRUS-guided approach on a subset of their patient populations 
who had a previous negative biopsy (n = 5771) sensitivity was 72.5% (range 60.6% to 96.3%). Pepe et al.97 
reported that a median of 23 cores (range 20 to 38) were taken.97 The other studies reported the number 
of cores to be taken as follows: four to six cores,88 at least four or six cores,103 six cores113 and eight cores.81 
Pinsky et al.99 did not report the number of cores taken.
In the indirect comparison the highest sensitivity was reported for MRS at 93% (95% CI 87% to 97%), 
whereas the highest specificity was for TRUS (used as an imaging test) at 88% (95% CI 79% to 94%). The 
combination of tests that produced the highest sensitivity was for ‘T2-MRI or MRS’ at 97% (95% CI 91% 
to 99%), whereas the combination of tests that produced the highest specificity was for ‘T2-MRI and 
MRS’ at 73% (95% CI 58% to 85%). There was marginal evidence that accuracy varied with threshold in 
the indirect comparison model (p = 0.065); however, to make comparative inferences would require the 
assumption that accuracy did not vary with threshold.
For the estimates from the indirect comparison model comparing T2-MRI with other tests, in terms of 
relative sensitivity, the direction of effect favoured (1) MRS, (2) ‘T2-MRI or DCE’ and (3) ‘T2-MRI or MRS’ 
over T2-MRI, while favouring T2-MRI over (1) DCE-MRI, (2) ‘T2-MRI and MRS’ and (3) TRUS. However, 
the only results that were statistically significant were for ‘T2-MRI or MRS’ compared with T2-MRI (‘T2 or 
MRS’ better) and T2-MRI compared with TRUS (T2-MRI better). In terms of relative specificity the direction 
of effect favoured (1) MRS, (2) ‘T2-MRI and MRS’ and (3) TRUS over T2-MRI, while favouring T2-MRI over 
(1) DCE-MRI, (2) ‘T2-MRI or DCE-MRI’ and (3) ‘T2-MRI or MRS’. The only results that were statistically 
significant were for ‘T2-MRI and MRS’ compared with T2-MRI (‘T2-MRI and MRS’ better), T2-MRI 
compared with TRUS (TRUS better) and ‘T2-MRI or MRS’ compared with T2-MRI (T2-MRI better). However, 
it should be noted that in practice MRS is acquired in combination with T2-MRI and would not usually be 
interpreted without taking into account this information.
In summary, the evidence from patient-level pooled estimates suggests that MRS has higher sensitivity 
(92%) and specificity (76%) than T2-MRI (86%, 55%), while combining both tests so that when either 
is positive the combination is positive further increases sensitivity (96%) but at the expense of specificity 
(31%). DCE-MRI has lower sensitivity (79%) and specificity (52%) than either MRS or T2-MRI, although 
this was based on only three studies.78,90,105 TRUS used as an imaging test has low sensitivity (27%) but 
high specificity (81%). Only one small study96 reported patient-level estimates for DW-MRI and only for 
sensitivity, which, however, was 100%.
Strengths and limitations of the assessment
In terms of strengths, a broad, robust literature search was undertaken with double screening of titles and 
double checking of data extraction. Risk of bias was assessed using a modified QUADAS-2 questionnaire, 
tailored to the needs of this review. A HSROC model was used, which takes account of the trade-off 
between true/false-positives and models between-study heterogeneity.172 Pooled estimates were performed 
at both patient and biopsy level and an indirect comparison of tests was also undertaken. Homogeneity 
was improved by having a robust inclusion criterion for meta-analysis and indirect comparison, and 
by performing an additional analysis using only those studies that directly compared tests. Indirect 
comparison allows relative estimation of sensitivity and specificity for each comparison by including all 
tests in one model.
In terms of limitations, there was variation in the use of tests, methodology and reporting of included 
studies. We could not test for the effects of covariates such as the number of previous biopsies on the 
results because the data captured were not conducive for such analysis. Non-English-language studies 
were excluded. Few studies were identified reporting DCE-MRI or DW-MRI, and few studies included a 
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period of follow-up as part of the reference standard, thereby potentially failing to identify a proportion 
of patients who might have been false-negative on the tests. The index and comparator tests were not 
independent of the reference standard (incorporation bias), as they provided the biopsy cores for the 
reference standard to assess for the presence or absence of disease.
Uncertainties
Dichotomising test results where studies reported an ‘equivocal’ category
Some studies reported suspicious results (test-positives), normal results (test-negatives) and a third 
category, neither positive nor negative, such as ‘equivocal’. In order to incorporate these results into a 
2 × 2 table and for inclusion in meta-analyses they had to be dichotomised as either positive or negative. 
Our position was to class equivocal results along with positive results rather than with negative results. This 
approach increased sensitivity and decreased specificity, whereas the reverse would have been the case if 
equivocal results had been classed along with negative results. In Appendix 8, when studies have reported 
an ‘equivocal’ category, where possible, we have shown sensitivity and specificity both for equivocal cases 
classed with positive results and for equivocal cases classed with negative results. For example, in the study 
by Yuen et al.,112 for MRS, when equivocal was classed as ‘suspicious’ sensitivity was 71.4% and specificity 
was 52.9%, whereas when equivocal was classed as ‘normal’ sensitivity was 57.1% and specificity was 
82.4%.
False-positives
Eleven studies57,74,76,78,79,101,106,108,109,133,137 provided some additional information on the nature of their 
false-positive results (i.e. the test detected an abnormal area but the histopathological assessment of the 
biopsy cores taken from that area was negative for cancer). The false-positive rate for patient-level analysis 
(six studies74,76,79,101,108,137) ranged from 2.4% to 100% and for biopsy-level analysis (five studies57,78,106,109,133) 
ranged from 13.0% to 46.2%. High-grade PIN and prostatitis accounted for a substantial proportion 
of false-positives. One study presented this information separately for MRS and T2-MRI.79 For MRS 
(11 false-positives), PIN accounted for six (54.5%), fibrosis for four (36.4%) and normal prostatic tissue for 
one (9.1%). For T2-MRI (13 false-positives) PIN accounted for three (23.0%), fibrosis for five (38.5%) and 
normal prostatic tissue for five (38.5%).
True-negatives
An extended TRUS/Bx procedure may miss cancers, as the transrectal approach renders sampling of apex 
tumours and anterior TZ tumours difficult. Using this as the approach to provide the biopsies for the 
reference standard has its limitations, especially if not combined with long-term follow-up. The number of 
true-negatives in these types of study could therefore potentially be lower than reported.
Detection of clinically significant disease
Using comprehensive (saturation) biopsy protocols based on TRUS/Bx may reduce the likelihood of missing 
cancers. However, although saturation biopsies may improve the detection rate of PC, solely increasing 
the number of biopsy cores may also lead to an increase in the detection of clinically insignificant disease. 
In addition, saturation biopsies have the disadvantage of possibly requiring anaesthesia and increasing 
the risk of adverse events.105 On the other hand Scattoni et al.173 reported that the detection rates of 
protocols including 20–38 cores ranged from 14% to 41% without significantly increasing the likelihood 
of detecting clinically insignificant cancers compared with initial or repeat biopsy.
One of the suggested advantages of MRS and other MRI techniques is the ability to detect clinically 
significant disease (Gleason score of ≥ 7). An explanation put forward for this in relation to MRS is that it is 
unable to detect the lowest grade of PC due to partial voluming of healthy surrounding tissue included in 
a spectroscopic voxel of spatial resolution 0.32 cm.106
Twenty-nine studies74,76,78–84,86,87,90,91,95–98,102–106,108–113,136 reported the Gleason score based on the biopsy 
results of patients diagnosed with PC. Most studies reported a median Gleason score of ≥ 6 and in the 
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one study96 reporting DW-MRI the median Gleason score was 7. Across six MRI studies reporting a median 
Gleason score of > 6,74,90,96,104,108,109 the percentage of patients with a Gleason score of ≥ 7 ranged from 
50% to 66.7%. The limited evidence suggests that, potentially, a substantial number of cancers detected 
by MRS and other MRI techniques in patients with raised PSA levels and previous negative biopsy may be 
clinically significant (Gleason score of ≥ 7 and/or volume > 0.5 ml).
The experience of clinical experts (Anwar Padhani, Mount Vernon Cancer Centre, July 2012, personal 
communication) suggests that DW-MRI is capable of detecting more clinically significant disease than 
TRUS/Bx, and that cancers missed on DW-MRI that are detected on TRUS/Bx are generally not clinically 
significant. However, there is a lack of evidence on the detection of clinically significant disease by 
DW-MRI in the population of men with a previously negative biopsy who still have raised PSA levels and 
a continuing suspicion for cancer. There is some evidence on the ability of DW-MRI to detect clinically 
significant disease in the wider population of men with PC; for example, Hambrock et al.64 undertook 
DW-MRI of 51 patients before prostatectomy and found that the median ADC in the tumours was 
negatively correlated with Gleason score in the PZ of the prostate. However, further research is needed to 
assess the extent to which this finding applies to men with suspected PC but a previously negative biopsy. 
In the TZ, although there is a small significant difference in ADC between Gleason 3 + 3 and Gleason 
4 + 4 cancers, the overlap in ADC between the two cancer groups is so large that discrimination on an 
individual level is not possible (Tom Scheenen, Radboud University Nijmegen Medical Centre, July 2012, 
personal communication).
Cancer detection in the transition zone by magnetic resonance spectroscopy 
and other magnetic resonance imaging techniques
Hoeks et al.87 commented that MRS had problems imaging the TZ and also noted that different choline–
creatine ratios were needed for cut-offs for a positive test result for the PZ and TZ. The authors stated that 
their relatively high detection rates of PC in the TZ in men with one or more negative TRUS-guided biopsies 
agreed with the results of Hambrock et al.86 (57% in the TZ). However, they noted that, in other reports 
by Roethke et al.104 and Franiel et al.,84 TZ cancer detection rates (47% and 35%, respectively) were lower 
than PZ cancer detection rates (53% and 64%, respectively). Testa et al.,106 in a region-based analysis, 
also reported sensitivity and specificity separately for the PZ and TZ for MRS and T2-MRI. For the PZ, MRS 
sensitivity and specificity were 64.9% and 85.8%, respectively, compared with 72.2% and 93.3% for the 
TZ. T2-MRI sensitivity and specificity for the PZ were 27.0% and 95.8% respectively, compared with 61.1% 
and 98.9% for the TZ.
Heterogeneity across the studies
Across the studies, the prevalence of PC ranged from 9.5%76 to 100%.117 The original biopsy scheme used 
will influence the prevalence of PC in patients with raised PSA and previously negative biopsy; the more 
cores taken during the original biopsy scheme(s), the more cancers are likely to be detected at this stage 
and consequently the prevalence of cancer in subsequent biopsies will be lower. The previous biopsy 
schemes reported by the studies ranged from four or six core57 to 12 core.74,78,93,116 The number of previous 
biopsy sessions reported by the studies for their patient populations ranged from 1 to 9, with different 
numbers of sessions occurring within studies as well as across studies.
Transrectal ultrasonography: imaging compared with obtaining biopsies
Transrectal ultrasonography is used to either visualise the prostate in order to obtain a systematic, 
predefined biopsy (TRUS/Bx) or inspect the prostate for evidence of cancer and biopsy highly suspicious 
areas. Based on advice from clinical experts, the most common use for TRUS in the NHS is to obtain a 
systematic, predefined biopsy. Therefore, TRUS sensitivity could mean:
 z The proportion of patients with prostate cancer correctly identified on systematic predefined 
biopsy This is complicated by the fact that TRUS is not independent from the reference standard, 
as discussed elsewhere. Therefore, to obtain the false-negatives necessary to calculate sensitivity, at 
least one repeat biopsy is needed. In studies that use this method, low-risk patients do not usually 
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undergo repeat biopsies. This can lead to a falsely high sensitivity, as it assumes that all patients who 
did not undergo a biopsy did not have cancer. Furthermore, if there is a considerable interval between 
biopsies, there is the potential that an individual may have developed cancer in the intervening period.
Alternatively, TRUS sensitivity could mean:
 z The proportion of patients with prostate cancer correctly identified when TRUS is used to identify 
suspicious lesions This scenario is complicated because often both systematic and targeted biopsies 
are taken and in reported studies is it unclear if the sensitivity refers to the combination or just the 
targeted lesions.
Systematic biopsies used in conjunction with magnetic resonance spectroscopy 
and other magnetic resonance imaging techniques
In studies reporting the sensitivity and specificity of MRS or other MRI techniques, a number of cores were 
targeted for biopsy, based on suspicious areas identified by the imaging test and a systematic (generally 
10- or 12-core) TRUS/Bx was also undertaken. In most studies it was unclear how the results from the 
systematic biopsy contributed to the sensitivity and specificity values reported for the imaging technique, 
i.e. it was unclear whether the sensitivity and specificity reported were for the imaging test alone or the 
imaging test plus the systematic biopsies.
Subsidiary questions from the protocol
There was insufficient information from the included studies to address the subsidiary questions of (1) 
identifying specific patient groups in which MRS and other MRI techniques are most clinically effective; 
(2) whether or not these techniques can identify cases in which PC is present but further procedures 
are unnecessary and (3) evidence of use of MRS and other MRI techniques leading to a change in 
patient management.
Other relevant factors
Ongoing studies
The search strategy identified a few ongoing studies, although none focused on our population of 
interest – men with suspected PC and elevated PSA level but previously negative biopsy. The largest of 
the ongoing studies identified was the UK multicentre study ‘PROstate MRI Imaging Study: evaluation 
of multiparametric magnetic imaging (MP-MRI) in the diagnosis and characterisation of PC (PROMIS)’ 
that was anticipated to start in March 2012 and end in April 2015.171 The objectives of this study are to 
(1) determine the ability of MP-MRI to identify men who can safely avoid biopsy; (2) assess the ability of 
the MP-MRI-based diagnostic pathway to improve the rate of detection of clinically significant cancer 
compared with TRUS/Bx; and (3) estimate the cost-effectiveness of an MP-MRI-based diagnostic pathway. 
The study design is described as a prospective validating paired cohort study. Participant inclusion criteria 
are men who (1) are aged ≥ 18 years who are at risk of PC and have been advised to have a prostate 
biopsy; (2) have a PSA level value of ≤ 15 ng/ml in the last 3 months; (3) have suspected stage of ≤ T2 on 
rectal examination (organ confined); and (4) are fit for general/spinal anaesthesia and all study procedures. 
Exclusion criteria include a previous history of prostate biopsy. The intervention is MP-MRI scan and 
combined prostate biopsy procedure (template prostate mapping biopsy) followed by TRUS/Bx. The 
primary outcome measures are (1) proportion of men who could safely avoid biopsy; (2) proportion of 
men correctly identified by MP-MRI to have clinically significant PC; and (3) primary definition of cancer 
according to biopsy: dominant Gleason pattern of ≥ 4 and/or cancer core length of ≥ 6 mm.
Another ongoing study is the ‘Prostate Cancer Localization With a Multiparametric Magnetic Resonance 
(MR) Approach’.174 This is a prospective, observational, international, multicentre study that started in 
June 2010. Its primary objective is to prove the diagnostic accuracy of in vivo 3-T multimodality MRI 
(high-resolution T2-MRI, DCE-MRI, MRS and DW-MRI techniques) in distinguishing carcinoma from other 
prostate tissue. Specific objectives include (1) determining the diagnostic accuracy of 3-T multimodality 
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non-endorectal coil MR imaging in localising PC and (2) proving that multimodality MR data allow for 
predicting tumour grade. Inclusion criteria include men with biopsy-proven diagnosis of PC in whom 
radical prostatectomy and histopathological examination are planned.
Comparison of our results with other systematic reviews
Our searches identified four other systematic reviews70,175–177 that assessed MRI techniques for detecting PC 
in men, although only the review by Lawrentschuk and Fleshner176 focused on men with previous negative 
biopsies and elevated PSA levels.
Umbehr et al.70 undertook a systematic review and meta-analysis of MRI combined with MRS in the 
diagnosis of PC. Thirty-one studies were included, seven of which recruited participants with a previous 
negative biopsy. Six74,76,79,100,101,112 of these seven studies74,76,79,100,101,112,178 were included in our review; the 
seventh178 was excluded as the participants did not have a previous negative biopsy or this was unclear. 
The authors performed a meta-analysis of seven studies57,74,76,79,100,101,112 examining patients with suspected 
PC and found a sensitivity of 82% (95% CI 59% to 95%) and specificity of 88% (95% CI 80% to 95%). 
However, in this meta-analysis only four74,76,79,112 of the seven studies57,74,76,79,100,101,112 involved men with a 
previously negative biopsy.
Lawrentschuk and Fleshner176 undertook a review of studies of MRI or MRS which recruited participants 
with a previous negative biopsy and persistently elevated PSA. Six studies were included, five of which were 
included in our review;57,74,79,101,112 the sixth179 was excluded as the test used was outwith our inclusion 
criteria. The authors did not statistically pool the results, but rather narratively presented each study. For 
MRI or combined MRI and MRS, they reported a sensitivity of 57% to 100% and a specificity of 44% to 
96%. The authors found that 54% of patients (34/63) were diagnosed with cancer solely on the basis of a 
MRI-targeted biopsy.
Wang et al.177 undertook a meta-analysis of PC studies that used MRS as a diagnostic tool. The inclusion 
criteria were not limited to men with suspected PC and previously negative biopsy. Seven studies were 
included, of which two were included in our review;101,112 the remaining five18,51,53,180,181 were excluded 
as the types of participants were outwith our inclusion criteria. The authors reported the sensitivity and 
specificity of MRS using a CC/C ratio cut-off of 0.75 as 82% and 68% respectively, and with a cut-off of 
0.86 as 64% and 86%, respectively.
Engelbrecht et al.175 performed a systematic review of local staging of PC using MRI. The authors included 
76 studies and calculated the area under the ROC curve using trapezium methodology. It was not reported 
how many of these studies included participants with a previous negative biopsy and raised PSA and the 
list of included studies was not included in the list of references. On the ROC curve the joint maximum 
sensitivity and specificity of MRI was at 71%; however, the authors found unexplained heterogeneity 
throughout the results.
Future technological developments
Magnetic resonance-guided biopsies are not usually carried out in the UK, resulting in challenges 
in ensuring the correspondence of TRUS/Bx spatial accuracies to suspicious areas identified by MRS/
MRI. Hoeks et al.87 stated that the clinical use of MR-guided biopsies was currently restricted by limited 
availability and long procedure times. They commented that the application of MRI–ultrasound fusion 
techniques, needle-guided tracking sequences, and implementation of robotics may improve these 
drawbacks in the near future and that, when these issues were resolved, multiparametric-MRI- and 
MR-guided biopsies could be applied on a larger scale for PC detection in patients with an elevated PSA 
level and one or more negative TRUS/Bx sessions.
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Cost-effectiveness
Statement of principal findings
The economic modelling found the cost-effectiveness of strategies to be highly sensitive to a number of 
key parameters and assumptions, as well as context. Our findings suggest that when the average cost of 
TRUS/Bx is ~£115 greater than the cost of obtaining a T2-MRI + MRS sequence (i.e. ~£300 per patient 
when holding the base-case T2-MRI + MRS cost estimate constant) then T2-MRI- and MRS-directed 
approaches dominate the systematic extended-cores approach in both 60- and 70-year-old cohorts (with 
cancer prevalence at 24%). In addition, the ICER for MRS compared with T2-MRI falls to < £30,000 in the 
60-year-old cohort (although not in the 70-year-old cohort). Such a difference in costs between TRUS/Bx 
and obtaining a MRS/MRI scan might be expected in hospitals where a significant proportion of biopsies 
are carried out as day-case activity, or if the average outpatient HRG cost significantly underestimates 
histopathology costs, as some personal communication suggests.
In both the 60- and 70-year-old low-prevalence cohorts, T2-MRI and MRS again dominate extended-
cores TRUS/Bx when the cost of biopsies is inflated to £300, although MRS does not achieve an ICER of 
< £30,000 in either age group. In the high-prevalence cohorts, this biopsy cost increase results in MRS 
having an ICER of ~£22,000 per QALY in 60-year-old men, whereas the ICER remains above £30,000 per 
QALY in 70-year-old men.
Under the assumption that all index repeat biopsies are carried out as outpatient procedures, at the lower 
cost of £212, we found the following:
1. The use of T2-MRI (for directing TRUS/Bx) may be considered cost-effective in comparison with 
systematic TRUS-guided extended-cores biopsy (60-year-old cohort with prevalence at 24%), but there 
is a high degree of uncertainty at the £30,000-per-QALY ceiling ratio.
2. T2-MRI dominates extended TRUS/Bx in cohorts in which the prevalence of cancer is low (10%).
3. MRS is borderline cost-effective in comparison with systematic TRUS/Bx in the 60-year-old cohort with 
prevalence set at 24%, and its cost-effectiveness improves in the high-prevalence 60-year-old cohort. 
The ICER for MRS compared with systematic TRUS/Bx remains > £30,000 for all 70-year old cohorts.
4. The ICER for MRS compared with T2-MRI is above £30,000 in both the low and the moderate 
prevalence 60- and 70-year-old cohorts but < £30,000 for the high-prevalence 60-year-old cohort.
5. The findings for point 4 (above) hold when it is assumed that MRI-/MRS-directed biopsies require 
fewer cores and so are carried out as outpatient procedures, whereas systematic extended-cores 
biopsies are carried out at higher cost.
6. Threshold cost analysis shows that when the cost of biopsy is on average ~£90 higher than the cost 
of obtaining an MRS sequence, the ICER for MRS falls to < £30,000 per QALY compared with T2-MRI 
(60-year-old cohort, cancer prevalence 24%).
When applying the lower outpatient costs to biopsies, the cost-effectiveness of MRS compared with 
T2-MRI was found to be particularly sensitive to the ability of MRS to discriminate between low-, 
moderate- and high-risk cancer. Applying the assumption that MRS detects all moderate- and high-risk 
disease (with false-negatives concentrated in the low-risk group) the ICER for MRS fell to < £30,000. By the 
same token, reducing the baseline risk of disease progression, and applying lower relative risk reductions 
for diagnosis and treatment, undermined the cost-effectiveness of MRS.
A probabilistic sensitivity analysis was carried out for the 60-year-old cohort, applying the lower outpatient 
procedure cost to all index repeat biopsies (MRS/MRI-targeted and non-targeted), with all other parameter 
distributions centred on their base-case point estimates. Under this scenario, none of the strategies 
showed a high probability of being preferred on grounds of cost-effectiveness (see Figure 28) at a 
threshold willingness-to-pay ratio of £30,000 per QALY gained. However, increasing the average index 
repeat biopsy cost (to £298, as described above) and adjusting the sensitivity of MRS by underlying grade 
of disease demonstrated how these changes would give rise to a higher probability (~57%) of MRS 
NIHR Journals Library www.journalslibrary.nihr.ac.uk
DIscussIOn
100
being cost-effective at the £30,000-per-QALY threshold (assuming that base-case progression rates and 
diagnoses/treatment effects hold). (Note: the 57% is calculated from the data behind Figure 29.) 
Finally, while we were unable to accurately assess the diagnostic accuracy of DW-MRI in this cohort, 
sensitivity analysis demonstrates that its lower cost could make it preferable to MRS if it could be shown to 
have similar diagnostic accuracy.
Strengths and limitations of the assessment
Strengths
Attempts have been made to use the best available evidence to model both the diagnostic pathways and 
subsequent treatment pathways and outcomes. The model provides a flexible framework allowing the 
comparison of many different diagnostic strategies in the context of the patient’s lifetime. It captures the 
trade-off between the increased upfront costs of imaging and the reduction in subsequent biopsies, and 
also the trade-off between earlier diagnosis and potential utility decrements associated with treatment 
side-effects. Further, the model is risk stratified to allow for comparison of strategies that vary in their 
ability to differentiate between tumours of different stage and grade. The model can easily be updated to 
incorporate new, more detailed evidence as it becomes available.
Limitations
The modelling was hampered by limited availability of data on the diagnostic accuracy of alternative 
diagnostic strategies, the natural history of cancer detected at repeat biopsy, and the impact of diagnosis 
and treatment on disease progression and health-related QoL.
The systematic review uncovered limited data on the relative sensitivity (cancer detection rates) of MRI-/
MRS-targeted biopsy techniques and systematic TRUS-guided approaches. In particular, there were no 
identified studies providing head-to-head comparisons of MRI-/MRS-targeted approaches and systematic 
TRUS-guided sampling schemes based on different numbers of cores. Further, it was not possible to obtain 
pooled estimates for the sensitivity/specificity of alternative MRS/MRI sequences by grade of tumour, which 
is potentially an important parameter for informing cost-effectiveness. There is therefore a need for a large 
comparative study to prospectively assess the sensitivity of systematic approaches and MRS/MRI sequences 
for detecting cancer by D’Amico risk strata. It would also be beneficial for follow-up to be built into such 
a cohort study to ascertain how contemporary cohorts are treated, how they progress over time, and how 
their health-related QoL is affected by diagnosis and subsequent treatment with different modalities.
Although the model attempted to capture all the important clinical and cost events, it was not possible 
to capture and/or value all the important factors that might influence cost-effectiveness. For example, we 
were not able to ascertain and assign utility decrements for pain and short-lived complications associated 
with undergoing biopsy. Further, we did not have a good source of EQ-5D utility weights for a UK-based 
cohort of patients undergoing repeat biopsy and follow-up, making it necessary to draw on alternative 
sources. It would be beneficial to incorporate a measure of health-state utility into future cohort studies 
assessing the accuracy of alternative approaches to diagnosis. In addition, with the survival and QALY gains 
being so small, and of questionable clinical significance, the choice between strategies might be better 
informed by patient or public preferences for process of care factors to which the standard QALY model 
may be insensitive.
Uncertainties
Uncertainty exists regarding the way that hospitals across England and Wales are, or would be, reimbursed 
for repeat biopsy procedures using the TRUS-guided extended-cores approach and MRI-/MRS-directed 
approaches. Although it is difficult to ascertain the average picture across the UK, it is clear to see from the 
analysis that the use of MRS/MRI is likely to be cost-effective if a high proportion of the biopsies averted by 
its use would otherwise be reimbursed as day-case procedures. Sensitivity analysis suggests that, in settings 
where the average cost of biopsies averted is ~£115 more than the cost of obtaining a MRS sequence, the 
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use of MRS might be cost-effective; the greater the saving from biopsies averted, the higher the likelihood 
of MRS being considered cost-effective.
In contexts/settings where index repeat biopsies averted (using standard TRUS guidance and/or MRS/
MRI direction) would otherwise only incur the outpatient procedure cost (£212), there is less certainty 
surrounding the relative cost-effectiveness of MRI-/MRS-directed approaches.
A high degree of uncertainty exists regarding the impact of a false-negative result at repeat biopsy on the 
time to final diagnosis, and also on the impact of any delay on disease progression. The base-case analysis 
relied on the assumption that all patients experience a relative risk reduction for progression to metastatic 
disease upon referral. However, recent data suggest that risk reductions associated with radical treatment 
for low-risk patients (and even moderate-risk patients) may be small and insignificant.149 If this is the case, 
it might undermine the cost-effectiveness of strategies that increase cancer detection rates and costs over 
standard practice, unless those strategies are able to discriminate by grade of tumour.
With index repeat biopsies costed as outpatient procedures, the more sensitive and more costly enhanced 
imaging techniques were found to be associated with small cost increases, for even smaller survival and 
QALY gains compared with T2-MRI and systematic TRUS/Bx. This results in the incremental cost-per QALY 
ratios being very sensitive to the baseline risks of progression and relative treatment effects. Recent data 
suggest that the underlying risk of progression for low-risk cancer, identified in the PSA era, may be lower 
than that reported for the low-risk subgroup identified by Bill-Axelson et al.148 However, the above point 
also highlights the potential benefit of utilising a pre-biopsy imaging test that could differentiate between 
low-, moderate- and high-risk cancer, so that only those patients in the moderate- and high-risk categories 
could be selected for biopsy. Our modelling suggests that if DW-MRI or MRS could be shown to provide 
such discrimination in the cohort of patients with elevated PSA level but previously negative biopsy, these 
tests could achieve levels of cost-effectiveness considered acceptable, even at the lower biopsy procedure 
costs. More detailed studies are required to assess the diagnostic accuracy of different sequences by stage/
grade of cancer in order to address this question.
A key driver in the cost-effectiveness analysis was the high sensitivity/specificity of systematic TRUS-guided 
extended-core biopsy carried out in the outpatient setting compared with MRS/MRI. As there were 
no available literature data directly comparing the relative accuracy of MRI-directed biopsies with this 
method for obtaining biopsies, we were forced to rely on a study in which the sensitivity of the systematic 
extended-cores biopsy was modelled using the results of a saturation biopsy as the reference standard. 
There is a degree of uncertainty about the assumption of saturation biopsy as the reference standard in 
this study because of the following reasons: a large number of cancers modelled were found to be of 
low risk; there was variable correlation with prostatectomy specimens; and a considerable risk exists of 
missing apex and anterior TZ tumours. If this derived high level of test accuracy for systematic TRUS-guided 
extended biopsy is not achieved in actual clinical practice within the NHS then the cost-effectiveness of the 
approach would be negatively altered and correspondingly the MRS/MRI approach would be improved. To 
mitigate operator-dependent variability of performing outpatient systematic TRUS-guided extended biopsy, 
it would be advantageous to be able to record by ultrasound the actual locations where cores are obtained 
as a quality measure.
Finally, a further issue contributing to the uncertainty surrounding the cost-effectiveness of alternative 
diagnostic approaches, and indeed the cost-effectiveness of radical treatment,9 is the impact of treatment 
on health-related QoL. In our base-case specification, we have applied utility values that suggest radical 
treatment complications do not impact heavily on health-related QoL as measured by the EQ-5D.163 
However, the incremental cost per QALY findings are highly sensitive to changes to these applied utility 
assumptions. When health-state utilities are adjusted downwards for those patients experiencing 
treatment complications, the cost-effectiveness of strategies that improve cancer detection rates, at an 
increased cost to the health service, decreases substantially. This highlights the potential importance of 
risk stratifying treatment appropriately, so that only those patients likely to experience a significant survival 
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benefit receive radical treatments. However, current data suggest that a substantial proportion of low-risk 
patients still elect for radical treatment, which undermines the cost-effectiveness of diagnostic strategies 
that result in more low-risk patients being diagnosed. This emphasises the potential benefit of reducing 
overdiagnosis of low-risk cancers, which MRS/MRI might be able to do.
Other relevant factors
The modelled differences in survival between strategies were found to be extremely small. Despite this, 
the more sensitive strategies do achieve a high probability of being more effective (in terms of LYs and 
QALYs) than less sensitive strategies. This is due to the application of a constant and significant relative 
treatment effect (at least in the 60-year-old cohort). However, the QALY model in this instance may fail to 
capture other important process-of-care factors that have important influences on patients’ preferences 
for alternative approaches to diagnosis and monitoring. Scope exists to carry out preference elicitation 
studies to identify and value the key factors influencing patients’ preferences for alternative diagnostic, 
monitoring, and subsequent treatment pathways. For example, one could design a preference elicitation 
study to directly assess patients’ willingness to trade between factors such as chance of a positive diagnosis 
being made, risk of biopsy complications, treatment options and likely survival benefit if diagnosed, risk 
of treatment complications, risk of progression if undiagnosed, frequency of monitoring if diagnosed/
undiagnosed, and need for repeat biopsies if undiagnosed. If the value ascribed by patients to these 
alternative attributes could be measured using a common numéraire such as willingness to pay, these 
values could then be applied within a decision analysis framework to help identify the optimal approach 
from the patient perspective in the modern NHS.
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Chapter 8 Conclusions
Implications for service provision
The evidence from the patient-level pooled estimates suggests that MRS has higher sensitivity (92%; 95% 
CI 86% to 95%) and specificity (76%; 95% CI 61% to 87%) than T2-MRI [sensitivity 86% (95% CI 74% to 
93%), specificity 55% (95% CI 44% to 66%)] in detecting PC in men with elevated PSA level but a previous 
negative biopsy. Combining both tests so that when either is positive the combination is considered 
positive further increases sensitivity (96%; 95% CI 90% to 98%) but at the expense of specificity (31%; 
95% CI 21% to 42%). The advantages of higher sensitivity (fewer false-negatives) have to be weighed 
against the disadvantages of lower specificity. As the combination of MR methods works as guidance for 
biopsies, which need to provide the final positive diagnosis, the lower specificity may be acceptable. The 
limited evidence for DCE-MRI (three studies) suggests that it has lower sensitivity (79%; 95% CI 69% to 
87%) and specificity (52%; 95% CI 44% to 66%) than either MRS or T2-MRI. Only one small study reported 
patient-level estimates for DW-MRI and only for sensitivity, which, however, was high at 100%. TRUS used 
as an imaging test has low sensitivity (27%; 95% CI 16% to 42%) but high specificity (81%; 95% CI 77% 
to 85%). The results from the indirect comparison of tests were broadly reflective of those of the pooled 
estimates of the individual tests.
Transrectal ultrasonography is no longer routinely used as an imaging test but rather is used to visualise 
the prostate in order to obtain a systematic predefined set of biopsies (TRUS/Bx). Six large population 
screening studies81,88,97,99,103,113 allowed the calculation of the sensitivity of TRUS used in this manner on 
a subset of their participants with a previously negative biopsy and continuing suspicion of cancer. The 
reference standard in these studies81,88,97,99,103,113 was a second, third or more, possibly extended-core, 
transrectal biopsy session. Across these studies81,88,97,99,103,113 the median sensitivity was moderately high at 
72.5% (range 60.6% to 96.3%). However, it should be borne in mind that in these studies,81,88,97,99,103,113 
patients classed as low risk do not usually proceed to further repeat biopsies. All of the remaining patients, 
therefore, will have a high suspicion of cancer and this could potentially lead to the sensitivity values 
reported being artificially high. Moreover, cancer foci that are difficult to sample transrectally in the apex or 
anteriorly in the TZ of the prostate could remain undetected for quite a long time.
Although saturation biopsies, through removing a higher number of cores than standard or extended 
biopsy schemes, may potentially improve cancer detection rates compared with these schemes, 
solely increasing the number of biopsy cores may also lead to an increase in the detection of clinically 
insignificant disease. Most of the MRS and other MRI imaging studies reported a median Gleason score 
of ≥ 6 and the one DW-MRI study96 reported a median Gleason score of 7. Across six studies74,90,96,104,108,109 
reporting a median Gleason score of > 6, the percentage of patients with a Gleason score of ≥ 7 ranged 
from 50.0% to 66.7%. The limited evidence suggests that, potentially, a substantial number of cancers 
detected by MRS and other MRI techniques in men with raised PSA level and previously negative biopsy 
may be clinically significant (Gleason score of ≥ 7 and/or volume of > 0.5 ml).
The cost-effectiveness modelling showed the relative cost-effectiveness of alternative strategies to be 
highly sensitive to a number of key parameters and structural assumptions. Given the level of uncertainty 
surrounding these key inputs, it is difficult to arrive at a definitive conclusion on the cost-effectiveness of 
using different MRS/MRI sequences to aid the localisation of prostate abnormalities for biopsy. However, 
our modelling suggests that under certain circumstances T2-MRI may be considered cost-effective in 
comparison with systematic TRUS/Bx. In addition, if MRS and DW-MRI can be shown to have high 
sensitivity for detecting moderate/high-risk cancer, while negating the need for patients with no cancer or 
low-risk disease to undergo biopsy, their use could represent a cost-effective approach to diagnosis.
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The cost-effectiveness of using MRS rather than T2-MRI to direct biopsies was also found to be sensitive 
to the cost of prostate biopsies relative to the cost of obtaining the MRS sequence. Threshold analysis 
suggests that MRS may be considered cost-effective in moderate prevalence cohorts (24%) in settings 
where the cost of obtaining the MRS sequence is at least ~£90 less than the average cost of any biopsies 
averted (holding all other base-case parameter values constant). The greater the cost of biopsies relative to 
the cost of MRS, the more cost-effective it becomes. Data from subgroup analysis also show that the use 
of MRS is more likely to be cost-effective in subgroups harbouring a higher prevalence of cancer, and also 
in younger cohorts. In cohorts harbouring a low prevalence of cancer, T2-MRI may be preferred over TRUS/
Bx and MRS. The most sensitive strategy of targeting all patients who are positive on either T2-MRI or MRS 
for biopsy did not compare favourably in terms of cost-effectiveness compared with using MRS findings 
alone. This is due to the significant drop in specificity for only a small increase in sensitivity compared 
with MRS.
The introduction of MRS and other MRI techniques (T2-MRI, DCE-MRI, DW-MRI) for evaluation of men 
with TRUS-guided negative biopsies but in whom there remains suspicion of cancer would have a range 
of implications for the NHS. These would arise primarily because of a shift in the test–treatment pathway 
for this group, with changes in the method of making diagnosis resulting in changes to the types of 
patients being treated, offered patient options and timings of treatments. This would have consequential 
effects on service provision, costs and training. If urological and/or radiological services were to undertake 
targeted biopsies of MRI-/MRS-suspicious regions then extra provision would be required for this. A new 
generation of equipment and software would be needed to enable accurate, documentable biopsies to 
be obtained from all regions of the prostate. If MRS/MRI identified more patients with localised disease 
with intermediate and high risk of progression, this would increase the proportion of patients considered 
eligible for radical therapies. If MRS/MRI detected few patients with low risk of progression disease then 
fewer patients in this category would undergo perhaps inappropriate radical therapies. Thus the total 
number of patients undergoing radical therapies would be appropriately decreased, thus requiring a 
rebalancing of current resources currently allocated to surgical and radiation therapy services. Furthermore, 
if MRS/MRI contributed to the more accurate classification of low-risk of progression patients, this 
would lead to an increase in the proportion of appropriately selected patients likely to undergo ‘active 
surveillance’ helping to mitigate the current high dropout rate of this approach. The implications for the 
follow-up of active surveillance patients would include utilisation of repeated PSA testing, repeated interval 
biopsies and follow-up clinics (much of this work is protocol driven and could be nurse practitioner led). 
Taken together, earlier, more accurate diagnoses and more appropriate treatments of PC may improve 
patient outcomes by reducing treatment-related morbidity, improved survival and, in the longer term, 
reduce the requirements on end-of-life and palliative care services. There would be cost implications of 
these service reconfigurations and for changes in treatment patterns mentioned above. Implementation 
would also result in the need for further training of all staff involved in delivering care to patients with PC.
Suggested research priorities
Although there is some evidence available for the sensitivity and specificity of MRS and standard 
T2-MRI for the detection of PC in men with suspected PC and elevated PSA level but previously negative 
biopsy, less evidence is available for DCE-MRI and even less for DW-MRI. More evidence is also needed 
for all of these tests of the extent to which they can differentiate between clinically significant and 
insignificant disease.
Therefore, prospective studies are required comparing the utility of the individual and combined 
components of a multiparametric magnetic resonance (MR) approach (MRS, DCE-MRI and DW-MRI) with 
both a MR-guided or -directed biopsy session and an extended 14-core TRUS/Bx scheme (the test currently 
most often used in the UK for a second biopsy where the first was negative but the patient still has a 
suspicion for PC) against a reference standard of histopathological assessment of biopsied tissue obtained 
via saturation biopsy, template biopsy or prostatectomy specimens. A follow-up time of 12 months should 
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be incorporated as part of the reference standard. Investigations of DW-MRI should be encouraged as it is 
already gaining widespread acceptance in normal radiological practice for investigating prostate diseases. 
These studies could take the form of fully paired direct (head-to-head) comparisons where all of the study 
population receives the index test(s), comparator test(s) and reference standard, or a randomised direct 
comparison in which study participants are randomly allocated to receive the index test or the comparator 
and all receive the reference standard.
These studies should also report the sensitivity of the tests in detecting clinically significant disease 
(Gleason score of ≥ 7 and/or volume of > 0.5 ml). In addition to diagnostic outcomes, adverse event 
data and impact of the tests on subsequent physician attitudes to patient management should also be 
obtained, and also cost-effectiveness data including impact of testing on health-related QoL.
Uncertainties surrounding cost-effectiveness could be significantly reduced by future research focusing on 
generating comparable estimates of (1) the sensitivity of MRI-/MRS-directed and systematic approaches to 
TRUS/Bx (using a robust and common reference standard); (2) the prospective sensitivity/specificity of MRS/
MRI sequences for detecting different grades of localised disease in the repeat biopsy cohort; and (3) the 
full economic costs of MRI sequences and systematic approaches to TRUS/Bx based on different numbers 
of cores.
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Appendix 1 Protocol
17 September 2010 (updated 9 November 2011)
HTA 09/146/01
1. Title of the project
Systematic review of the diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy 
and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities 
for biopsy
2. Name of TAR team and project ‘lead’
Aberdeen Health Technology Assessment Group 
Pawana Sharma 
Research Fellow 
Health Services Research Unit (HSRU) 
3rd Floor 
University of Aberdeen 
Health Sciences Building 
Foresterhill 
Aberdeen 
AB25 2ZD 
Tel: 01224 559055 
Fax: 01224 554580 
E-mail: p.sharma@abdn.ac.uk
Reserve contact: 
Graham Mowatt 
Senior Research Fellow 
Health Services Research Unit 
3rd Floor 
University of Aberdeen 
Health Sciences Building 
Foresterhill 
Aberdeen AB25 2ZD 
Tel: 01224 552494 
Email: g.mowatt@abdn.ac.uk
3. Plain English summary
In the UK prostate cancer is the most common cancer in men and the second most common cause of 
cancer death in men after lung cancer. Cases are rare in men aged under 50 years, but it becomes more 
common as they grow older. In its early stages prostate cancer usually develops without any symptoms. 
However, when a tumour causes the prostate gland to become enlarged or cancer spreads beyond the 
prostate, a range of symptoms can result, including increased frequency of passing urine, problems 
starting or stopping passing urine, a painful burning sensation or blood in urine.
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Techniques commonly used to diagnose prostate cancer include digital rectal examination (DRE), the 
prostate specific antigen (PSA) blood test, and trans-rectal ultrasound (TRUS)-guided needle biopsy. 
Although a DRE and the PSA test collectively are able to identify abnormalities that might indicate prostate 
cancer, a diagnosis can only be confirmed following a prostate biopsy. However, the PSA test can cause 
false alarms and give false reassurance (15–30% of men with prostate cancer have normal PSA and even 
in those patients with abnormal PSA results, 7 of 10 men will not have prostate cancer diagnosed in the 
next two years). Biopsies also have their limitations because prostate cancers cannot be seen during biopsy 
procedures (so biopsies may miss at least 20–30% of cancers that are present) and biopsy results may 
not be reliable, underestimating cancer aggressiveness in more than 20–30% of cases. Current diagnostic 
methods (DRE, TRUS, PSA) are unable to distinguish non-aggressive disease (requiring careful monitoring) 
from virulent prostate cancer (requiring definitive treatment).
Magnetic resonance imaging (MRI) can be used to assess what stage the prostate cancer is at and in 
helping to decide whether an operation is needed. MRI relies on identifying tissue changes within the 
prostate to diagnose the presence and extent of cancer. However, these changes often do not accurately 
reveal whether cancer is present or its size. MRI can be performed with add-ons including three-
dimensional magnetic resonance spectroscopy (MRS), dynamic contrast enhanced MRI (DCE-MRI) and 
diffusion weighted MRI (DW-MRI). DCE-MRI is sensitive to differences in the amount of blood and the 
permeability of blood vessels that can be associated with the development of tumours and is performed 
by obtaining a sequence of images before, during and following the injection of a contrast agent. DW-MRI 
measures the diffusion of water molecules in tissue and may help to distinguish between cancerous and 
normal prostate tissue. MRS measures the level of certain chemicals in the prostate. The concentration 
of these chemicals may be altered in the presence of prostate cancer, and hence this technique may be 
helpful in identifying this type of cancer.
Many men find themselves with the dilemma of having a raised PSA level and a negative prostate biopsy, 
and the best way to manage these patients remains uncertain. Sometimes these men undergo many 
repeated, blind biopsies which can be painful and may provide little additional yield. DCE-MRI, DW-MRI 
and MRS may be able to provide better information on tumour location, size and aggressiveness. These 
techniques may also be able to help identify cases where undertaking invasive biopsy may be avoided 
because the tumours are small, or not aggressive.
This review will assess the diagnostic accuracy of MRS, DCE-MRI and DW-MRI and the clinical effectiveness 
and cost-effectiveness of strategies involving their use in men with suspected prostate cancer and elevated 
PSA but previously negative biopsy.
The analysis will also focus on the impact that MRS, DCE-MRI and DW-MRI have for diagnosis, and what 
the overall impact of introducing these techniques would be on NHS services and patient morbidity and 
mortality. Cost-effectiveness will be assessed from the perspective of the NHS and personal social services.
Information on the diagnostic accuracy and population subgroups for which the technique is most 
clinically effective will be derived by systematically reviewing relevant studies. Information on cost-
effectiveness will be derived from an economic model which will be developed and which will use the 
findings of the diagnostic accuracy review to help provide estimates of the relative cost-effectiveness of 
diagnostic strategies that involve MRS, DCE-MRI or DW-MRI.
4. Decision problem
In the UK prostate cancer is the most common cancer in men and the second most common cause of 
cancer death in men after lung cancer.1 Each year around 35,000 men in the UK are diagnosed with 
prostate cancer and more than 10,000 die from it.1 The 5-year survival rate is around 77%.2 Cases are rare 
in men aged under 50 years, but it becomes more common as they grow older, and almost 60% of cases 
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are diagnosed in men aged over 70 years.1 There is evidence of a higher incidence of prostate cancer in 
men of African or Caribbean origin.3
The prostate is located in the pelvis and in a normal young adult male the gland is approximately 3 cm 
long and weighs around 20 grams.4 In its early stages prostate cancer usually develops without exhibiting 
any symptoms. However when a tumour causes the prostate gland to enlarge to a significant degree, 
or cancer spreads to areas beyond the prostate, a range of symptoms can result, including increased 
frequency of urination, problems starting or stopping urination, a painful burning sensation or blood 
in urine.5
Four procedures are commonly used to diagnose prostate cancer: digital rectal examination (DRE), the 
prostate specific antigen (PSA) blood test, trans-rectal ultrasound (TRUS) and needle biopsy.6 PSA is a 
protein produced by cells of the prostate gland, and the test measures the level of PSA in the blood. 
The PSA test is specific to the prostate but not to prostate cancer, and so serum levels may be elevated 
in the presence of benign prostatic hyperplasia, prostatitis and other non-malignant conditions. TRUS 
has two potential roles in the diagnosis of prostate cancer: to identify lesions suspected of malignancy 
(done rarely as the majority of prostate cancers are not visible by TRUS) and to improve the accuracy of 
prostate biopsy.7 TRUS is a blind procedure that involves the clinician taking 10–12 biopsies in a manner 
that attempts to obtain representative tissue within the peripheral zone of the prostate. However, TRUS 
has limitations in that several parts of the gland are not well sampled using this approach. The anterior 
part of the gland may be missed as a result of its greater distance from the rectum, tissue in the midline 
may be missed due to efforts to avoid the urethra, while the apex of the prostate is often inaccessible by 
the transrectal route. Collectively a DRE and the PSA test are able to identify abnormalities that could be 
indicators of prostate cancer. However, neither test is conclusive and a diagnosis can only be confirmed 
following the examination of cells taken from a biopsy of prostate tissue. The aim of prostate biopsy 
is to detect those prostate cancers with the potential for causing harm. It has been estimated that, of 
asymptomatic men in whom prostate cancer is detected by prostate biopsy following PSA measurement, 
around 50% do not require active treatment.(NICE guideline prostate cancer) The use of these tests in 
the diagnosis of prostate cancer has led to many thousands more patients being identified at increasingly 
younger ages and earlier (and therefore potentially treatable) stages of disease than occurred previously.8
The stage of prostate cancer is classified using the TNM classification of malignant tumours criteria.9 This 
describes the extent of the primary tumour (T stage), the absence or presence of spread to nearby lymph 
nodes (N stage) and the absence or presence of metastasis (M stage). The most commonly used system for 
grading prostate cancer is the Gleason sum score. The system describes a score between 2 and 10, with 
2 being the least aggressive and 10 being the most aggressive,10 although most pathologists now group 
scores 1 ≤ 6 as Gleason 6.11
Magnetic resonance imaging (MRI) can be used in the local staging of prostate cancer and has 
acquired a role in pre-operative assessment.12 Conventional MRI of the prostate relies on abnormal 
signal intensities that result from morphologic changes within the prostate to define the presence and 
extent of cancer. However, these changes often do not accurately reflect the presence and extent of 
active tumour.13 MRI can be performed with add-ons including three-dimensional magnetic resonance 
spectroscopy (MRS), dynamic contrast enhanced MRI (DCE-MRI) and diffusion weighted MRI (DW-MRI) 
in a multifunctional examination that may provide more specific information relating to tumour location, 
size and aggressiveness. DCE-MRI is sensitive to differences in blood volume and vascular permeability 
that can be associated with tumour related development of new blood vessels and is performed by 
obtaining sequential magnetic resonance images before, during and following the injection of a contrast 
agent.14 DW-MRI measures the diffusion of water molecules in tissue and may help differentiate between 
malignant and benign prostatic tissue on the basis of lower apparent diffusion coefficient (ADC) values 
of prostate cancer compared with normal prostate tissue.15 MRS measures the level of specific chemicals 
(including choline, creatine, and citrate) in the targeted tissue. The concentration of these chemicals may 
be altered in the presence of prostate cancer and this phenomenon may be exploited to identify areas of 
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tumour activity. MRS may also potentially have a role to play in assessing the aggressiveness of any tumour 
activity identified.
The management of localised prostate cancer depends on the TNM stage of the disease as well as the PSA 
level, Gleason score, personal preferences of the patients, their physicians, and other available expertise, 
equipment and resources. The treatment options for men with localised prostate cancer are: watchful 
waiting, active surveillance, radical prostatectomy, radical external beam radiotherapy (EBRT), radical 
brachytherapy, high intensity focused ultrasound (HIFU) and cryotherapy. Treatment of men with localised 
prostate cancer may be associated with a wide range of significant adverse effects. Adverse effects that 
are common, long-lasting and that may seriously affect quality of life include rectal problems, sexual 
dysfunction and urinary incontinence.16
Many men find themselves with the dilemma of having an elevated PSA level and a prostatic biopsy with 
negative findings, and the best way to manage these patients remains uncertain.17 These men may have 
enlarged central prostate glands due to benign prostatic hyperplasia, which present sampling problems for 
TRUS-guided biopsies, or they may have cancer present in locations that are difficult to biopsy.18 A negative 
biopsy or biopsies for a persistently raised PSA may have two possible explanations, either a missed 
cancer (for example through sampling error) or there is no cancer (PSA false positive). The use of MRS 
and enhanced MRI techniques may help to differentiate between these two situations, thereby avoiding 
unnecessary further biopsies in the false positives, while at the same time expediting the diagnosis of those 
men with cancers which are otherwise difficult to diagnose.
Both the National Institute for Health and Clinical Excellence (NICE) and the European Association of 
Urology (EAU) have issued guidelines on prostate cancer, including diagnosis and staging.6,7 The NICE 
guideline states that imaging is not routinely recommended for men in whom no radical treatment is 
intended. MRS is not recommended for men with prostate cancer except in the context of a clinical trial.6
The EAU guidelines state in relation to MRI and MRS for staging prostate cancer:
 z Local staging (T-staging of) prostate cancer is based on findings from DRE and possibly MRI.
 z In comparison with DRE, TRUS, and CT, MRI demonstrates higher accuracy for the assessment of 
uni- or bilobar disease (T2), extracapsular extension and seminal vesicle invasion (T3), as well as the 
invasion of adjacent structures (T4).
 z The addition of DCE-MRI can be helpful in equivocal cases.
 z The addition of MRS to MRI also increases accuracy and decreases inter-observer variability in the 
evaluation of extracapsular extension.7
This review will assess the diagnostic accuracy of MRS, DCE-MRI and DW-MRI and the clinical effectiveness 
and cost-effectiveness of strategies involving their use in men with suspected prostate cancer and elevated 
PSA but previously negative biopsy.
Subsidiary questions to be addressed relating to these techniques include:
 z In which patient group are they most clinically effective?
 z Can they identify cases where prostate cancer is present but further procedures are unnecessary?
 z Does their use lead to changes in patient management?
5. Report methods for synthesis of evidence of clinical effectiveness
Systematic review. A systematic review of the evidence for the diagnostic accuracy of MRS, DCE-MRI and 
DW-MRI techniques in aiding the localisation of prostate abnormalities for biopsy will be undertaken 
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following the general principles of the Centre for Reviews and Dissemination (CRD) guidance for 
undertaking reviews in health care19 and reported in accordance with the PRISMA statement.20
5.1 Population
The population considered will be men with suspected prostate cancer and elevated prostate specific 
antigen (PSA) up to 20 ng/ml but previously negative biopsy.
The setting is secondary or tertiary care.
5.2 Index tests
The following tests will be considered, alone or in combination:
 z Magnetic resonance spectroscopy (MRS) guided biopsy;
 z Dynamic contrast enhanced MRI (DCE-MRI) guided biopsy; and
 z Diffusion weighted MRI (DW-MRI) guided biopsy.
If sufficient data are available we may undertake sensitivity analysis around when the studies took place, to 
assess the effects of changes in the technology over time. For example, for MRS, given sufficient data we 
will consider the different approaches used, including single voxel and 3D-MRSI (chemical shift imaging).
5.3 Comparator tests
The comparator tests considered will be:
 z Standard (T2-weighted) MRI;
 z Transrectal ultrasound guided prostate biopsy.
5.4 Reference standard
The reference standard considered will be histopathological assessment of biopsied tissue. Tissue samples 
may be obtained by transrectal needle biopsy, saturation biopsy, transperineal template biopsy or from 
prostatectomy specimens.
We will incorporate a follow-up time of 12 months as part of the reference standard, to help distinguish 
between tumours missed by the index/comparator tests (subsequently detected within this 12 month 
period) and interval tumours that were not missed (and are subsequently detected after the 12-month 
follow-up time for histology).
5.5 Outcomes
Included studies must report relevant and interpretable data.
The following outcomes will be considered:
 z Diagnostic performance of MRS, DCE-MRI and DW-MRI in the localisation of abnormalities of 
the prostate.
In studies reporting the above outcome, the following outcomes will also be recorded, if reported:
 z Altered treatment as a result of the tests;
 z Acceptability of the tests;
 z Interpretability of the tests;
 z Effect of testing on quality of life (disease-specific and generic instruments);
 z Adverse effects of testing.
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Studies reporting test performance must report the absolute numbers of true positives, false positives, 
false negatives and true negatives, or provide information allowing their calculation, and report a 
per-patient analysis.
5.6 Search strategy
Extensive sensitive electronic searches will be conducted to identify reports of published and ongoing 
studies on the diagnostic accuracy and cost-effectiveness of MRS, DCE-MRI and DW-MRI techniques 
in aiding the localisation of prostate abnormalities for biopsy. Highly sensitive search strategies will be 
designed, including appropriate subject headings and text word terms, interventions under consideration 
and included study designs. Searches will be restricted to years from 1995 onwards, reflecting the 
introduction of these techniques for the evaluation of prostate cancer, and restricted to the English 
language. A draft MEDLINE search is reproduced in Appendix 1. Databases to be searched will include 
MEDLINE, MEDLINE in process, Embase, Science Citation Index, Biosis and the Cochrane Controlled 
Trials Register. Reports of relevant evidence syntheses will also be sought from the Cochrane Database 
of Systematic Reviews (CDSR), Database of Abstracts of Review of Effects (DARE), the HTA Database 
and MEDION.
Conference abstracts for the years 2006 onwards from meetings of the European, American and British 
Urological Associations will be searched. Ongoing studies will be identified through searching the WHO 
International Clinical Trials Registry, Current Controlled Trials, Clinical Trials, NIHR Portfolio and NIH National 
Cancer Institute database. Full text searching of key urology journals will also be undertaken. Websites 
of manufacturers, professional organisations, regulatory bodies and the HTA agencies will be checked to 
identify unpublished reports.
Reference lists of all included studies will be scanned in order to identify additional potentially relevant 
reports. We will also ask our clinical advisers to provide details of any additional potentially relevant reports 
that they are aware of.
5.7 Inclusion criteria
For diagnostic accuracy of MRS, DCE-MRI and DW-MRI the following types of studies will be included:
 z Direct (head-to-head) studies in which index test(s), comparator test(s) and reference standard test are 
done independently in the same group of people.
 z Randomised controlled trials (RCTs) in which people are randomised to the index and comparator 
test(s) and all receive the reference standard test.
If there is insufficient evidence from direct and randomised studies, we will consider indirect (between-
study) comparisons by meta-analysing studies that compare each single test or combination of tests 
with the reference standard test, and making comparisons between meta-analyses of the different tests. 
However, this type of study design is less reliable than direct studies as differences in diagnostic accuracy 
are susceptible to confounding factors between studies. The following types of studies will be considered:
 z Observational studies, including case series, in which the sample is created by identifying all people 
presenting at the point of testing (without any reference to the test results).
 z Case-control studies in which two groups are created, one known to have the target disease and one 
known not to have the target disease, where it is reasonable for all included to go through the tests. 
We may exclude case-control studies comparing severely diseased people with very healthy controls or 
studies excluding people with other urological disease such that the spectrum of disease and non-
disease is unlike that to be encountered in a diagnostic situation.
If the number of studies meeting our inclusion criteria is sufficiently large, we may limit them by type of 
study design and taking into account the importance of other factors such as study size.
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5.8 Exclusion criteria
The following types of report will be excluded:
 z Reviews, editorials and opinions;
 z Case reports;
 z Reports investigating technical aspects of a test;
 z Non-English-language reports.
5.9 Data extraction strategy
One reviewer will screen the titles (and abstracts if available) of all reports identified by the search strategy. 
Full text copies of all studies deemed to be potentially relevant will be obtained and two reviewers will 
independently assess them for inclusion. Any disagreements will be resolved by consensus or arbitration by 
a third party.
A data extraction form will be developed and piloted. Two reviewers will independently extract details from 
full text studies of study design, participants, index, comparator and reference standard tests and outcome 
data. Any disagreements will be resolved by consensus or arbitration by a third party.
5.10 Quality assessment strategy
Two reviewers will independently assess the quality of all included diagnostic studies using the quality 
assessment of diagnostic accuracy studies (QUADAS) checklist. The QUADAS checklist was developed for 
use in systematic reviews of diagnostic studies21 and is designed to be adapted to make it more applicable 
to a specific review topic. QUADAS was developed through a formal consensus method and was based on 
empirical evidence. The QUADAS tool will be adapted to make it more applicable to assessing the quality 
of studies of tests for detecting prostate cancer.
Two reviewers will independently assess the quality of any diagnostic studies reporting additional 
effectiveness outcomes (see section 5.5 above) using one of two separate checklists depending on study 
design. A 14-question checklist will be used to assess the quality of RCTs. An 18-question checklist will be 
used to assess non-randomised comparative studies, with the same checklist minus four questions used to 
assess the methodological quality of case series. The checklist for RCTs was adapted from Verhagen et al.22 
and the checklist for non-randomised studies and case series was adapted from several sources, including 
the Centre for Reviews and Dissemination’s guidance for undertaking reviews in health care19 Verhagen et 
al.,22 Downs and Black23 and the Generic Appraisal Tool for Epidemiology (GATE).24 Both checklists were 
developed through the Review Body for Interventional Procedures (ReBIP). ReBIP is a joint venture between 
the Health Services Research Unit, University of Aberdeen and Health Services Research at Sheffield 
University and works under the auspices of the National Institute for Health and Clinical Excellence (NICE) 
Interventional Procedures programme. The tools rate bias and generalisability, sample definition and 
selection, description of the intervention, outcome assessment, adequacy of follow up and performance of 
the analysis.
For both the QUADAS and ReBIP checklists, each question is worded so that a rating of ‘Yes’ is always 
optimal in terms of methodological quality. Any disagreements will be resolved by consensus or arbitration 
by a third party.
5.11 Methods of analysis/synthesis
The results of the individual diagnostic studies will be tabulated and sensitivity, specificity, positive and 
negative predictive values, positive and negative likelihood ratios and diagnostic odds ratios (DORs) 
calculated. If reported in a given study, a separate 2×2 table will be derived for patient-level and prostate 
site-level analyses.
Summary receiver operating characteristic (SROC) curves will be produced for each test where three or 
more diagnostic studies report sufficient data in RevMan 5. Where studies report 2×2 data for a number 
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of different cutoff values then the most frequently used cutoff value across studies will be chosen. Meta-
analysis models will be fitted using the hierarchical summary receiver operating characteristic (HSROC) 
model25 in SAS 9.1. A symmetric SROC model will be used. This model takes proper account of the 
diseased and non-diseased sample sizes in each study, and allows estimation of random effects for the 
threshold and accuracy effects. Summary sensitivity, specificity, positive and negative likelihood ratios and 
diagnostic odds ratios (DORs) for each model will be reported as point estimate and 95% confidence 
interval (CI).
Sensitivity and specificity will be pooled using the weighted average method26 if numerical difficulties are 
encountered with the HSROC model and there is no evidence of a threshold effect. Pooled likelihood ratios 
and DOR will be calculated using the DerSimonian and Laird random effects method.27 Where a study has 
an empty cell, a correction of 0.5 will be added to all four cells. These analyses will be carried out using 
Metadisc software.28 Heterogeneity will be assessed using the I2 statistic, which describes the percentage 
of the variability in effect estimates that is due to heterogeneity rather than sampling error. A value greater 
than 50% may be considered to represent substantial heterogeneity.29 Where data permit we will explore 
heterogeneity amongst parameter estimates on a variety of characteristics of the primary studies, e.g. 
PSA threshold.
For additional non-diagnostic outcomes reported (see section 5.5 above), where appropriate, meta-analysis 
will be employed to estimate a summary measure of effect. Dichotomous outcome data will be combined 
using the Mantel-Haenszel relative risk (RR) method and continuous outcomes will be combined using 
the inverse-variance weighted mean difference (WMD) method. For the estimates of RR and WMD 95% 
CIs and p-values will be calculated. The results will be reported using a fixed-effect model. Chi-squared 
tests and I-squared statistics will be used to explore statistical heterogeneity across studies. Possible 
reasons for heterogeneity will be explored using sensitivity analysis. Where there is no obvious reason 
for heterogeneity, the implications will be explored using a random-effects model. Where a quantitative 
synthesis is considered to be inappropriate or not feasible, a narrative synthesis of results will be provided.
6. Report methods for synthesising evidence of cost-effectiveness
The economic objectives are:
 z To estimate the costs of standard practice (i.e. transrectal ultrasound-guided biopsy) and alternative 
guided biopsies in the form of MRS, DCE-MRI and DW-MRI techniques in the diagnosis of 
prostate abnormalities.
 z To estimate the cost-effectiveness of MRS, DCE-MRI and DW-MRI in comparison to standard practice 
in men with suspected prostate cancer.
An economic model will be developed using data from the literature and expert opinion. The model will 
be populated using results of the systematic review, other focused reviews for key parameters (e.g. utilities) 
and if necessary study specific estimates (e.g. for some costs). Bibliographic databases that will be searched 
include MEDLINE, MEDLINE in process, Embase, Science Citation Index, Health Management Information 
Consortium (HMIC), NIHR Economic Evaluations Database (NEED) and the HTA database. Using this 
and other routine information such as the cost of treatment, the effectiveness and cost-effectiveness of 
alternative methods of diagnosis of prostate cancer will be modelled.
6.1 Economic modelling using the results of the systematic reviews to 
determine the effectiveness and cost-utility of different options
Diagnostic techniques and any subsequent treatment need not only to be effective but also cost-effective. 
The proposed research will evaluate, using Markov modelling methods, the clinical effectiveness and 
cost-effectiveness of various diagnostic technologies to aid the localisation of prostate abnormalities 
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Mowatt et al. under the terms of a commissioning contract issued by the Secretary of State for 
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17200 HealtH tecHnOlOgy assessment 2013 VOl. 17 nO. 20
131
for biopsy. The economic model will describe the pathway of individuals from the point where a choice 
exists about the form of biopsy that a patient might receive. It will cover the period of diagnosis using the 
biopsy, subsequent treatment/management and the consequences during that time period. The structure 
of the model will be based upon detailed care pathways. To formulate the care pathways we will see how 
previous economic models in this area have been modelled, and recommendations from current clinical 
guidelines. We will also seek advice from clinical experts involved in this study to identify pathways for all 
of the options to be included in the economic model.
The economic model represents a further level of evidence synthesis that will integrate information on the 
relative effectiveness of diagnostic techniques derived from the systematic review along with information 
on natural history, costs, and utilities of diagnosing and treating prostate cancer. The economic model will 
compare the alternative diagnostic techniques for a hypothetical cohort of men with suspected prostate 
cancer or elevated prostate specific antigen. This cohort will reflect the average population of men 
presenting with these abnormalities. The time horizon of the model will be the patient’s lifetime although 
shorter time horizons will be explored in a sensitivity analysis.
Data on the resource use and costs incurred for the different diagnostic options and their consequences 
will be derived from consultation with experts, published literature, including of the existing published 
economic evidence, manufacturers and other suppliers and other routine sources e.g. NHS reference 
costs. As noted above, study specific costs will be generated if suitable data from other sources are not 
available and research resources permit. One area we will investigate is the impact of procedure time 
of the different MRI techniques and whether any differences in procedure time are reflected in existing 
cost data or whether we need to devise study specific costs to reflect differences in procedure time. The 
primary perspective of costs will be the NHS and PSS. Cost data will include the direct health service costs 
associated with each diagnostic option, treatment and subsequent patient management.
Data on utilities associated with prostate cancer and the possible differences in quality of life of the 
different options will be derived from the published literature, including a structured review of economic 
evaluations as well as a search of the CEA Registry.30
The results of the model will be presented in terms of a cost-consequence analysis (e.g. costs, number of 
cases detected, etc). Results will also be presented as incremental cost per quality adjusted life-year gained 
(QALY). The modelling exercise will use a net benefit framework to combine cost and benefit estimates. 
The results of the analysis will be presented as point estimates of mean incremental costs, effects, and for 
any cost utility analysis, incremental cost per QALY. Sensitivity analysis will be used to address parameter 
and other forms of uncertainty. Cost per QALY data will be presented in terms of cost and effect plots and 
cost-effective acceptability curves (CEACs).
7. Expertise in this TAR team
The TAR team are experienced in conducting reviews of this nature in both the clinical and technical 
aspects required to address the commissioning brief. Graham Mowatt, Luke Vale and Cynthia Fraser have 
been involved in a number of similar studies and the remaining TAR team members are also familiar with 
and experienced in systematic reviews and economic modelling.
7.1 TAR centre
The Aberdeen Technology Assessment Group has a track record of producing these types of focused 
reports whilst keeping to tight timescales for various policy customers such as the National Institute 
for Health and Clinical Excellence (NICE), the National Screening Committee and the NHS R&D HTA 
programme. In recent years the following similar types of systematic reviews have been completed:
NIHR Journals Library www.journalslibrary.nihr.ac.uk
appenDIx 1
132
 z Screening for open angle glaucoma;
 z 64-slice computed tomography angiography as an alternative to invasive coronary angiography in the 
investigation of coronary artery disease;
 z Detection and treatment of staphylococcus aureus infection for patients on peritoneal dialysis for end 
stage renal disease;
 z Rapid point of care tests for the detection of genital Chlamydia;
 z Photodynamic diagnosis, urine biomarkers and cytology for the detection and follow-up of 
bladder cancer.
7.2 Team members’ contributions
Pawana Sharma, Research Fellow, will be technical lead on this project and will be responsible for the day-
to-day running of the review, as well as undertaking the reviews of test performance and effectiveness, and 
will be supervised by Graham Mowatt, Senior Research Fellow. Graham Scotland, Research Fellow, Health 
Economics Research Unit will undertake the economic evaluation. Cynthia Fraser, Information Officer, 
will develop and run the search strategies and will be responsible for obtaining papers and reference 
management. Charles Boachie, Statistician, will provide statistical advice and support. Thomas Lam, 
Specialist Registrar, Department of Urology, Aberdeen Royal Infirmary, Justine Royle, Consultant Urologist, 
Department of Urology, Aberdeen Royal Infirmary, Lutfi Kurban, Consultant Radiologist and Honorary 
Senior Lecturer, Department of Radiology, University of Aberdeen, Anwar Padhani, Consultant Radiologist 
and Head of Imaging Research, Mount Vernon Cancer Centre, Northwood, Middlesex, and Tom Scheenen, 
MR Physicist, Department of Radiology, Radboud University, Nijmegen Medical Center, Netherlands, will 
provide clinical support and advice to the team.
8. Competing interests of authors
None.
9. Timetable/milestones
2011:
November–December Develop care pathways, screening, data extraction and quality assessment forms, 
develop and run searches, assess studies for inclusion, start to develop economic model.
2012:
January–February Data extraction and quality assessment, develop economic model.
March–April Data analysis, develop economic model.
May–July  Prepare draft report.
End July  Submit report.
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Appendix 1: Draft MEDLINE search strategy
1. exp Diffusion Magnetic Resonance Imaging/
2. Magnetic Resonance Imaging/mt [Methods]
3. magnetic resonance spectroscop$.tw. 1
4. dce-mri.tw.
5. (dynamic contrast enhanced adj3 (MRI or magnetic)).tw.
6. dw-mri.tw.
7. (diffusion weight$ adj3 (MRI or magnetic)).tw.
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8. or/1-7 6
9. Prostate-Specific Antigen/
10. Prostatic Neoplasms/
11. psa.tw.
12. (prostat$ adj3 (cancer or carcinoma$ or neoplasm$ or malignan$)).tw.
13. or/9-12
14. 8 and 13
15. “sensitivity and specificity”/
16. roc curve/
17. predictive value of tests/
18. false positive reactions/
19. false negative reactions/
20. du.fs. use mesz
21. sensitivity.tw.
22. distinguish$.tw.
23. differentiat$.tw.
24. identif$.tw.
25. detect$.tw.
26. diagnos$.tw.
27. (predictive adj4 value$).tw
28. accura$.tw.
29. comparison.tw.
30. or/15-29
31. 14 and 30
32. limit 31 to english language
33. limit 32 to yr = “1995 -Current”
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Appendix 2 Search strategies
Diagnostic accuracy
MEDLINE 1946 to week 1 March 2012, MEDLINE In-Process Citations 14 March 2012, 
EMBASE 1980 to week 10 2012 
Ovid Multifile Search. 
URL: https://shibboleth.ovid.com/
1. prostatic neoplasms/ use mesz
2. exp prostate cancer/ use emez
3. (prostat$ adj3 (cancer or carcinoma$ or neoplasm$ or malignan$)).tw.
4. Prostate-Specific Antigen/
5. psa.tw.
6. prostat$ specific antigen$.tw.
7. or/1-6
8. Magnetic Resonance Imaging/ use mesz
9. Nuclear Magnetic Resonance imaging/ use emez
10. exp Diffusion Magnetic Resonance Imaging/ use mesz
11. Diffusion Weighted Imaging/ use emez
12. exp Magnetic Resonance Spectroscopy/ use mesz
13. Nuclear Magnetic Resonance Spectroscopy/ use emez
14. Prostate/us use mesz
15. Transrectal Ultrasonography/ use emez
16. magnetic resonance imag$.tw.
17. magnetic resonance spectroscop$.tw.
18. mrs.tw.
19. (dynamic contrast enhanced adj3 (MRI or magnetic)).tw.
20. dce-mri.tw.
21. (diffusion weight$ adj3 (MRI or magnetic)).tw.
22. dw-mri.tw.
23.  (transrectal adj1 (ultrasound or ultrason$)).tw.
24. trus.tw.
25. (previous$ or initial$) adj3 negative$).tw
26. or/8-25
27. 7 and 26
28. biopsy/
29. biopsy, needle/ or biopsy, fine-needle/ use mesz
30. needle biopsy/ use emez
31. (biopsy or biopsies).tw.
32. (histopathol$ or pathol).tw.
33. (locali?ation or locali?ing).tw.
34. or/28-33
35. 27 and 34
36. exp animals/ not humans/
37. nonhuman/ not human/
38. 35 not (36 or 37)
39. 38 not case report/
40.  (comment or editorial or letter or note).pt.
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41. 39 not 40
42. limit 41 to english language
43. limit 42 to yr = 1995 - current
44. remove duplicates from 43
Science Citation Index (1995 – 14 March 2012), BIOSIS (1995 – 9 March 2012), 
Conference Proceedings Citation Index-Science (1995–14 March 2012)
ISI Web of Knowledge. URL: http://wok.mimas.ac.uk/
#1 (TS = (prostat* NEAR/3 (cancer OR carcinoma* OR neoplasm* OR malignan*)))
#2 (TS = PSA)
#3 (TS = (prostat* NEAR/1 specific) AND TS = (specific NEAR/1 antigen*))
#4 #3 OR #2 OR #1
#5 (TS = “magnetic resonance spectroscopy”)
#6 (TS = “dce-mri”)
#7 (TS = “dynamic contrast enhanced magnetic”)
#8 (TS = “dynamic contrast enhanced MRI”)
#9 (TS = “dw-mri”)
#10 (TS = (Diffusion NEAR/1 weight*) AND TS = (weight* NEAR/1 magnetic))
#11 (TS = (Diffusion NEAR/1 weight*) AND TS = (weight* NEAR/1 MRI))
#12 (TS = “diffusion weighted imaging”)
#13 (TS = “magnetic resonance imaging”)
#14 (TS = mri)
#15 (TS = mrs)
#16 (TS = (transrectal NEAR/1 ultrasonograph*))
#17 (TS = (transrectal NEAR/1 ultrasound))
#18 (TS = TRUS)
#19 #18 OR #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR 
#6 OR #5
#20 #19 AND #4
#21 (TS = (localising or localizing or staging))
#22 (TS = (localisation or localization))
#23 (TS = (histapathol* or pathol*))
#24 (TS = (biopsy or biopsies))
#25 #24 OR #23 OR #21 OR #22
#26 #25 AND #20 AND Language = (English)
The Cochrane Library (Issue 3 2012)
URL: http://www3.interscience.wiley.com/
#1 MeSH descriptor Prostatic Neoplasms, this term only
#2 MeSH descriptor Prostate-Specific Antigen, this term only
#3 (psa):ti,ab,kw or (prostat* specific antigen*):ti,ab,kw
#4 (prostat* NEAR/4 cancer):ti,ab,kw or (prostat* NEAR/4 carcinoma*):ti,ab,kw or (prostat* NEAR/4 
neoplasm*):ti,ab,kw or (prostat* NEAR/4 malignan*):ti,ab,kw
#5 (#1 OR #2 OR #3 OR #4)
#6 MeSH descriptor Magnetic Resonance Imaging, this term only
#7 MeSH descriptor Diffusion Magnetic Resonance Imaging explode all trees 
#8 MeSH descriptor Magnetic Resonance Spectroscopy explode all trees
#9 MeSH descriptor Prostate, this term only with qualifier: US
#10 (magnetic resonance NEAR/4 imag*):ti,ab,kw or (magnetic resonance NEAR/4 spectroscop*):ti,ab,kw 
or (mrs):ti,ab,kw
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#11 (dynamic contrast enhanced NEAR/4 MRI):ti,ab,kw or (dynamic contrast enhanced NEAR/4 
magnetic):ti,ab,kw or (dce-mri):ti,ab,kw or (dce mri):ti,ab,kw
#12 (diffusion weight NEAR/4 MRI):ti,ab,kw or (diffusion weight NEAR/4 magnetic):ti,ab,kw or 
(dw-mri):ti,ab,kw or (dw mri):ti,ab,kw
#13 (transrectal ultrasound):ti,ab,kw or “trus”:ti,ab,kw
#14 (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13)
#15 (#5 AND #14)
#16 MeSH descriptor Biopsy, this term only
#17 MeSH descriptor Biopsy, Needle explode all trees
#18 MeSH descriptor Neoplasm Staging this term only
#19 (biopsy):ti,ab,kw or (biopsies):ti,ab,kw or (histopathol*):ti,ab,kw or (pathol*):ti,ab,kw
#20 (localisation):ti,ab,kw or (localization):ti,ab,kw or (localising):ti,ab,kw or (localizing):ti,ab,kw or 
(staging):ti,ab,kw
#21 (#16 OR #17 OR #18 OR #19)
#22 (#15 AND #21)
Health Technology Assessment/Database of Abstracts of Reviews of Effects databases 
(March 2012)
Centre for Reviews & Dissemination. URL: http://nhscrd.york.ac.uk/welcome.htm
1. MeSH DESCRIPTOR prostatic neoplasms WITH QUALIFIER undefined 3
2. MeSH DESCRIPTOR Prostate-Specific Antigen EXPLODE ALL TREES
3. #1 OR #2
4. MeSH DESCRIPTOR Magnetic Resonance Imaging EXPLODE ALL TREES
5. MeSH DESCRIPTOR Magnetic Resonance Spectroscopy EXPLODE ALL TREES
6. MeSH DESCRIPTOR Diffusion Magnetic Resonance Imaging EXPLODE ALL TREES
7. MeSH DESCRIPTOR prostate EXPLODE ALL TREES WITH QUALIFIERS undefined, US
8. (“dynamic contrast enhanced”) OR (dce-mri) OR (“diffusion weighted”) OR (dw-mri)
9. (“transrectal ultrasound”) OR (“transrectal ultrasonography”) OR (trus)
10. #4 OR #5 OR #6 OR #7 OR #8 OR #9
11. #3 AND #10
Medion (March 2012)
URL: www.mediondatabase.nl/
KW = male genital system OR urology
AND medical imaging
Clinical Trials (March 2012)
URL: http://clinicaltrials.gov/ct/gui/c/r
Disease = prostatic neoplasms Intervention = magnetic
Current Controlled Trials (March 2012)
URL: www.controlled-trials.com/
Prostat% and magnetic
International Clinical Trials Registry Platform (ICTRP) (March 2012)
World Health Organization URL: www.who.int/ictrp/en/
Prostat* AND magnetic
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National Institutes of Health Research Portfolio Online Reporting Tool (NIH RePORTER) 
(March 2012)
URL: http://projectreporter.nih.gov/reporter.cfm
Prostat% and magnetic
Conference proceedings
American Society of Clinical Oncolology. 
URL: www.asco.org
 z Annual Meeting, Orlando, FL, 29 May to 2 June 2009
 z Annual Meeting, Chicago, IL, 4–8 June 2010
 z Annual Meeting, Chicago, IL, 3–7 June 2011
Websites consulted
American Society of Clinical Oncology. URL: www.asco.org
American Urological Association. URL: www.auanet.org/
Cancer Research UK. URL: http://info.cancerresearchuk.org/cancerstats/
European Association of Urology. URL: www.uroweb.org/
Economic evaluations
NIHR Economic Evaluations Database (March 2012)
Centre for Reviews & Dissemination. URL: http://nhscrd.york.ac.uk/welcome.htm
1. MeSH DESCRIPTOR Prostatic Neoplasms EXPLODE ALL TREES WITH QUALIFIERS TH, SU,RT,DT 
IN NHSEED
2. MeSH DESCRIPTOR Prostatic Neoplasms EXPLODE ALL TREES WITH QUALIFIERS DI, RA, RI, US 
IN NHSEED
3. #1 OR #2
Health Management Information Consortium 1979 – January 2012
Ovid. URL: https://shibboleth.ovid.com/
1 prostate cancer/
2 (prostat$ adj3 (cancer or carcinoma$ or neoplasm$ or malignan$)).tw.
3 1 or 2
4 exp economic analysis/
5 economic models/
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6 (cost$ adj2 (effective$ or utilit$ or benefit$ or minimis$)).tw.
7 (economics$ or pharmacoeconomic$ or pharmo-economic$).ti.
8 (price$ or pricing$).tw.
9 (financial or finance or finances or financed).tw.
10 (value adj2 (money or monetary)).tw.
11 markov$.tw.
12 monte carlo.tw.
13 (decision$ adj2 (tree? or analy$ or model$)).tw.
14 or/4-13
15 3 and 14
MEDLINE 1966 to March week 1 2012, MEDLINE In-Process Citations 16 March 2012, 
EMBASE 1980 to 2012 week 11
Ovid Multifile Search. URL: https://shibboleth.ovid.com/
1 prostatic neoplasms/ use mesz
2 exp prostate cancer/ use emez
3 (prostat$ adj3 (cancer or carcinoma$ or neoplasm$ or malignan$)).tw.
4 Prostate-Specific Antigen/
5 psa.tw.
6 prostat$ specific antigen$.tw.
7 or/1-6
8 Magnetic Resonance Imaging/ use mesz
9 Nuclear Magnetic Resonance imaging/ use emez
10 exp Diffusion Magnetic Resonance Imaging/ use mesz
11 Diffusion Weighted Imaging/ use emez
12 exp Magnetic Resonance Spectroscopy/ use mesz
13 Nuclear Magnetic Resonance Spectroscopy/ use emez
14 Prostate/us use mesz
15 Transrectal Ultrasonography/ use emez
16 magnetic resonance imag$.tw.
17 magnetic resonance spectroscop$.tw.
18 mrs.tw.
19 (dynamic contrast enhanced adj3 (MRI or magnetic)).tw.
20 dce-mri.tw.
21 (diffusion weight$ adj3 (MRI or magnetic)).tw.
22 dw-mri.tw.
23 transrectal adj (ultrasound or ultason$).tw.
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24 trus.tw.
25 or/8-24
26 7 and 25
27 prostatic neoplasms/di, ra, ri, us use mesz
28 exp prostate cancer/di use emez
29 26 or 27 or 28
30 exp “costs and cost analysis”/ use mesz
31 exp economic evaluation/ use emez
32 economics/
33 health economics/ use emez
34 exp economics,hospital/ use mesz
35 exp economics,medical/ use mesz
36 economics,pharmaceutical/ use mesz
37 exp budgets/
38 exp models, economic/ use mesz
39 exp decision theory/
40 monte carlo method/
41 markov chains/
42 exp technology assessment, biomedical/
43 cost$.ti.
44 (cost$ adj2 (effective$ or utilit$ or benefit$ or minimis$)).ab.
45 economics model$.tw.
46 (economic$ or pharmacoeconomic$).tw.
47 (price or prices or pricing).tw.
48 (value adj1 money).tw.
49 markov$.tw.
50 monte carlo.tw.
51 (decision$ adj2 (tree? or analy$ or model$)).tw.
52 or/30-51
53 29 and 52
Quality of life
MEDLINE 1966 to week 1 March 2012, MEDLINE In-Process Citations 16 March 2012, 
EMBASE 1980 to week 11 2012 
Ovid Multifile Search. URL: https://shibboleth.ovid.com/
1. prostatic neoplasms/ use mesz
2. exp prostate cancer/ use emez
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3. (prostat$ adj3 (cancer or carcinoma$ or neoplasm$ or malignan$)).tw.
4. Prostate-Specific Antigen/
5. psa.tw.
6. prostat$ specific antigen$.tw.
7. or/1-6
8. Magnetic Resonance Imaging/ use mesz
9. Nuclear Magnetic Resonance imaging/ use emez
10. exp Diffusion Magnetic Resonance Imaging/ use mesz
11. Diffusion Weighted Imaging/ use emez
12. exp Magnetic Resonance Spectroscopy/ use mesz
13. Nuclear Magnetic Resonance Spectroscopy/ use emez
14. Prostate/us use mesz
15. Transrectal Ultrasonography/ use emez
16. magnetic resonance imag$.tw.
17. magnetic resonance spectroscop$.tw.
18. mrs.tw.
19. (dynamic contrast enhanced adj3 (MRI or magnetic)).tw.
20. dce-mri.tw.
21. (diffusion weight$ adj3 (MRI or magnetic)).tw.
22. dw-mri.tw.
23. transrectal adj (ultrasound or ultason$).tw.
24. trus.tw.
25. or/8-24
26. 7 and 25
27. quality of life/
28. quality adjusted life year/
29. “Value of Life”/ use mesz
30. health status indicators/ use mesz
31. health status/ use emez
32. sickness impact profile/ use mesz
33. disability evaluation/ use mesz
34. disability/ use emez
35. activities of daily living/ use mesz
36. exp daily life activity/ use emez
37. cost utility analysis/ use emez
38. rating scale/
39. questionnaires/
40. (quality adj1 life).tw.
41. quality adjusted life.tw.
42. disability adjusted life.tw.
43. (qaly? or qald? or qale? or qtime? or daly?).tw.
44. (euroqol or euro qol or eq5d or eq 5d).tw.
45. (hql or hqol or h qol or hrqol or hr qol).tw.
46. (hye or hyes).tw.
47. health$ year$ equivalent$.tw.
48. (hui or hui1 or hui2 or hui3).tw.
49. (health adj3 (utilit$ or disutili$)).tw.
50. (health adj3 (state or status)).tw.
51. (sf36 or sf 36 or short form 36 or shortform 36).tw.
52. (sf6 or sf 6 or short form 6 or shortform 6).tw.
53. (sf12 or sf 12 or short form 12 or shortform 12).tw.
54. (sf16 or sf 16 or short form 16 or shortform 16).tw.
55. (sf20 or sf 20 or short form 20 or shortform 20).tw.
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56. willingness to pay.tw.
57. standard gamble.tw.
58. trade off.tw.
59. conjoint analys?s.tw.
60. discrete choice.tw.
61. or/27-60
62. (case report or editorial or letter).pt.
63. case report/
64. 61 not (62 or 63)
65. 26 and 64
66. remove duplicates from 65
67. limit 66 to english language
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Appendix 3 Quality assessment of diagnostic 
accuracy studies (version 2) checklist
Magnetic resonance spectroscopy and enhanced MRI techniques in aiding the localisation of prostate abnormalities for biopsy – QUADAS-2 risk of bias tool.
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Domain 1: patient selection
A. Risk of bias
Yes No Unclear
Signalling questions:
1. Was a consecutive or random sample of patients enrolled?
2. Was a case–control design avoided?
3. Did the study avoid inappropriate exclusions?
Risk
Low High Unclear
Could the selection of patients have introduced bias?
B. Concerns regarding applicability
Concern
Low High Unclear
Is there concern that the included patients do not match the review question?
Domain 2: index & comparator test(s)
A. Risk of bias
Yes No Unclear
Signalling questions: 
4. Were the index test results interpreted without knowledge of the results of the reference 
standard?
5. If a threshold was used, was it pre-specified?
6. For a test requiring subjective interpretation, was it interpreted by someone experienced 
in interpreting such tests? 
Risk
Low High Unclear
Could the conduct or interpretation of the index test have introduced bias?
B. Concerns regarding applicability
Concern
Low High Unclear
Is there concern that the index test, its conduct, or interpretation differ from the review 
question?
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Domain 3: reference standard
A. Risk of bias
Yes No Unclear
Signalling questions:
7. Is the reference standard likely to correctly classify the target condition?
8. Were the reference standard results interpreted without knowledge of the results of 
the index test?
9. Were the results of the reference standard test interpreted by someone experienced in 
interpreting such tests?
10. Was a follow-up included in the reference standard?
Risk
Low High Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias?
B. Concerns regarding applicability
Concern
Low High Unclear
Is there concern that the target condition as defined by the reference standard does not 
match the review question?
Domain 4: flow and timing
A. Risk of bias
Yes No Unclear
Signalling questions:
11. Was there an appropriate interval between index test(s) and reference standard?
12. Did all patients receive a reference standard?
13. Did patients receive the same reference standard? 
14. Were all patients included in the analysis?
Risk
Low High Unclear
Could the patient flow have introduced bias?
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Appendix 7 Results of risk of bias and 
applicability for the individual full-text studies (n = 39)
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Study
Risk of bias Applicability concerns
Patient 
selection
Index 
test
Reference 
standard
Flow and 
timing
Patient 
selection
Index 
test
Reference 
standard
Amsellem-Ouazana 200574 J J L J J J J
Babaian 200075 ? J L J J J J
Beyersdorff 200257 J J L L J J J
Bhatia 200776 J J L J J ? J
Campodonico 200677 ? J ? J J J J
Cheikh 200978 J J L J J J J
Cirillo 200879 J J L J J L J
De la Rosette 200980 J J L J J J J
Djavan 200181 J J ? J J J J
Engelhard 200682 ? J L J J J J
Eskicorapci 200783 ? J L J J J J
Franiel 201184 J J L J J J J
Hambrock 201086 J J L J J J J
Hoeks 201287 J J ? L J J J
Keetch 199488 ? J ? J J J J
Labanaris 201089 J J L J L J J
Lattouf 200790 J J L J J J J
Lin 200891 J J ? J J J J
Lopez-Corona 200392 J J ? J J J J
Ozden 200593 J J L J J J J
Panebianco 201195 J J L J J J J
Park 200896 ? J L J J J J
Pepe 201097 J J ? J J J J
Philip 200698 ? J ? J J J J
Pinsky 200799 J J ? J J J J
Portalez 2010100 J J L J J L J
Prando 2005101 J J L J J L J
Quinlan 2009102 ? J ? J J J J
Roehl 2002103 ? J ? J J J J
Roethke 2012104 J J L J J J J
Sciarra 2010105 J J L J J J J
Testa 2010106 J J L J J J J
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Study
Risk of bias Applicability concerns
Patient 
selection
Index 
test
Reference 
standard
Flow and 
timing
Patient 
selection
Index 
test
Reference 
standard
Ukimura 1997107 J J ? J J J J
Wetter 2005108 J J L J J J J
Yakar 2011109 J J L L J J J
Yanke 2006110 ? J ? J L J J
Yuen 2004111 J J L J J L J
Yuen 2004112 J J L J J J J
Zackrisson 2004113 J J ? J J J J
L, high risk; J, low risk; ?, unclear.
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Appendix 8 Individual study results (n = 51)
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Appendix 9 Sensitivity analysis of magnetic 
resonance spectroscopy subgrouped into year of 
publication
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Appendix 10 Sensitivity analysis of T2-weighted 
magnetic resonance imaging subgrouped into year of 
publication
M
R
I p
re
 2
00
7
Se
n
si
ti
vi
ty
 a
n
d
 s
p
ec
if
ic
it
y 
– 
in
d
iv
id
u
al
 s
tu
d
y 
re
su
lt
s 
M
R
I p
re
 2
00
7
SR
O
C
 c
u
rv
e
Se
n
si
ti
vi
ty
Sp
ec
if
ic
it
y 
D
O
R
LR
+
LR
–
0.
83
 (
0.
63
 t
o
 0
.9
4)
0.
56
 (
0.
39
 t
o
 0
.7
1)
6.
30
 (
1.
91
 t
o
 2
0.
73
)
1.
88
 (
1.
26
 t
o
 2
.7
9)
0.
30
 (
0.
12
 t
o
 0
.7
4)
St
u
d
y
A
m
se
lle
m
-O
ua
za
na
 2
00
57
4
B
ab
ai
an
 2
00
07
5
Pe
ro
tt
i 2
00
21
27
Pr
an
d
o
 2
00
51
01
W
ef
er
 2
00
01
34
W
et
te
r 
20
05
10
8
Y
o
u
n
es
 2
00
11
37
Y
u
en
 2
00
41
12
9 12 16 15 7 1 14 4
9 19 17 18 2 2 6 4
6 0 1 2 3 1 0 3
18 7 40 7 12 2 7 13
0.
60
 (
0.
32
 t
o
 0
.8
4)
1.
00
 (
0.
74
 t
o
 1
.0
0)
0.
94
 (
0.
71
 t
o
 1
.0
0)
0.
88
 (
0.
64
 t
o
 0
.9
9)
0.
70
 (
0.
35
 t
o
 0
.9
3)
0.
50
 (
0.
01
 t
o
 0
.9
9)
1.
00
 (
0.
77
 t
o
 1
.0
0)
0.
57
 (
0.
18
 t
o
 0
.9
0)
0.
67
 (
0.
46
 t
o
 0
.8
3)
0.
27
 (
0.
12
 t
o
 0
.4
8)
0.
70
 (
0.
57
 t
o
 0
.8
2)
0.
28
 (
0.
12
 t
o
 0
.4
9)
0.
86
 (
0.
57
 t
o
 0
.9
8)
0.
50
 (
0.
07
 t
o
 0
.9
3)
0.
54
 (
0.
25
 t
o
 0
.8
1)
0.
76
 (
0.
50
 t
o
 0
.9
3)
TP
FP
FN
TN
Se
n
si
ti
vi
ty
Sp
ec
if
ic
it
y
M
R
I 2
00
7 
o
n
w
ar
d
s
St
u
d
y
B
h
at
ia
 2
00
77
6
C
h
ei
kh
 2
00
97
8
C
ir
ill
o
 2
00
87
9
Fr
an
ie
l 2
01
18
4
La
tt
o
u
f 
20
07
90
Te
st
a 
20
10
10
6
Y
ao
 2
00
91
36
2 11 17 18 13 16 14
4 39 13 22 10 12 10
0 12 0 3 1 6 1
15 31 24 11 2 20 16
1.
00
 (
0.
16
 t
o
 1
.0
0)
0.
48
 (
0.
27
 t
o
 0
.6
9)
1.
00
 (
0.
80
 t
o
 1
.0
0)
0.
86
 (
0.
64
 t
o
 0
.9
7)
0.
93
 (
0.
66
 t
o
 1
.0
0)
0.
73
 (
0.
50
 t
o
 0
.8
9)
0.
93
 (
0.
68
 t
o
 1
.0
0)
0.
79
 (
0.
54
 t
o
 0
.9
4)
0.
44
 (
0.
32
 t
o
 0
.5
7)
0.
65
 (
0.
47
 t
o
 0
.8
0)
0.
33
 (
0.
18
 t
o
 0
.5
2)
0.
17
 (
0.
02
 t
o
 0
.4
8)
0.
63
 (
0.
44
 t
o
 0
.7
9)
0.
62
 (
0.
41
 t
o
 0
.8
0)
TP
FP
FN
TN
Se
n
si
ti
vi
ty
Sp
ec
if
ic
it
y
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
M
R
I 2
00
7 
o
n
w
ar
d
s
Se
n
si
ti
vi
ty
Sp
ec
if
ic
it
y 
D
O
R
LR
+
LR
–
0.
88
 (
0.
72
 t
o
 0
.9
5)
0.
55
 (
0.
41
 t
o
 0
.6
9)
8.
92
 (
2.
97
 t
o
 2
6.
79
)
1.
95
 (
1.
41
 t
o
 2
.7
0)
0.
22
 (
0.
09
 t
o
 0
.5
4)
0.
0 1
.0
0.
9
0.
8
0.
7
0.
6
0.
5
0.
4
0.
3
0.
2
0.
1
Sp
ec
if
ic
it
y
Sensitivity
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Po
o
le
d
 e
st
im
at
es
 (
95
%
 C
I)
M
R
I p
re
 2
00
7 
su
m
m
ar
y 
cu
rv
e
M
R
I 2
00
7 
o
n
w
ar
d
s 
su
m
m
ar
y 
cu
rv
e
M
R
I p
re
 2
00
7
M
R
I 2
00
7 
o
n
w
ar
d
s
M
R
I p
re
 2
00
7 
su
m
m
ar
y 
p
o
in
t
M
R
I 2
00
7 
o
n
w
ar
d
s 
su
m
m
ar
y 
p
o
in
t
Se
n
si
ti
vi
ty
(9
5%
 C
I)
Sp
ec
if
ic
it
y
(9
5%
 C
I)
Se
n
si
ti
vi
ty
(9
5%
 C
I)
Sp
ec
if
ic
it
y
(9
5%
 C
I)
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Mowatt et al. under the terms of a commissioning contract issued by the Secretary of State for 
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17200 HealtH tecHnOlOgy assessment 2013 VOl. 17 nO. 20
253
Appendix 11 Transrectal ultrasonography 
individual study results (patient-level analysis)
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Appendix 12 Studies directly comparing two or 
more tests
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Appendix 13 Results of the indirect comparison
Appendix 13.1: Biopsy-level pooled estimates from indirect comparison: 
comparing the sensitivity and specificity of T2-weighted magnetic 
resonance imaging with the other tests
Parameter Estimate, % (95% CI) Ratio (95% CI) p-value
Sensitivity for T2-MRI 83 (75 to 89) 1
Sensitivity for DCE 87 (74 to 94) 1.04 (0.93 to 1.17) 0.499
Sensitivity for MRS 93 (87 to 97) 1.12 (1.03 to 1.22) 0.008
Sensitivity for T2 and MRS 71 (50 to 85) 0.85 (0.67 to 1.07) 0.172
Sensitivity for T2 or DCE 92 (81 to 97) 1.10 (1.00 to 1.21) 0.046
Sensitivity for T2 or MRS 97 (91 to 99) 1.16 (1.07 to 1.26) 0.001
Sensitivity for TRUS 24 (13 to 39) 0.28 (0.16 to 0.50) < 0.001
Specificity for T2-MRI 57 (47 to 67) 1
Specificity for DCE 40 (25 to 56) 0.70 (0.49 to 0.98) 0.041
Specificity for MRS 64 (52 to 75) 1.12 (0.95 to 1.32) 0.194
Specificity for T2 and MRS 73 (58 to 85) 1.28 (1.06 to 1.55) 0.011
Specificity for T2 or DCE 24 (13 to 39) 0.42 (0.26 to 0.68) < 0.001
Specificity for T2 or MRS 34 (23 to 46) 0.59 (0.44 to 0.78) < 0.001
Specificity for TRUS 88 (79 to 94) 1.54 (1.27 to 1.86) < 0.001
Appendix 13.2: Patient-level pooled estimates from indirect comparison: 
comparing the sensitivity and specificity of T2-weighted magnetic 
resonance imaging with the other tests
Parameter Estimate, % (95% CI) Ratio (95% CI) p-value
Sensitivity for MRI 57 (43 to 69) 1
Sensitivity for MRS 66 (53 to 78) 1.23 (1.02 to 1.49) 0.03
Sensitivity for T2 or MRS 75 (61 to 86) 1.35 (1.15 to 1.60) 0.00
Specificity for MRI 87 (78 to 93) 1
Specificity for MRS 84 (72 to 91) 0.98 (0.94 to 1.03) 0.40
Specificity for T2 or MRS 76 (62 to 86) 0.86 (0.77 to 0.95) 0.00
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Appendix 13.3: Hierarchical summary receiver operating characteristic 
plot comparing tests at patient level, assuming no underlying difference 
in the shape parameter
Appendix 13.4: Hierarchical summary receiver operating characteristic 
plot comparing tests at biopsy level, assuming no underlying difference 
in the shape parameter
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Appendix 13.5: Sensitivity analysis of the patient-level pooled estimate 
from the indirect comparison, assuming there is no common underlying 
shape
Parameter Estimate
95% CI
Lower Upper
Sensitivity for T2-MRI 0.84 0.75 0.90
Sensitivity for DCE 0.82 0.70 0.89
Sensitivity for MRS 0.92 0.86 0.95
Sensitivity for T2 and MRS 0.73 0.44 0.90
Sensitivity for T2 or DCE 0.92 0.78 0.97
Sensitivity for T2 or MRS 0.97 0.91 0.99
Sensitivity for TRUS 0.23 0.11 0.42
Specificity for T2-MRI 0.56 0.48 0.64
Specificity for DCE 0.50 0.24 0.77
Specificity for MRS 0.63 0.45 0.78
Specificity for T2 and MRS 0.77 0.65 0.85
Specificity for T2 or DCE 0.24 0.09 0.49
Specificity for T2 or MRS 0.33 0.25 0.42
Specificity for TRUS 0.84 0.76 0.89
DOR for MRI 6.78 3.58 12.84
DOR for DCE 4.49 1.23 16.43
DOR for MRS 19.51 7.51 50.69
DOR for T2 and MRS 8.85 2.23 35.06
DOR for T2 or DCE 3.51 1.05 11.74
DOR for T2 or MRS 16.55 4.80 57.04
DOR for TRUS 1.53 0.55 4.29
LR+ for MRI 1.92 1.57 2.33
LR+ for DCE 1.64 0.90 2.99
LR+ for MRS 2.50 1.58 3.96
LR+ for T2 and MRS 3.11 1.77 5.48
LR+ for T2 or DCE 1.21 0.95 1.53
LR+ for T2 or MRS 1.46 1.28 1.66
LR+ for TRUS 1.41 0.63 3.17
LR– for MRI 0.28 0.17 0.46
LR– for DCE 0.36 0.12 1.06
LR– for MRS 0.11 0.05 0.23
LR– for T2 and MRS 0.42 0.12 1.42
LR– for T2 or DCE 0.37 0.12 1.10
LR– for T2 or MRS 0.08 0.02 0.29
LR– for TRUS 1.44 0.24 8.84
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Appendix 13.6: Patient-level comparative estimates from indirect 
comparison model, comparing estimates of T2-weighted magnetic 
resonance imaging with other tests
Parameter Estimate p-value
95% CI
Lower Upper
TP odds ratio DCE vs T2 0.83 0.65 0.38 1.83
TP odds ratio MRS vs T2 2.14 0.06 0.97 4.69
TP odds ratio T2 and MRS vs T2 0.51 0.26 0.16 1.66
TP odds ratio T2 or DCE vs T2 2.11 0.22 0.64 6.91
TP odds ratio T2 or MRS vs T2 6.21 0.00 1.94 19.89
TP odds ratio TRUS vs T2 0.06 < 0.0001 0.02 0.16
TN odds ratio DCE vs T2 0.80 0.68 0.27 2.33
TN odds ratio MRS vs T2 1.35 0.35 0.72 2.51
TN odds ratio T2 and MRS vs T2 2.56 0.00 1.41 4.65
TN odds ratio T2 or DCE vs T2 0.25 0.01 0.08 0.73
TN odds ratio T2 or MRS vs T2 0.39 < 0.0001 0.26 0.60
TN odds ratio TRUS vs T2 4.06 < 0.0001 2.30 7.18
Relative sensitivity DCE vs T2 0.97 0.65 0.85 1.11
Relative sensitivity MRS vs T2 1.09 0.08 0.99 1.20
Relative sensitivity T2 and MRS vs T2 0.87 0.38 0.63 1.19
Relative sensitivity T2 or DCE vs T2 1.09 0.14 0.97 1.23
Relative sensitivity T2 or MRS vs T2 1.15 0.00 1.06 1.26
Relative sensitivity TRUS vs T2 0.27 0.00 0.13 0.55
Relative specificity DCE vs T2 0.90 0.70 0.52 1.54
Relative specificity MRS vs T2 1.13 0.30 0.90 1.42
Relative specificity T2 and MRS vs T2 1.37 0.00 1.15 1.62
Relative specificity T2 or DCE vs T2 0.43 0.04 0.18 0.98
Relative specificity T2 or MRS vs T2 0.60 < 0.0001 0.46 0.76
Relative specificity TRUS vs T2 1.50 < 0.0001 1.27 1.76
RDOR DCE vs T2 0.66 0.53 0.19 2.37
RDOR MRS vs T2 2.88 0.04 1.05 7.86
RDOR T2 and MRS vs T2 1.30 0.70 0.34 4.99
RDOR T2 or DCE vs T2 0.52 0.27 0.16 1.66
RDOR T2 or MRS vs T2 2.44 0.15 0.73 8.16
RDOR TRUS vs T2 0.23 0.01 0.07 0.75
RDOR, relative diagnostic odds ratio.
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Appendix 13.7: Hierarchical summary receiver operating characteristic 
plot comparing tests at patient level
Appendix 13.8: Biopsy-level pooled estimates from indirect comparison 
model
Parameter Estimate
95% CI
Lower Upper
Sensitivity for MRI 0.55 0.45 0.66
Sensitivity for MRS 0.68 0.49 0.83
Sensitivity for T2 or MRS 0.75 0.63 0.84
Specificity for MRI 0.88 0.78 0.94
Specificity for MRS 0.86 0.81 0.90
Specificity for T2 or MRS 0.75 0.59 0.87
DOR for MRI 9.04 4.53 18.05
DOR for MRS 13.52 6.27 29.17
DOR for T2 or MRS 9.23 4.21 20.24
LR+ for MRI 4.58 2.53 8.32
LR+ for MRS 4.96 3.48 7.06
LR+ for T2 or MRS 3.05 1.79 5.20
LR– for MRI 0.51 0.41 0.63
LR– for MRS 1.79 0.31 10.26
LR– for T2 or MRS 0.34 0.21 0.54
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Appendix 13.9: Biopsy-level comparative estimates from indirect 
comparison model, comparing estimates of T2-weighted magnetic 
resonance imaging with other tests
Parameter Estimate p-value
95% CI
Lower Upper
TP odds ratio MRS vs T2 1.74 0.07 0.95 3.20
TP odds ratio T2 or MRS vs T2 2.42 0.00 1.48 3.95
TN odds ratio MRS vs T2 0.86 0.47 0.57 1.30
TN odds ratio T2 or MRS vs T2 0.42 < 0.0001 0.33 0.54
Relative sensitivity MRS vs T2 1.23 0.03 1.02 1.49
Relative sensitivity T2 or MRS vs T2 1.35 0.00 1.15 1.60
Relative specificity MRS vs T2 0.98 0.40 0.94 1.03
Relative specificity T2 or MRS vs T2 0.86 0.00 0.77 0.95
RDOR MRS vs T2 1.50 0.34 0.66 3.40
RDOR T2 or MRS vs T2 1.02 0.94 0.59 1.76
RDOR, relative diagnostic odds ratio.
Appendix 13.10: Hierarchical summary receiver operating characteristic 
plot comparing tests at biopsy level
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Appendix 13.11: Patient-level pooled estimates from indirect comparison 
after removing the Franiel study84
Parameter Estimate
95% CI
Lower Upper
Sensitivity for T2-MRI 0.85 0.74 0.92
Sensitivity for DCE 0.82 0.70 0.90
Sensitivity for MRS 0.92 0.85 0.96
Sensitivity for T2 and MRS 0.76 0.45 0.92
Sensitivity for T2 or DCE 0.95 0.69 1.00
Sensitivity for T2 or MRS 0.98 0.91 0.99
Sensitivity for TRUS 0.35 0.18 0.58
Specificity for T2-MRI 0.57 0.48 0.65
Specificity for DCE 0.52 0.24 0.79
Specificity for MRS 0.63 0.44 0.79
Specificity for T2 and MRS 0.77 0.64 0.86
Specificity for T2 or DCE 0.21 0.09 0.44
Specificity for T2 or MRS 0.33 0.24 0.44
Specificity for TRUS 0.90 0.81 0.95
DOR for MRI 7.54 3.25 17.51
DOR for DCE 4.97 1.22 20.23
DOR for MRS 19.26 6.61 56.16
DOR for T2 and MRS 10.20 2.18 47.79
DOR for T2 or DCE 5.75 0.93 35.46
DOR for T2 or MRS 21.31 4.44 102.37
DOR for TRUS 4.91 1.37 17.60
LR+ for MRI 1.97 1.55 2.52
LR+ for DCE 1.71 0.89 3.30
LR+ for MRS 2.49 1.51 4.10
LR+ for T2 and MRS 3.23 1.78 5.85
LR+ for T2 or DCE 1.21 1.01 1.46
LR+ for T2 or MRS 1.47 1.26 1.72
LR+ for TRUS 3.53 1.34 9.27
LR– for MRI 0.26 0.14 0.50
LR– for DCE 0.34 0.11 1.06
LR– for MRS 0.11 0.05 0.26
LR– for T2 and MRS 0.35 0.12 1.02
LR– for T2 or DCE 0.21 0.03 1.68
LR– for T2 or MRS 0.07 0.01 0.33
LR– for TRUS 0.64 0.14 2.89
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Appendix 13.12: Patient-level pooled estimates from indirect comparison 
after removing the Franiel study84 and also TRUS as test
Parameter Estimate
95% CI
Lower Upper
Sensitivity for T2-MRI 0.83 0.73 0.89
Sensitivity for DCE 0.87 0.73 0.94
Sensitivity for MRS 0.94 0.87 0.97
Sensitivity for T2 and MRS 0.71 0.50 0.85
Sensitivity for T2 or DCE 0.92 0.80 0.97
Sensitivity for T2 or MRS 0.97 0.90 0.99
Specificity for T2-MRI 0.61 0.49 0.72
Specificity for DCE 0.42 0.26 0.59
Specificity for MRS 0.65 0.52 0.76
Specificity for T2 and MRS 0.75 0.59 0.86
Specificity for T2 or DCE 0.26 0.14 0.44
Specificity for T2 or MRS 0.34 0.22 0.48
DOR for MRI 7.31 3.70 14.41
DOR for DCE 4.78 1.64 13.93
DOR for MRS 26.76 10.90 65.71
DOR for T2 and MRS 7.05 2.34 21.24
DOR for T2 or DCE 4.31 1.14 16.33
DOR for T2 or MRS 15.11 4.31 53.02
LR+ for MRI 2.10 1.56 2.83
LR+ for DCE 1.50 1.10 2.03
LR+ for MRS 2.67 1.88 3.79
LR+ for T2 and MRS 2.77 1.56 4.95
LR+ for T2 or DCE 1.25 1.00 1.57
LR+ for T2 or MRS 1.46 1.20 1.78
LR– for MRI 0.29 0.18 0.46
LR– for DCE 0.31 0.14 0.72
LR– for MRS 0.10 0.05 0.21
LR– for T2 and MRS 0.39 0.21 0.75
LR– for T2 or DCE 0.29 0.09 0.92
LR– for T2 or MRS 0.10 0.03 0.31
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Mowatt et al. under the terms of a commissioning contract issued by the Secretary of State for 
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17200 HealtH tecHnOlOgy assessment 2013 VOl. 17 nO. 20
265
Appendix 13.13: Hierarchical summary receiver operating characteristic 
plot comparing tests at patient level, assuming no underlying difference 
in the shape parameter
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Appendix 13.14: Patient-level pooled estimates from indirect comparison 
after removing the Franiel study84 and also TRUS as test, assuming 
accuracy does not vary with threshold
Parameter Estimate
95% CI
Lower Upper
Sensitivity for T2-MRI 0.84 0.73 0.91
Sensitivity for DCE 0.82 0.71 0.90
Sensitivity for MRS 0.92 0.86 0.96
Sensitivity for T2 and MRS 0.76 0.45 0.92
Sensitivity for T2 or DCE 0.94 0.65 0.99
Sensitivity for T2 or MRS 0.97 0.90 0.99
Specificity for T2-MRI 0.58 0.49 0.66
Specificity for DCE 0.51 0.24 0.78
Specificity for MRS 0.65 0.47 0.79
Specificity for T2 and MRS 0.77 0.65 0.86
Specificity for T2 or DCE 0.20 0.07 0.44
Specificity for T2 or MRS 0.33 0.25 0.44
DOR for MRI 7.29 3.56 14.96
DOR for DCE 4.95 1.33 18.39
DOR for MRS 22.13 8.37 58.53
DOR for T2 and MRS 10.26 2.37 44.48
DOR for T2 or DCE 4.14 0.77 22.15
DOR for T2 or MRS 18.26 4.34 76.77
LR+ for MRI 2.00 1.62 2.48
LR+ for DCE 1.69 0.91 3.14
LR+ for MRS 2.61 1.63 4.15
LR+ for T2 and MRS 3.25 1.86 5.66
LR+ for T2 or DCE 1.18 0.99 1.41
LR+ for T2 or MRS 1.46 1.26 1.70
LR– for MRI 0.27 0.16 0.49
LR– for DCE 0.34 0.11 0.99
LR– for MRS 0.10 0.04 0.21
LR– for T2 and MRS 0.37 0.13 1.08
LR– for T2 or DCE 0.29 0.04 2.02
LR– for T2 or MRS 0.08 0.02 0.34
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Appendix 13.15: Magnetic resonance spectroscopy compared with 
T2-weighted magnetic resonance imaging patient-level analysis: 
sensitivity, specificity, pooled estimates and summary receiver operating 
characteristic curve, assuming an underlying common shape
T2
 M
R
I
Se
n
si
ti
vi
ty
 a
n
d
 s
p
ec
if
ic
it
y 
– 
in
d
iv
id
u
al
 s
tu
d
y 
re
su
lt
s 
M
R
S 
p
o
o
le
d
 e
st
im
at
es
 (
95
%
 C
I)
SR
O
C
 c
u
rv
e
Se
n
si
ti
vi
ty
Sp
ec
if
ic
it
y 
D
O
R
LR
+
LR
–
0.
89
 (
0.
78
 t
o
 0
.9
5)
0.
69
 (
0.
57
 t
o
 0
.7
8)
18
.3
7 
(6
.8
0 
to
 4
9.
59
)
2.
84
 (
1.
67
 t
o
 3
.4
4)
0.
15
 (
0.
07
 t
o
 0
.3
5)
St
u
d
y
A
m
se
lle
m
-O
u
az
an
a 
20
05
74
B
h
at
ia
 2
00
77
6
C
ir
ill
o
 2
00
87
9
Te
st
a 
20
10
10
6
W
et
te
r 
20
05
10
8
Y
u
en
 2
00
41
12
9 2 17 16 1 4
9 4 13 12 2 4
6 0 0 6 1 3
18 15 24 20 2 13
0.
60
 (
0.
32
 t
o
 0
.8
4)
1.
00
 (
0.
16
 t
o
 1
.0
0)
1.
00
 (
0.
80
 t
o
 1
.0
0)
0.
73
 (
0.
50
 t
o
 0
.8
9)
0.
50
 (
0.
01
 t
o
 0
.9
9)
0.
57
 (
0.
18
 t
o
 0
.9
0)
0.
67
 (
0.
46
 t
o
 0
.8
3)
0.
79
 (
0.
54
 t
o
 0
.9
4)
0.
65
 (
0.
47
 t
o
 0
.8
0)
0.
63
 (
0.
44
 t
o
 0
.7
9)
0.
50
 (
0.
07
 t
o
 0
.9
3)
0.
76
 (
0.
50
 t
o
 0
.9
3)
TP
FP
FN
TN
Se
n
si
ti
vi
ty
Sp
ec
if
ic
it
y
M
R
S
St
u
d
y
A
m
se
lle
m
-O
u
az
an
a 
20
05
74
B
h
at
ia
 2
00
77
6
C
ir
ill
o
 2
00
87
9
Te
st
a 
20
10
10
6
W
et
te
r 
20
05
10
8
Y
u
en
 2
00
41
12
14 2 15 20 2 5
1 5 11 18 1 8
1 0 2 2 0 2
26 14 26 14 3 9
0.
93
 (
0.
68
 t
o
 1
.0
0)
1.
00
 (
0.
16
 t
o
 1
.0
0)
0.
88
 (
0.
64
 t
o
 0
.9
9)
0.
91
 (
0.
71
 t
o
 0
.9
9)
1.
00
 (
0.
16
 t
o
 1
.0
0)
0.
71
 (
0.
29
 t
o
 0
.9
6)
0.
96
 (
0.
81
 t
o
 1
.0
0)
0.
74
 (
0.
49
 t
o
 0
.9
1)
0.
70
 (
0.
53
 t
o
 0
.8
4)
0.
44
 (
0.
26
 t
o
 0
.6
2)
0.
75
 (
0.
19
 t
o
 0
.9
9)
0.
53
 (
0.
28
 t
o
 0
.7
7)
TP
FP
FN
TN
Se
n
si
ti
vi
ty
Sp
ec
if
ic
it
y
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
T2
-M
R
I p
o
o
le
d
 e
st
im
at
es
 (
95
%
 C
I)
Se
n
si
ti
vi
ty
Sp
ec
if
ic
it
y 
D
O
R
LR
+
LR
–
0.
75
 (
0.
60
 t
o
 0
.8
6)
0.
69
 (
0.
57
 t
o
 0
.7
8)
6.
66
 (
2.
92
 t
o
 1
5.
15
)
2.
39
 (
1.
67
 t
o
 3
.4
4)
0.
36
 (
0.
21
 t
o
 0
.6
1)
0.
0 1
.0
0.
9
0.
8
0.
7
0.
6
0.
5
0.
4
0.
3
0.
2
0.
1
Sp
ec
if
ic
it
y
Sensitivity
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Se
n
si
ti
vi
ty
(9
5%
 C
I)
Sp
ec
if
ic
it
y
(9
5%
 C
I)
Se
n
si
ti
vi
ty
(9
5%
 C
I)
Sp
ec
if
ic
it
y
(9
5%
 C
I)
T2
 M
R
I s
u
m
m
ar
y 
cu
rv
e
M
R
S 
su
m
m
ar
y 
cu
rv
e
T2
 M
R
I
M
R
S
T2
 M
R
I s
u
m
m
ar
y 
p
o
in
t
M
R
S 
su
m
m
ar
y 
p
o
in
t
95
%
 C
I o
f
95
%
 C
I o
f

© Queen’s Printer and Controller of HMSO 2013. This work was produced by Mowatt et al. under the terms of a commissioning contract issued by the Secretary of State for 
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17200 HealtH tecHnOlOgy assessment 2013 VOl. 17 nO. 20
269
Appendix 14 False-positives
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Appendix 15 Gleason scores reported by the 
studies
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Study ID Test(s)
No. 
analysed
No. 
with PC Prevalence (%)
Median 
(range) 
Gleason score
Percentage 
with Gleason 
score ≥ 7
Amsellem-
Ouazana 200574
T2-MRI/MRS 42 15 35.7 6.6 (5–9) NR
Bhatia 200776 T2-MRI/MRS 21 2 9.5 (6, 6) 0.0
Cheikh 200978 T2-MRI/DCE 93 23 24.7 6 (5–9) 30.4
Cirillo 200879 T2-MRI/MRS 54 17 31.5 6 (4–8) 29.4
De la Rosette 
200980
TRUS 139 20 14.4 6 (4–8) NR
Djavan 200181 TRUS 820 123 15.0 See notes NR
Engelhard 200682 T2-MRI 37 14 37.8 4.5 (3–7) 21.4
Eskicorapci 200783 TRUS 211 54 25.6 See notes NR
Franiel 201184 T2-MRI/MRS/DCE/
DW
54 21 38.9 6 (6–10) 47.6
Hambrock 201086 T2-MRI/DCE/DW 68 40 58.8 6 (5–9) 20.3
Hoeks 201287 T2-MRI/DCE/DW 264 117 44.3 NR NR
See notes
Lattouf 200790 T2-MRI/DCE 26 14 53.8 6.5 (5–9) 50.0
Lin 200891 TRUS 366 47 12.8 6.7 (SD 1.0)
7.6 (SD 1.3)
NR
Panebianco 201195 MRS/DCE 41 28 68.3 NR 46.4
Park 200896 DW-MRI 43 17 39.5 7 (6–9) NR
Pepe 201097 TRUS 423 82 19.4 See notes NR
Philip 200698 TRUS 241 42 17.4 6.5 (6–8) NR
Quinlan 2009102 TRUS 111 27 24.3 See notes NR
Roehl 2002103 TRUS 634 188 29.7 See notes 23.0
Roethke 2011104 T2-MRI/MRS/DCE/
DW
100 52 52.0 7 (5–9) 59.7
Sciarra 2010105 MRS/DCE 90 44 48.9 NR 61.6
Testa 2010106 T2-MRI/MRS 54 22 40.7 6 (1–9) 27.3
Wetter 2005108 T2-MRI/MRS 6 2 33.3 (6, 7) 50.0
Yakar 2011109 T2-MRI/DCE/DW 9 5 55.6 7 (6–8) 66.7
Yanke 2006110 TRUS 416 144 34.6 See notes 51.0
Yao 2009136 T2-MRI 41 15 36.6 NR NR
See notes
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Study ID Test(s)
No. 
analysed
No. 
with PC Prevalence (%)
Median 
(range) 
Gleason score
Percentage 
with Gleason 
score ≥ 7
Yuen 2004111 TRUS 57 15 26.3 5.4 (2.5–6.0)
6.8 (4.0–8.0)
NR
Yuen 2004112 T2-MRI/MRS 24 7 29.2 6 (6–7) 42.9
Zackrisson 2004113 TRUS 706 169 23.9 See notes NR
MRGB, MR-guided biopsy; NR, not reported; TCCL, total cancer core length.
Notes
Amsellem-Ouazana 2005:74 mean Gleason score reported.
Djavan 2001:81 mean (SD) Gleason biopsy scores: biopsy 2, 5.7 (0.5); biopsy 3, 4.6 (0.4); biopsy 4, 4.4 (0.7). Mean (SD) 
Gleason radical prostatectomy scores: biopsy 2, 4.9 (0.8), biopsy 3, 4.2 (0.3); biopsy 4, 4.0 (0.4).
Eskicorapci 2007:83 35 men underwent radical prostatectomy. 32/35 had clinically important cancer (T2a, n = 7; T2b, 
n = 20; T3a, n = 6; T3b, n = 2).
Hoeks 2012:87 when prostatectomy was not performed, clinical significance of MRGB-detected prostate cancer was 
defined by (1) a PSA level > 10ng/ml and a PSA density > 0.15 ng/ml per ml; (2) clinical stage ≥ T2b; (3) a Gleason grade 
4 or 5 within the biopsy specimen; or (4) a TCCL ≥ 10 mm, where TCCL is the total cancer length in all MRGB cores from 
one cancer-suspicious region (definition based on Epstein and D’Amico criteria). In case of performed prostatectomy, 
PC was considered clinically significant when PC volume was ≥ 0.5 ml or a stage ≥ pT3 or a Gleason grade 4 or 5 was 
present. Hoeks et al.87 reported that the majority of detected cancers were clinically significant: a total of 87% (94 of 
108) met the clinical criteria and 93% (26 of 28) met radical prostatectomy specimen criteria.
Lin 2008:91 reported Gleason scores as mean plus SD [6.7 (SD 1.0) for the second session and 7.6 (SD 1.3) for the 
third session].
Pepe 2010:97 mean (range) Gleason scores: PZ cancer (n = 76) 6.5 (6–8); PZ + TZ cancer (n = 4) 6.8 (6–8); TZ cancer 
(n = 2) 6.
Philip 2006:98 mean (range) Gleason score reported. All but three had a Gleason score ≥ 6.
Quinlan 2009:102 mean (range) Gleason scores reported by biopsy number: biopsy 1, 6.1 (6–8); biopsy 2, 6.5 (6–7); 
biopsy 3, 6.25 (6–7); biopsy 4, 6.3 (6–7).
Roehl 2002:103 Gleason 2–4: n = 48 (8%); Gleason 5–6: n = 397 (69%); Gleason 7: n = 107 (19%); Gleason 8–10: n = 25 
(4%).
Yakar 2011:109 Gleason scores reported are for six cancer-suspicious regions of five patients.
Yanke 2006:110 Gleason 4 to 6: n = 30 (49%); Gleason 7: n = 26 (43%); Gleason 8–10: n = 5 (8%).
Yao 2009:136 reported that cancers detected by MRI were generally clinically significant with a Gleason score > 6 in 10 of 
12 tumours (83%).
Yuen 2004:111 mean (range) Gleason score reported. Yuen et al. reported that the mean (range) Gleason score was 5.4 
(2.5 to 6.0) for biopsy 2 and 6.8 (4.0 to 8.0) for biopsy 3.
Zackrisson 2004:113 number (%) of Gleason score ≤ 3 reported by biopsy: biopsy 1, n = 322 (84%); biopsy 2, n = 104 
(87%); biopsy 3, n = 32 (97%); biopsy 4, n = 5 (83%).
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Appendix 16 Adverse events related to 
transrectal ultrasonography-guided biopsy
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Study ID
No. 
analysed
No. (%) 
experiencing event Type of event
Beyersdorff 200257 38 2 (5%) Haemorrhage in the prostate
Bhatia 200776 21 Most patients Transient haematuria (self-resolving) after TRUS biopsy
None Sepsis
None Severe bleeding
Djavan 200181 820 57% Mild haematuria
16.6% Recurrent mild haematuria
11.3% UTI
10.2% Delayed haematospermia
6.8% Persistent dysuria
2.4% Rectal bleeding
2.3% Delayed fever
1.4% Moderate to severe vasovagal episodes
0.5% Severe haematuria
0.1% Major rectal bleeding
Engelhard 200682 37 None Collateral effects or complications
Hambrock 201086 68 1 (1.5%) Transurethral haemorrhage (self-limiting)
1 (1.5%) UTI (uncomplicated) 
Hoeks 201287 264 1 (0.4%) Sepsis with hospitalisation
4 (1.5%) Vasovagal reaction
aLabanaris 201089 260 190 (73%) Macroscopic haematuria lasting an average of 4 days 
(range 1–18 days)
146 (56%) Haematospermia lasting an average 11 days 
(range 1–30 days)
96 (37%) Minor rectal bleeding lasting an average of 1.3 days 
(range 0–15 days)
173 2 (1.2%) Prostatic infection (fever and required hospitalisation)
Yakar 2011109 9 None Complications relating to the biopsy procedure in terms of 
bleeding, infection, sepsis or other medical conditions
Yuen 2004111 57 3 (1.4%) Macroscopic haematuria (treated conservatively as inpatient)
5 (2.3%) Fever (treated conservatively as inpatient)
5 (2.3%) Acute retention of urine (treated conservatively as inpatient)
1 (0.5%) Bleeding per rectum (admitted to hospital) 
Not stated Transient haematuria, haematospermia and orchitis (treated 
in the outpatient setting) 
Yuen 2004112 24 Most patients Transient haematuria and haematospermia (self-resolving)
None Sepsis requiring inpatient treatment
None Severe bleeding requiring inpatient treatment
a Nos of those experiencing adverse events calculated from the percentages reported.
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Appendix 17 Supplementary results from cost-
effectiveness analysis
TABLE 39 Costs of diagnosis and pre-diagnosis monitoring, biopsy complications and cancer treatment by diagnostic 
strategy: 60-year-old cohort 
Strategy
Costs (£)
Diagnosis and 
prediagnosis 
monitoring Biopsy complications Cancer treatment Total
TRUS 773 11 3111 3895
MRI 780 7 3115 3902
MRS 822 5 3125 3952
DCE 873 7 3104 3984
MRI or MRS 892 9 3130 4031
MRI or DCE 928 10 3118 4056
TABLE 40 Costs of diagnosis and pre-diagnosis monitoring, biopsy complications and cancer treatment by diagnostic 
strategy: 70-year-old cohort
Strategy
Costs (£)
Diagnosis and 
pre-diagnosis 
monitoring Biopsy complications Cancer treatment Total
TRUS 595 11 2593 3199
MRI 603 7 2596 3206
MRS 644 5 2607 3256
DCE 694 7 2586 3287
MRI or MRS 714 9 2613 3336
MRI or DCE 750 10 2600 3360
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TABLE 41 Expected numbers of unnecessary and appropriate biopsies: 60-year-old cohort
Strategy
Expected no. of 
unnecessary biopsiesa
Expected no. of 
appropriate biopsiesb
Total expected no. of 
biopsies
TRUS 0.758 0.378 1.137
MRI 0.341 0.338 0.679
MRS 0.182 0.338 0.520
DCE 0.364 0.338 0.702
MRI or MRS 0.523 0.338 0.861
MRI or DCE 0.652 0.338 0.990
a Biopsies taken in men with no detectable prostate cancer.
b Biopsies taken in men with detectable prostate cancer.
TABLE 42 Expected numbers of unnecessary and appropriate biopsies: 70-year-old cohort
Strategy
Expected no. of 
unnecessary biopsiesa
Expected no. of 
appropriate biopsiesb
Total expected no. of 
biopsies
TRUS 0.756 0.360 1.116
MRI 0.340 0.320 0.660
MRS 0.181 0.320 0.502
DCE 0.363 0.320 0.683
MRI or MRS 0.522 0.320 0.842
MRI or DCE 0.650 0.320 0.970
a Biopsies taken in men with no detectable prostate cancer.
b Biopsies taken in men with detectable prostate cancer.
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TABLE 43 Deterministic sensitivity analysis scenarios using LYs as unit of outcome (men aged 60 years; cancer 
prevalence 24%)
Strategy
Average 
cost (£)
Incremental 
cost (£)a Average LYs
Incremental 
LYsa ICERa (£)
ICER vs 
common 
baseline (£)
Scenario 1. Biopsy costs inflated to account for additional pathology time associated with > 10 cores; MRS/
MRI costs also adjusted to the NHS reference costs 
Syst. TRUS 4018 b 14.16796 b b b
T2-MRI 4024 7 14.16890 0.000936 7198 7198
MRS 4060 35 14.17081 0.001911 18,565 14,826
DCE 4108 49 14.16669 –0.004120 Dominated Dominated
MRI or MRS 4169 109 14.17203 0.001221 89,122 37,123
MRI or DCE 4205 37 14.16949 –0.002540 Dominated 122,622
Scenario 2. Sensitivity of MRS adjusted to miss only low-grade cancer
Syst. TRUS 3895 b 14.16796 b b b
T2-MRI 3902 7 14.16890 0.000936 7447 7447
MRS 3956 54 14.17243 0.003535 15,214 13,588
DCE 3984 28 14.16669 –0.005750 Dominated Dominated
MRI or MRS 4031 75 14.17203 –0.00040 Dominated 33,425
MRI or DCE 4056 100 14.16949 –0.00294 Dominated 105,351
Scenario 3. Sensitivity of comparator reduced to 60% 
Syst. TRUS 3882 b 14.15943 b b b
T2-MRI 3899 16 14.16768 0.008258 1975 1975
MRS 3948 49 14.16959 0.001911 25,861 6463
DCE 3981 32 14.16547 –0.004120 Dominated 16,216
MRI or MRS 4028 80 14.17082 0.001221 65,219 12,761
MRI or DCE 4053 25 14.16828 –0.002540 Dominated 19,269
Scenario 4. Application of sensitivity/specificity estimates obtained from the indirect comparison (T2-MRI 
sensitivity 0.84/specificity 0.58; MRS sensitivity 0.92/specificity 0.65)
Syst. TRUS 3895 b 14.16796 b b b
MRI 3895 0 14.16827 0.000309 174 174
MRS 3970 75 14.17080 0.002529 29,604 26,403
DCE 3986 16 14.16669 –0.004110 Dominated Dominated
MRI or MRS 4029 59 14.17234 0.001548 37,870 30,451
MRI or DCE 4052 23 14.17139 –0.000960 Dominated 45,713
continued
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Strategy
Average 
cost (£)
Incremental 
cost (£)a Average LYs
Incremental 
LYsa ICERa (£)
ICER vs 
common 
baseline (£)
Scenario 5. Biopsy costs uplifted for systematic TRUS (assumes 14-core TRUS biopsy is £86 more costly than 
MRS/MRI-directed biopsy, and £112 more costly than MRS)
MRI 3907 b 14.16890 b b b
MRS 3955 48 14.17081 0.001911 25,032 25,032
DCE 3991 36 14.16669 –0.004120 Dominated Dominated
Syst. TRUS 3991 36 14.16796 –0.002850 Dominated Dominated
MRI or MRS 4034 79 14.17203 0.001221 64,355 40,363
MRI or DCE 4061 27 14.16949 –0.002540 Dominated 258,868
Scenario 6. MRI reduces the risk of biopsy complications by 50%
Syst. TRUS 3895 b 14.16796 b b b
MRI 3899 4 14.16893 0.000968 4284 4284
MRS 3949 50 14.17083 0.001902 26,362 18,917
DCE 3981 32 14.16672 –0.004110 Dominated Dominated
MRI or MRS 4027 78 14.17207 0.001242 62,656 32,125
MRI or DCE 4052 25 14.16954 –0.002530 Dominated 99,198
Scenario 7. Subsequent repeat biopsy offers have 80% uptake (repeat offer every 12 months for those 
remaining with undiagnosed cancer)
Syst. TRUS 3888 b 14.16628 b b b
MRI 3895 8 14.16737 0.001091 6891 6891
MRS 3946 51 14.16962 0.003334 22,544 17,420
DCE 3976 30 14.16478 –0.001510 Dominated Dominated
MRI or MRS 4026 80 14.17106 0.004777 55,739 28,990
MRI or DCE 4050 24 14.16808 0.001796 Dominated 90,288
Scenario 8. LYs discounted at 1.5% per annum
Syst. TRUS 3895 b 17.18299 b b b
MRI 3902 7 17.18416 0.001172 5953 5953
MRS 3952 49 17.18656 0.002393 20,637 15,811
DCE 3984 32 17.18140 –0.005160 Dominated Dominated
MRI or MRS 4031 80 17.18809 0.001531 52,000 26,684
MRI or DCE 4056 25 17.18491 –0.003180 Dominated 84,112
TABLE 43 Deterministic sensitivity analysis scenarios using LYs as unit of outcome (men aged 60 years; cancer 
prevalence 24%) (continued)
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Strategy
Average 
cost (£)
Incremental 
cost (£)a Average LYs
Incremental 
LYsa ICERa (£)
ICER vs 
common 
baseline (£)
Scenario 9. Disease progression calibrated to prostate cancer mortality rates observed in the PIVOT trial149
Syst. TRUS 3751 b 14.27118 b b b
MRI 3758 7 14.27176 0.000580 12,035 12,035
MRS 3808 49 14.27291 0.001145 43,122 32,678
DCE 3840 32 14.27044 –0.002460 Dominated Dominated
MRI or MRS 3887 80 14.27362 0.000711 112,027 55,830
MRI or DCE 3913 25 14.27210 –0.001520 Dominated 175,577
Scenario 10. Use extended-cores biopsy for all patients negative on MRS/MRI
Syst. TRUS 3895 b 14.16796 b b b
MRI 4007 112 14.17252 0.004559 24,525 24,525
MRS 4087 80 14.17284 0.000318 250,318c 39,251
DCE 4087 80 14.17305 0.000530 150,695 37,668
MRI or MRS 4090 3 14.17215 –0.000900 Dominated 46,462
MRI or DCE 4090 3 14.17262 –0.000420 Dominated 41,839
Syst. TRUS, systematic TRUS-guided extended-cores (15) biopsy.
a Incremental costs and LYs are estimated in comparison with the next less costly non-dominated strategy.
b Common baseline.
c Strategy dominated by combinations of other strategies.
TABLE 43 Deterministic sensitivity analysis scenarios using LYs as unit of outcome (men aged 60 years; cancer 
prevalence 24%) (continued)
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